

Mutant Selections Linking Physiology, Inhibitors, and Genotypes

ROBERT A. LAROSSA

139

OVERVIEW

Inhibitory conditions result in the selection of genetic variants. Such variants have been useful as selectable markers facilitating studies of rare genetic events such as recombination and mutagenesis (619). Many such selections have also defined the sites of agrichemical and drug action. These inhibitory agents, resultant selections, and mutants have been crucial probes allowing insights into the broad range of biological mechanisms occurring in bacteria. Studies of surface phenomena, transport, central and peripheral metabolic events, transcription, translation, specific and global regulatory mechanisms, protein folding, and replication have been advanced by such analyses. The aim of this chapter is to provide a catalog of such inhibitory agents and their targets. It is my belief that such a catalog provides an important connection between the genome and the physiology of an organism.

SELECTIONS AND SCREENS

Chemical, physical, and biological insults can be applied to *Escherichia coli* and *Salmonella typhimurium* (official designation, *Salmonella enterica* serovar Typhimurium). The response of a bacterial strain, i.e., its phenotype, is a complex function of the organism's genetic constitution, or genotype, its natural history, and its current environment. Conditions allowing all but a few cells to grow result in selections of genetic variants that overcome the environmental challenges. In other cases, rare mutants unable to grow under conditions in which the vast majority of organisms thrive can be obtained by screening. The analysis of both mutational classes can be most revealing; thorough study often rewards the dedicated researcher with fundamental new insights into biological phenomena.

SOME TOOLS OF THE TRADE

Environment

To devise a selection or a screen, the experimenter customizes the microbial environment. This customization may encompass manipulation of nutritional parameters and physical conditions such as temperature, pressure, and irradiation. Such manipulations by themselves can constitute positive selections or effective screens. These manipulations can also be utilized in conjunction with inhibitory agents to optimize selection or screening protocols.

Mutagenesis

Mutagenesis protocols can influence both the recovery of mutants and the spectrum of mutations obtained. It is thus useful to employ a variety of mutagens with a defined selection. For example, spontaneous hydrogen peroxide-resistant mutants have not been obtained from *S. typhimurium* despite repeated attempts with a tight and powerful selection; such mutants are recovered readily after chemical mutagenesis (131). Moreover, various protocols can lead to the preponderance of different mutational

classes. Many chemical treatments yield point mutations, while spontaneous mutations are often small deletions (460). Transposon mutagenesis most often results in loss of gene function (411). In addition, the high efficiency (=1) of recovering mutations by selection for drug resistance after exposure to transposons such as Tn5, Tn10, and Mud (Ap lac) facilitates selection of mutants resistant to a second agent and makes the screening for hypersensitive loss-of-function mutants manageable (411, 443, 796).

Inhibitory Agents

Energy, chemicals, and living things have the capacity to either inhibit bacterial growth or kill cells. Energy in many forms, including heat, visible light, UV rays, and gamma rays, can compromise cells. Chemical inhibitors may be elements, simple inorganic molecules, complex organic molecules, or natural products produced by an organism for a variety of reasons, including protection of its ecological niche or repelling of predators. A rich collection of antibacterial agents has arisen from the synthetic organic chemical practices of the modern pharmaceutical and agrichemical industries, the natural product isolation and screening of the pharmaceutical industry, and the development of novel compounds for a variety of uses by the chemical industry. Bacterial viruses, mammalian macrophages, and other microbes are also capable of efficient destruction of bacterial populations. These tools have been repeatedly exploited by bacterial geneticists to provide both fundamental and applied knowledge.

Modern Genetic Technologies

A wide variety of genetic methods are applicable to the characterization of selectable phenotypes. A few of general utility are mentioned here. Transposon-mediated insertion mutations that are linked to alleles conferring resistance or sensitivity or that are themselves responsible for the phenotype (411, 443, 796) can be physically isolated by using drug resistance as a selectable marker in *in vivo* or *in vitro* molecular cloning experiments (524). Such DNA fragments can be mapped accurately to the *E. coli* genome by powerful computer-assisted restriction digest matching and hybridization methodologies (414, 661). Multicopy plasmid libraries representative of the *E. coli* and *S. typhimurium* genomes are easy to construct. These libraries can be used to isolate resistant or hypersensitive variants that result from the amplification of small regions of the chromosome (see, e.g., reference 250 and 472). Again, such “meromultiploids” can be rapidly and accurately mapped by computer-assisted restriction enzyme digestion analyses or by hybridization to the ordered library of *E. coli* fragments present in phage lambda vectors (414, 661).

PATHWAY FOR INHIBITOR ACTION

To inhibit the growth of *E. coli* or *S. typhimurium*, a generic inhibitor must pass through the aqueous culture medium and one or both of the cellular membranes. Within the cytoplasm, periplasm, or cellular membranes, the inhibitory substance must compromise a vital cellular function. The response to the inhibitory substance may be modulated by altering (i) the efficiency with which it reaches its target, (ii) the target structure, (iii) the target quantity, (iv) the catabolism of the inhibitory substance, (v) the metabolic responses to target inhibition, or (vi) the functional alternatives to the inhibited target. Thus, inhibitor hypersensitivity (Fig. 1) can arise from (i) lessening of permeability barriers or efflux mechanisms (e.g., *tolC* [536, 653]), (ii) creation of targets with a greater affinity for the inhibitor (*hisG* [698]), (iii) decreased intracellular levels of targets (e.g., *his* promoter down-mutations [208]), (iv) increased conversion of a proinhibitor to an inhibitor, (v) destruction of inhibitor detoxification systems (e.g., inactivation of neomycin phosphotransferase) or inactivation of fueling pathways (e.g., *pta-ack*) that can degrade otherwise toxic products to more benign substances (see, e.g., reference 797), and (vi) destruction of




FIGURE 1 Some causes of inhibitor-hypersensitive mutants. Consider a cell in which enzyme U catalyzes the conversion of substrated to product e. The relative amounts of d and e are indicated by whether the symbol is an uppercase or lowercase letter (larger and smaller amounts, respectively). The inhibitor of enzyme U can be in the extracellular space (K_e) or internalized within the Cell (K_i). Within the cytoplasm, the inhibitor can bind to its target or be catabolized by a second protein, C, to metabolites m and n. Substrate d may be consumed by either enzyme U, an isozyme V, or another enzyme, R, yielding an alternative product, f. Inhibitor-hyper-sensitive mutants can arise by (i) mutations that increase entry of the inhibitor into the cell, (ii) structural alterations of target enzyme U that result in increased affinity for the inhibitor, (iii) regulatory mutations that lower the concentration of enzyme U, (iv) alleles that prevent catabolism of inhibitor K by protein C, (v) mutations that cause the accumulation of metabolic intermediates to toxic levels, or (vi) loss-function mutations that inactivate inhibitor-resistant isozymes of enzyme U.




FIGURE 2 Some mechanisms underlying inhibitor-resistant mutants. A cell in which enzyme T catalyzes the conversion of substrate a to product b is depicted. The relative amounts of a and b are indicated by whether the symbol is an uppercase or lowercase letter (larger and smaller amounts, respectively). The inhibitor of enzyme T can be in the extracellular space (I_e) or internalized within the cell (I_i). Within the cytoplasm, the inhibitor can bind to its target or be catabolized by a second protein, C, to metabolites m and n. Substrate a may be consumed by enzyme T, an isozyme Z, or another enzyme, R, yielding an alternative product, j. Resistance can arise by (i) exclusion of inhibitor I from the cellular compartment containing enzyme T, (ii) structural alterations of enzyme T such that its affinity for inhibitor I is diminished, (iii) regulatory mutations increasing the intracellular concentration of enzyme T, (iv) mutations that cause the catabolism of inhibitor I, (v) alleles that prevent the accumulation of substrate a to toxic levels, and (vi) evolution of cryptic isozymes of enzyme T, the target of inhibitor I, that are unaffected by the inhibitor.

isozymes (see, e.g., reference 442). Conversely, resistance (Fig. 2) can arise by (i) preventing binding or permeation of molecules or organisms (e.g., phage λ [88, 134, 135, 253, 644, 766], colicin E1 [449, 536, 653], and histidine analogs [13–15]), (ii) creating target structures with lowered affinities for an inhibitor (781; e.g., *hisG* [540, 698, 699, 824]), (iii) elevating target levels (781; e.g., *hisO*, *hisR*, *hisS*, *hisT*, *hisU*, and *hisW* [23, 98, 126, 148, 657, 658, 660, 705, 706, 784]), (iv) transforming an inhibitor to an inactive form or preventing proinhibitor transformation to a toxic form (e.g., fluoroacetate to fluorocitrate [96, 281, 463, 797] and glycylvaline to valine [1, 178]), (v) obviating deleterious accumulations behind the block imposed by either a mutation or an inhibitor, and (vi) evolving cryptic enzyme activities (e.g., *ebg* [118] and *ilvF* [174, 610]).

ALTERING METABOLIC CAPACITY

E. coli and *S. typhimurium* utilize a large, though limited, number of organic compounds as sole sources of carbon, nitrogen, phosphorus, sulfur, and energy. Positive genetic selections that expand the metabolic repertoire of these organisms have been devised. These include the utilization of D-amino acids for protein synthesis, utilization of a single amino acid as a sole nitrogen or carbon source, utilization of organophosphates as a sole phosphorus source, utilization of djenkoic acid as a sole sulfur source, and utilization of many carbon compounds as energy sources. Although single mutations can expand metabolic capacity, mutation of several genes may be required to satisfy these selections.

An interesting twist on expanding metabolic capacity comes from gene amplification. In this regard, a discussion of the multiple transaminases is illuminating. These enzymes have overlapping specificities in vitro. Amplification of *ilvE*, which encodes the branched-chain amino acid transaminase B, allows production of physiologically significant levels of tyrosine, which are not obtained with the haploid *ilvE* gene. Similarly, amplification of *tyrB* allows transaminase B to act in alanine synthesis, while overproduction of transaminase A or C is sufficient to meet the metabolic demand for leucine in an *ilvE* mutant. Thus, function may be modulated by changing enzyme concentrations in vivo via alteration of gene dosage or expression (61).

Loss of metabolic capacity can also be detected. Many positive selections for loss of function are known. Indirect screening methods (replica plating, indicator media) allow identification of interesting phenotypes. One such indirect method, hypersensitivity to a herbicide, has been useful in metabolic studies (443) and has led to the development of a new selection for *ilvA* alleles (231). Moreover, the indirect method has been extremely powerful in defining the responses of cells to DNA-damaging regimens (810).

LESSONS AND IMPACTS

Resistance-determining alleles have been exploited in several ways. They have served as selectable markers in genetic crosses. This utility is being supplanted by new techniques and use of drug resistance-specifying insertion alleles in strain construction. Nevertheless, a lasting legacy of these selections has been the definition of a very broad range of biological phenomena that have been intensively studied. A few examples illustrating this generality in conjunction with Fig. 2 may be illuminating.

Alleles preventing association of an inhibitory agent with the cell (Fig. 2, part i) have contributed much to our present understanding of surface architecture and membrane transport systems. Mutations that decrease inhibitor-target interactions (Fig. 2, part ii) have advanced our knowledge of antibiotic and agrichemical action, allosteric, feedback inhibition, and repression. Mutations that increase the intracellular concentration of a target macromolecule (Fig. 2, part iii) have led directly to the genetic regulatory concepts of attenuation, repression, and activation.

Interference with inhibitor metabolism (Fig. 2, part iv) has led to findings both obvious and surprising. It is understood that fluoroacetate is a poison only if it enters the tricarboxylic acid cycle. Thus, mutations preventing the formation of fluoroacetyl coenzyme A are expected to confer resistance to fluoroacetate; such mutations have been obtained (96, 281, 463, 797). In contrast, if multiple phages are used as the inhibitory agents, bacterial Gro mutants both blocked in phage killing and defective in cellular metabolism are selected (256–260). It is worth emphasizing that this latter approach has had a profound effect on our understanding of protein folding, the cellular redox state, and transcription.

Preventing substrate accumulation (Fig. 2, part v) has been the basis of selections that have helped demonstrate that accumulations of sugar phosphates and 2-ketoacids are toxic (569, 752, 796, 797). These same selections are being used in the detailed dissection of protein structure-function and fine-structure genetic mapping (231). The recruitment of alternative functions (Fig. 2, part vi) has intriguing evolutionary implications. Selections have uncovered silent, cryptic genes that are activated by mutation (see, e.g., references 118, 174, 361, and 610). Further analyses have indicated that a gene encoding one isozyme may be cryptic in *E. coli* and expressed in *S. typhimurium*, while the gene encoding the second

isozyme is silent in *S. typhimurium* and functional in *E. coli* (782). Moreover, studies of evolved β -galactosidase and transaminases together indicate that a new *in vivo* function to meet a selection can be accomplished by changes in enzyme structure or changes in enzyme quantity or both (61, 118).

Analyses of hypersensitive and resistant alleles that use a single inhibitory agent can be most informative in the study of a single phenomenon. Analysis of mutations altered in both responses to an amino acid antagonist has defined the multiple components of the yeast general control system (841). Similarly, extensive genetic, physiological, and enzymatic studies of feedback-hypersensitive and feedback-resistant alleles of *hisG* have been most useful in understanding the role of the *hisG* gene product (698, 824). Several other such examples are well known.

An interesting contrast is provided by studies of sulfonylurea herbicide resistance and hypersensitivity in *S. typhimurium*. Resistance mutations precisely define acetolactate synthase as the site of action of these herbicides (441). Numerous transposon-induced, herbicide-hypersensitive mutations have also been collected (796). Studies of these mutations demonstrated that the accumulation of 2-ketobutyrate upon acetolactate synthase inhibition is toxic (443). This observation suggests that such toxic accumulation may be an important factor in herbicide target selection and that schemes can be conceived in which selections and screens may be used to mimic inborn errors of human metabolism (444).

These positive selections have also had direct economic and clinical impact. The sites of action of vital pharmaceutical and agrichemical agents have been and continue to be defined by mutant analyses of *E. coli* and *S. typhimurium*. Feedback-insensitive mutations of *E. coli*, *S. typhimurium*, and other bacteria play a critical role in pathway engineering designed to produce small biological molecules by schemes involving fermentation or agriculture.

LIMITATIONS OF INHIBITOR AND MUTANT ANALYSES

Mutations often cause an adverse situation in which cellular growth is not optimal. Even under permissive conditions, compensatory secondary mutations may accumulate. Conclusions attributing a phenotype to a mutation may be erroneous if that phenotype is actually a consequence of both the primary mutation and compensatory alterations. Hypotheses drawn from mutants can often be buttressed by analyzing growth disadvantages created by the addition of very specific chemical inhibitors of particular enzymes. In such cases, the time for selection and expression of compensatory mutations is minimized. Analysis of such transient phenocopies is, however, complicated; inhibitor specificity may not be absolute. For example, various oxalyl hydroxamates inhibit both isopropyl malate dehydrogenase (the *leuB* product) and acetohydroxy acid isomeroreductase (the *ilvC* product [839]). Thus, mutually supportive physiological and genetic data derived from a single inhibitory condition are most desirable.

TABLES

Tables 1 through 3 build upon the splendid effort of Vinopal (803). Table 1 provides a list of selections by which mutations have been obtained. It is apparent that a single selection can often yield mutations in a wide variety of genes. Table 2 (p. 2551), cross-referencing Table 1, lists alphabetically those genes for which resistant alleles have been obtained by positive selections. From this table, one can see that alleles of single genes can often be obtained by a variety of selections. It is often useful to have access to a range of inhibitors interfering with a class of metabolic reactions. To address this need, the genes listed in Tables 1 and 2 are regrouped in Table 3 (p. 2571) by metabolic function following the convention of Riley (643). As can be seen, selections for a broad spectrum of metabolic functions have been devised. For genes in the amino acid and cofactor biosynthesis domain, selections based on mechanisms other than false feedback inhibition are relatively few. By providing these three tables, I hope to provide maximal access to the contents of this chapter for geneticists, biochemists, and physiologists. An array of inhibitory agents with different specificities is therefore presented. As in the past, the utility of these tools for scientific investigation is limited only by the imagination of the experimenter.

A cautionary note is in order. I hope that the cross-referenced tables emphasize that, unlike the one-

to-one correspondence between gene and gene product, the relationship between phenotype and genotype is more complicated. Many different genotypes can give rise to a single phenotype. Similarly, many different selections can alter a single gene.

TABLE 1 Selections giving rise to mutants of *E.coli* and *S.typhimurium*^a

Selection purpose and technique	Mutant gene
Expansion of metabolic capacity	
Acetate + gluconate as C source in <i>ppc</i>	<i>gntR</i>
Acetate + gluconate as C source in <i>ppc</i>	<i>gntS</i>
Acetyl(<i>N</i>)histidine + ornithine satisfaction of <i>his</i>	<i>argB</i>
Acetyl(<i>N</i>)histidine + ornithine satisfaction of <i>his</i>	<i>argC</i>
Acetyl(<i>N</i>)histidine + ornithine satisfaction of <i>his</i>	<i>argE</i>
Acetyl(<i>N</i>)histidine + ornithine satisfaction of <i>his</i>	<i>argH</i>
Acetylhistidine satisfaction of <i>his</i>	<i>argR</i>
Acetyl(<i>N</i>)lactonate as sole N source	<i>lacI</i> , operator
Acetylmethionine satisfaction of <i>met</i>	<i>argR</i>
Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	<i>argA</i>
Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	<i>argB</i>
Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	<i>argC</i>
Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	<i>argD</i>
Adenosine as C source in <i>upp deoD</i>	<i>xapR</i>
Aminobutyrate as N source	<i>gabC</i>
Arabinitol (D) resistance	<i>mtlA</i>
Arabinose (L) as C source in <i>cya</i> or <i>crp</i>	<i>rpoD</i>
Arabinose (L) as C source in presence of <i>lac</i> operon inducer	<i>lacY</i>
Arabinose (D) as C source	<i>fucA</i>
Arabitol as C source	<i>gatACD</i>
Arabitol (D) as C source in <i>fuc</i>	<i>dgd</i>
Arbutin as a C source	<i>bgIBC</i>
Arbutin as C source)	<i>osmZ</i> (<i>bgIY</i>)
Arginine as N source	<i>hisP</i>
Arginine-independent growth of <i>pyrH</i> in presence of uracil	<i>pyrB</i>
Arginine-independent growth of <i>pyrH</i> in presence of uracil	<i>pyrC</i>
Arginine-independent growth of <i>pyrH</i> in presence of uracil	<i>pyrD</i>
Arginine-resistant, proline-independent growth of Δ <i>pro</i>	<i>argR</i>
β -Glycerol-phosphate as C source in presence of high phosphate	<i>phoA</i>
β -Glycerol-phosphate as C source in presence of high phosphate	<i>phoR</i>
β -Glycerol-phosphate as C source in presence of high phosphate	<i>phoS</i>
β -Glycerol-phosphate as C source in presence of high phosphate	<i>phoT</i>
Biotin sulfoxide utilization in <i>chl bio</i>	<i>chlE</i>
Branched-chain amino acid satisfaction of Δ <i>ilvDC hisT</i>	<i>ilvA</i>
Butyrate as C source in <i>fadR</i> (Con)	<i>atoC</i>
Butyrate or valerate as better C source	<i>iclR</i>
Cellobiose as C source	<i>celABCF</i>
Chemostat growth improved	<i>mut</i>
Citrate as C source	<i>cit</i>
Citrate as C source in presence of low cAMP	<i>cpd</i>
D-Amino acid satisfaction of amino acid auxotrophy	<i>dadA</i>
DAP-independent growth of Δ (<i>mal-asd</i>) in the presence of serine, methionine, and glycine	
D-Histidine + glycylglutamine satisfaction of <i>his</i> auxotrophs	<i>glnA</i>
Decanoate as C source	<i>fadR</i>
Deoxyadenosine (low) satisfaction of purine requirement	<i>add</i>

Selection purpose and technique	Mutant gene
Deoxyadenosine + hypoxanthine satisfaction of purine requirement	<i>add</i>
Diamino (2,6)purine satisfaction of purine auxotrophy	<i>deoR</i>
Erythromycin growth dependence	<i>mac</i>
Ethanol as C source	<i>adh</i>
Ethyleneglycol as C source in propanediol utilizer	<i>fucA</i>
Fructose as C source in <i>ptsF</i> or <i>ptsM</i>	<i>srlD</i>
Fructose 1-phosphate as C source	<i>uhpR</i>
Fucose (L) as C source in propanediol utilizer	<i>fucA</i>
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglA</i>
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglB</i>
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglC</i>
Galactose as C source for <i>gal</i> (leader)::IS	<i>rho</i>
Galacturonide as C source	<i>uidA</i>
Galacturonide as C source	<i>uidR</i>
Glucanate as C source in <i>eda</i>	<i>edd</i>
Glucosamine as C source	<i>ptsG</i>
Glucosamine 6-phosphate as C source	<i>uhpR</i>
Glucosamine as anaerobic C source in <i>ptsG</i>	<i>dgsA</i>
Glucose 1-phosphate as C source	<i>uhpR</i>
Glucose as C source in $\Delta ptsHI$	<i>galC</i>
Glucose as C source in <i>ppc</i>	<i>iclR</i>
Glucose as C source in $\Delta ptsHI$	<i>galR</i>
Glucosides (β) as C source	<i>gyrA</i> (<i>hisU</i>)
Glucosides (β) as C source	<i>gyrB</i> (<i>hisW</i>)
Glutamate as C source	<i>gadS</i>
Glutamate as C source	<i>gltH</i>
Glutamate as C source	<i>gltS</i>
Glutamate as C source at 42°C	<i>gltR</i>
Glutamine as C source	<i>glnP</i>
Glycerol as C source in <i>ppc</i>	<i>iclR</i>
Glycerol + gluconate as C source in <i>eda</i>	<i>gntM</i>
Glycerol + methylglucuronide as C source in <i>eda</i>	<i>gurBCD</i>
Glycerol 3-phosphate as C source in <i>glpT ugpAB</i>	
Hemin satisfaction of <i>hemA</i> auxotroph	<i>hemB</i>
Hemin satisfaction of <i>hemA</i> auxotroph	<i>rfa</i>
Hexuronate as C source in noninducible strain	<i>exuR</i>
Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C	<i>his</i> structural genes
Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C	<i>hisG</i>
Histidine (D) satisfaction of <i>his</i> auxotroph requirement	<i>his</i> structural genes
Histidine (D) satisfaction of <i>his</i> auxotroph requirement	<i>hisG</i>
Histidine (D) satisfaction of <i>his</i> auxotroph requirement	<i>dhuA</i>
Histidine as C source	<i>hut</i>
Histidine as N source	<i>hut</i>
Improved growth in <i>icd</i>	<i>gltA</i>
Inosine as C source in <i>upp deoD</i>	<i>xapR</i>
Inosine as improved C source	<i>deoR</i>
Keto(2)-3-deoxygalactonate as C source	<i>kdgR</i>
Keto(2)-3-deoxygalactonate as C source	<i>dgoR</i>
Lactate + fumarate as anaerobic energy source	<i>chlABDE</i>
Lactate + nitrate as anaerobic energy source (<i>chl</i> to <i>chl^t</i>)	<i>chlE</i>
Lactitol as C source <i>lacI</i> , operator	

Selection purpose and technique	Mutant gene
Lactobionic acid as C source	<i>lacI</i> , operator
Lactobionic acid as C source	<i>lacZ</i>
Lactose utilization after conjugation of F' lac into <i>Salmonella</i> sp.	<i>hsd</i>
Lactose utilization in $\Delta lacZ$	<i>ebgA</i>
Leucine (D) satisfaction of <i>leu</i> auxotrophs	<i>lrp</i> (<i>livR</i> , <i>lstR</i> , <i>lss</i> , <i>mbl</i> , <i>oppI</i>)
Lyxose (D) as C source	<i>manC</i>
Malate (L) as improved C source	<i>dct</i>
Malate (D) as C source	<i>dml</i>
Maltose as C source in <i>malT</i>	<i>malP</i>
Maltose as C source in <i>malT</i>	<i>malQ</i>
Maltose utilization in <i>malT</i>	<i>bymA</i>
Mannitol (limiting) as C source	<i>mtlC</i>
Mannose as C source	<i>ptdG</i>
Melibiose as C source	<i>lacI</i> , operator
Melibiose as C source and acetyl(N)lactonate as N source	<i>lacI</i> , operator
Methyl- β -galactoside-supported growth	<i>mglD</i>
Methylgalacturonide as C source	<i>uidA</i>
Methylgalacturonide as C source	<i>uidR</i>
Methylgalacturonide as C source	<i>uxuR</i>
Methyl(β)glucoside as C source	<i>bgIT</i>
Methylglucuronide + glycerol-supported growth	<i>uidA</i>
Neolactose as C source	<i>lacI</i> , operator
Nicotinamide as sole N source	<i>pncA</i>
Phenylgalactoside as C source	<i>lacI</i> , operator
Proline as sole N source with glucose as C source	<i>putA</i>
Proline-independent growth of <i>proAB</i>	<i>argD</i>
Propanediol as C source	<i>fucA</i>
Propionate as C source	<i>prp</i>
Raffinose as C source in <i>lacI</i>	<i>mel</i> (generic)
Raffinose as C source	<i>lacI</i> , operator
Ribitol utilization	<i>gatACD</i>
Salicin as C source	<i>bglB,C</i>
Salicin as C source	<i>osmZ</i>
Serine (L) as C source	<i>cpxA</i>
Serine (L) as C source	<i>ecfB</i>
Sorbitose (L) as C source in crosses with wild strains	<i>sorAT</i>
Streptomycin independence of <i>rpsL</i>	<i>rpsD</i>
Streptomycin independence of <i>rpsL</i>	<i>rpsE</i>
Succinate as improved C source	<i>cpd</i>
Succinate-independent growth in <i>lpd</i>	<i>sdh</i>
Sucrose as C source	<i>dsdA</i>
Sucrose as C source	<i>dsdC</i>
Threonine as N source	<i>ilvA</i>
Tyramine as N source	<i>tyn</i>
Uridine as C source, improved utilization	<i>cytR</i>
Valerate as C source in <i>fadR</i> (Con)	<i>atoC</i>
Xylitol as C source in propanediol utilizer	<i>fucA</i>
Resistance to inorganic chemicals	
Acid resistance	<i>atr</i>
Acid resistance	<i>phoE</i>
Arsenate resistance	<i>glpT</i>

Selection purpose and technique	Mutant gene
Arsenate resistance	<i>phoR</i>
Arsenate resistance	<i>phoS</i>
Arsenate resistance	<i>phoT</i>
Arsenate resistance	<i>pstABC</i>
Arsenate resistance	<i>pit</i>
Azide resistance	<i>atpA-atpE</i>
Azide resistance	<i>cysB</i>
Azide resistance	<i>cysK</i>
Azide resistance	<i>seca</i>
Chlorate resistance	<i>chlABCDEG</i>
Chlorate resistance	<i>narCG</i>
Chlorate resistance	<i>narH</i>
Chromate + selenate resistance	<i>cysL</i>
Chromate resistance	<i>cysA</i>
Chromate resistance	<i>cysB</i>
Chromate resistance	<i>cysC</i>
Chromate resistance	<i>cysD</i>
Chromate resistance	<i>cysH</i>
Chromate resistance	<i>cysI</i>
Chromate resistance	<i>cysJ</i>
Copper resistance in <i>ompC</i>	<i>ompF</i>
Copper resistance	<i>ompR</i>
Diazoborine resistance	<i>envM</i>
Lithium resistance (multicopy)	<i>nhaA</i>
Lithium-resistant utilization of melibiose	<i>melB</i>
Manganese resistance	<i>corABCD</i>
Manganese resistance	<i>fur</i>
Manganese resistance	<i>mng</i>
Nickel resistance	<i>corABCD</i>
Osmotolerance	<i>crp</i>
Osmotolerance	<i>cyaA</i>
Osmotolerance	<i>osmB</i>
Osmotolerance	<i>proA</i>
Osmotolerance	<i>proB</i>
Peroxide resistance	<i>oxyR</i>
Selenate resistance	<i>cysA</i>
Selenate resistance	<i>cysB</i>
Selenate resistance in <i>cysM</i>	<i>cysB</i>
Selenate resistance	<i>cysK</i>
Selenate resistance	<i>cysL</i>
Selenite resistance	<i>cysK</i>
Selenite resistance	<i>gshA</i>
Selenite resistance	<i>gshB</i>
Tellurite resistance	<i>phoB</i>
Tributyl tin resistance	<i>atpA-atpE</i>
Resistance to biological and organic chemicals	
Acetyl norvaline resistance in <i>argR</i> (Con)	<i>argE</i>
Acetyl norvaline resistance in <i>argR</i> (Con)	<i>argR</i>
Acridine resistance	<i>dnaE</i>
Actinomycin D resistance in the presence of EDTA	<i>pldA</i>
Adenine resistance in <i>hpt gpt</i>	<i>apt</i>
Adenine resistance in <i>hpt gpt</i>	<i>purR</i>
Alafosfalin resistance	<i>pepA</i>
Alafosfalin resistance	<i>tpp</i>
Alanyl-2-aminopropionate resistance	<i>oppA</i>
Albicidin resistance <i>tsx</i>	

Selection purpose and technique	Mutant gene
Albomycin resistance	<i>exbB</i>
Albomycin resistance	<i>fhuA</i>
Albomycin resistance	<i>fhuB</i>
Albomycin resistance	<i>pepN</i>
Albomycin resistance	<i>sidCF</i>
Albomycin resistance	<i>sidK</i>
Albomycin resistance	<i>tonB</i>
Aldohexuronate resistance in <i>eda</i>	<i>exuT</i>
Aldohexuronate resistance in <i>eda</i>	<i>exuR</i>
Allyl alcohol resistance	<i>adhE</i>
Amidinopenicillin tolerance	<i>sloB</i>
Amikacin resistance	<i>cpxA</i>
Amino(2)purine resistance in <i>dam</i>	<i>mutH</i>
Amino(2)purine resistance in <i>dam</i>	<i>mutL</i>
Amino(2)purine resistance in <i>dam</i>	<i>mutS</i>
Amino(4)phenylalanine resistance	<i>aroF</i>
Amino(4)phenylalanine resistance	<i>tyrA</i>
Amino(4)phenylalanine resistance	<i>tyrR</i>
Amino(6)nicotinamide resistance	<i>nadA</i>
Amino(6)nicotinamide resistance	<i>nadD</i>
Amino(6)nicotinamide resistance	<i>pncA</i>
Amino(6)nicotinamide resistance	<i>pncB</i>
Amino(6)nicotinamide resistance	<i>pncX</i>
Amino(6)nicotinate resistance	<i>pncB</i>
Aminobutyrate resistance	<i>ilv</i> structural genes
Aminobutyrate resistance	<i>ilvB</i>
Aminobutyrate resistance	<i>ilvH</i>
Aminobutyrate resistance	<i>ilvI</i>
Aminoethylcysteine (thialysine) resistance	<i>lysC</i>
Aminoethylcysteine (thialysine) resistance	<i>lysP</i>
Aminoethylcysteine (thialysine) resistance	<i>lysS</i>
Aminoglycoside resistance	<i>nek</i>
Amino(2)hydroxy(3)pentoate resistance	<i>thr</i> structural genes
Aminopterin resistance	<i>thyA</i>
Aminotriazole resistance	<i>amtA, amtB</i>
Aminotriazole resistance	<i>his</i> structural genes
Aminotriazole resistance in <i>relA</i>	<i>gyrB</i>
Ampicillin resistance	<i>ampC</i>
Ampicillin resistance	<i>ampD</i>
Ampicillin resistance	<i>ampE</i>
Ampicillin resistance	<i>envZ</i>
Ampicillin resistance	<i>galU</i>
Ampicillin resistance	<i>hipA</i>
Ampicillin resistance	<i>hipQ</i>
Ampicillin resistance	<i>ompC</i>
Ampicillin resistance	<i>ompF</i>
Ampicillin resistance	<i>ompR</i>
Ampicillin resistance	<i>ptsI</i>
Ampicillin resistance	<i>rfa</i> (general)
Ampicillin resistance	<i>tolD</i>
Ampicillin resistance	<i>tolE</i>
Arabinitol (D) resistance	<i>mtIA</i>
Arbitol (D) resistance	<i>gatACD</i>
Arbutin resistance in <i>dkg</i>	<i>mdoB</i>
Arginine-resistant, proline-independent growth of Δpro	<i>argR</i>
Auroventin resistance	<i>atpA-atpE</i>
Aza(5)cytidine resistance	<i>dcm</i>
Azadeoxycytidine resistance	<i>cdd</i>
Aza(6)uracil resistance	<i>gpt</i>

Selection purpose and technique	Mutant gene
Aza(8)guanine resistance	<i>ndk</i>
Aza(8)guanine resistance	<i>upp</i>
Azaleucine resistance	<i>aroP</i>
Azaleucine resistance	<i>azl</i>
Azaleucine resistance	<i>tolB</i>
Azaleucine resistance	<i>leuS</i>
Azaleucine resistance	<i>livG</i>
Azaleucine resistance	<i>livH</i>
Azaserine + tryptophan resistance	<i>dhuA</i>
Azaserine + tryptophan resistance in <i>dhuA</i>	<i>hisJ</i>
Azaserine resistance	<i>aroP</i>
Azaserine resistance	<i>azaAB</i>
Azaserine resistance	<i>cysA</i>
Azaserine resistance	<i>cysB</i>
Azaserine resistance	<i>cysC</i>
Azaserine resistance	<i>cysD</i>
Azaserine resistance	<i>cysE</i>
Azaserine resistance	<i>cysG</i>
Azaserine resistance	<i>cysH</i>
Azaserine resistance	<i>cysI</i>
Azaserine resistance	<i>cysJ</i>
Azaserine resistance	<i>cysK</i>
Azaserine resistance	<i>cysM</i>
Azaserine resistance	<i>mut</i> (generic)
Azetidine carboxylate resistance	<i>proB</i>
Azetidine carboxylate resistance	<i>putA</i>
Azetidine carboxylate resistance	<i>putP</i>
Azidothymidine resistance	<i>tdk</i>
Bacilysin resistance	<i>dppA</i>
Bacitracin resistance	<i>rfa</i>
Bacteriocin resistance	<i>tol</i>
Bacteriocin 4-59 resistance	<i>ompA</i>
Bacteriocin 4-59 resistance	<i>tonB</i>
Bacteriocin JF246 resistance	<i>ompA</i>
Baikiaiin resistance in constitutive background	<i>putA</i>
β-Glycerol-phosphate resistance in <i>glpD</i>	<i>phoA</i>
Beta-lactam conjugate resistance	<i>fhuA</i>
Beta-lactam resistance (see mecillinam resistance)	<i>crp</i>
Beta-lactam resistance	<i>cyaA</i>
Beta-lactam resistance	<i>lyt</i>
Beta-lactam resistance	<i>alaS</i>
Beta-lactam resistance	<i>argS</i>
Bialaphos resistance	<i>dppA</i>
Borrelidin resistance	<i>thrs</i>
Bromodeoxyuridine + UV light resistance	<i>ung</i>
Cadaverine resistance	<i>cadB</i>
Caffeine resistance	<i>glnV</i>
Calmodulin inhibitor resistance	<i>leuW</i>
cAMP + glucose 6-phosphate + D-xylose + L-arabinose resistance	<i>crp</i>
cAMP + glucose 6-phosphate resistance	<i>crp</i>
Camphor resistance	<i>mbrABCD</i>
Canavanine + azauracil resistance	<i>argR</i>
Canavanine + thiouracil resistance	<i>upp</i>
Canavanine + thiouracil resistance	<i>argP</i>
Canavanine resistance	<i>argS</i>
Canavanine resistance	<i>argP</i>
Canavanine resistance	<i>argR</i>
CCCP resistance	<i>atpA-atpE</i>
CCCP resistance due to gene dosage	<i>emrB</i>

Selection purpose and technique	Mutant gene
Cephalosporin E-0702 resistance	<i>tonB</i>
Cephalothin resistance	<i>rfa</i>
Chelator resistance	<i>ompA</i>
Chloramphenicol resistance	<i>cmlA</i>
Chloramphenicol resistance	<i>marA</i>
Chloramphenicol resistance	<i>rrn</i>
Chloramphenicol resistance	<i>ompF</i>
Chloramphenicol resistance	<i>ompR</i>
Chloro(β)-D-alanine resistance	<i>dadA</i>
Chloro(β)-D-alanine resistance	<i>metC</i> (<i>ecfA</i>)
Chloro-3-hydroxyacetone resistance in <i>uhp</i> (Con)	<i>uhpT</i>
Chloroacetaldehyde resistance	<i>adhCE</i>
Chloroacetate(β) resistance	<i>cbt</i>
Chlorobiocin resistance	<i>gyrB</i>
Chloroethanol resistance	<i>adhCE</i>
Chlorohydroxyacetone phosphate resistance	<i>glpT</i>
Chlormazazine resistance	<i>lon</i>
Chuangxinmycin resistance	<i>trpR</i>
Cloacin DF13 resistance	<i>ompF</i>
Coenzyme A feedback resistance	<i>coaA</i>
Colicin "K-type" tolerance	<i>hemB</i>
Colicin (multiple) resistance	<i>envZ</i>
Colicin (other) resistance	<i>exbB</i>
Colicin (other) resistance	<i>exbC</i>
Colicin A tolerance	<i>cpxA</i>
Colicin A tolerance	<i>ompF</i>
Colicin A group tolerance	<i>cira</i>
Colicin A group tolerance	<i>tolQ</i>
Colicin B resistance	<i>exbC</i>
Colicin B resistance	<i>fepABCDG</i>
Colicin B resistance	<i>tonB</i>
Colicin B tolerance	<i>cbt</i>
Colicin D resistance	<i>cbt</i>
Colicin D tolerance	<i>tolB</i>
Colicin E resistance	<i>tolC</i>
Colicin E1 tolerance	<i>cet</i>
Colicin E1 tolerance	<i>tolQAB</i>
Colicin E2 tolerance	<i>ompF</i>
Colicin E3 tolerance	<i>btuB</i>
Colicin E3 tolerance	<i>tolR</i>
Colicin E2 and E3 tolerance	<i>tolE</i>
Colicin E2 and E3 tolerance	<i>tolZ</i>
Colicin E2, E3, D, Ia, and Ib tolerance	<i>toll</i>
Colicin I resistance	<i>exbB</i>
Colicin I resistance	<i>exbC</i>
Colicin I resistance	<i>ecfB</i>
Colicin Ia and Ib tolerance	<i>tolJ</i>
Colicin K resistance	<i>metC</i> (<i>ecfA</i>)
Colicin K resistance	<i>tsx</i>
Colicin K resistance	<i>ompA</i>
Colicin K tolerance	<i>ompA</i>
Colicin K tolerance	<i>ompF</i>
Colicin L tolerance	<i>envZ</i>
Colicin L tolerance	<i>ompF</i>
Colicin L tolerance	<i>fhuA</i>
Colicin L, A, and S4 tolerance	<i>fepABCDG</i>
Colicin M resistance	<i>tonB</i>
Colicin M resistance	<i>tolM</i>
Colicin M tolerance	<i>tolD</i>
Coumermycin resistance	<i>gyrB</i>
Coumermycin resistance	<i>hisW</i>
Cyclopentane glycine resistance	<i>ilv</i> structural genes
Cyclopentane glycine resistance	<i>ilvA</i>
Cycloserine resistance	<i>hipA</i>
Cycloserine (D) resistance	<i>cycA</i>
Dapsone resistance	<i>thdA</i>

Selection purpose and technique	Mutant gene
Dehydrobiotin resistance	<i>bio</i> operon
Dehydrobiotin resistance	<i>bioP</i>
Dehydrobiotin resistance	<i>birA</i>
Dehydroproline + azetidine carboxylate resistance at high osmolarity in <i>putA putP</i>	<i>proU</i>
Dehydroproline resistance	<i>proB</i>
Dehydroproline resistance in <i>putA putP</i>	<i>proP</i>
Deoxy(2)adenosine resistance in <i>deoC</i>	<i>deoD</i>
Deoxyadenosine + fluorouracil resistance in <i>upp</i>	<i>deoA</i>
Deoxyadenosine + fluorouracil resistance in <i>upp</i>	<i>deoD</i>
Deoxydihydroxyphosphonyl methyl fructose resistance	<i>uhpT</i>
Deoxy(3)-3-fluoroglucose-independent utilization of lactate	<i>ptsHIG</i>
Deoxy(3)-3-fluoroglucose-independent utilization of fructose	<i>ptsG</i>
Deoxy(3)-3-fluoroglucose resistance	<i>ptsI</i>
Deoxy(2)galactitol resistance in galactitol utilizer	<i>gatACD</i>
Deoxy(2)galactose resistance	<i>gal</i> operon
Deoxy(2)galactose resistance	<i>galE</i>
Deoxy(2)galactose resistance	<i>galK</i>
Deoxy(2)galactose resistance	<i>galP</i>
Deoxy(2)glucose-resistant utilization of melibiose	<i>melB</i>
Deoxyglucose resistance	<i>manXYZ</i>
Deoxy(2)glucose-6-phosphate resistance	<i>uhpT</i>
Deoxy(2)glucose-resistant fructose utilization	<i>fruA</i>
Deoxy(2)glucose-resistant fructose utilization	<i>ptsG</i>
Deoxy(2)-2-iodoacetamidoglucose resistance	<i>nagE</i>
Diamino(2,6)purine resistance	<i>apt</i>
Diamino(2,6)purine resistance in <i>pnp</i>	<i>apt</i>
Dicyclohexylcarbodiimide resistance in <i>rfa</i>	<i>rfb</i>
Dideoxy(2',3')thymidine resistance	<i>tmk</i>
Dihydropyroline resistance	<i>putP</i>
Dihydroxybutylphosphonate resistance	<i>cls</i>
Dihydroxybutylphosphonate resistance	<i>glpT</i>
Dihydroxybutylphosphonate resistance in <i>glpT</i>	<i>ugpA,B</i>
Dihydroxybutylphosphonate resistance in <i>uhp</i> (Con)	<i>uhpT</i>
Dimethyl sulfoxide resistance	<i>pss</i>
Dinitropyrene resistance	<i>atoB</i>
Dipeptide (valine containing) resistance	<i>dppA</i>
Drug-resistant gene maintenance	<i>dor</i>
Erythromycin growth dependence	<i>rrn</i>
Erythromycin resistance	<i>eryC</i>
Erythromycin resistance	<i>eryD</i>
Erythromycin resistance	<i>mac</i>
Erythromycin resistance	<i>rplD</i>
Erythromycin resistance	<i>rplV</i>
Erythromycin resistance	<i>rplC</i>
Ethanol resistance	<i>pss</i>
Ethionine resistance	<i>metG</i>
Ethionine resistance	<i>metJ</i>
Fluoroacetate resistance	<i>ack</i>
Fluoroacetate resistance	<i>pta</i>
Fluorocitrate resistance	<i>tct</i>
Fluoro(5)cytosine resistance	<i>coda</i>
Fluoro(5)cytosine resistance	<i>cod</i>
Fluorodeoxycytidine resistance	<i>cdd</i>

Selection purpose and technique	Mutant gene
Fluorodeoxycytidine resistance	<i>nupC</i>
Fluorodeoxycytidine resistance	<i>nupG</i>
Fluoro(5)deoxyuridine resistance	<i>tdk</i>
Fluorodeoxyuridine resistance	<i>nupC</i>
Fluorodeoxyuridine resistance	<i>nupG</i>
Fluorodeoxyuridine + uracil resistance in <i>deoA</i>	<i>tdk</i>
Fluoro(2)-L-erythrocitrate resistance	<i>tct</i>
Fluoro-3-hydroxyacetone resistance in <i>uhp</i> (Con)	<i>uhpT</i>
Fluorohydroxyacetone phosphate resistance	<i>ugpAB</i>
Fluorohydroxyacetone phosphate resistance	<i>glpT</i>
Fluoro(3)malate resistance	<i>dct</i>
Fluoro(5)orotic acid resistance	<i>pyrF</i>
Fluoro(5)orotic acid resistance	<i>pyrH</i>
Fluoro(4)phenylalanine resistance	<i>tyrR</i>
Fluoro(4)phenylalanine resistance	<i>pheA</i>
Fluoro(4)phenylalanine resistance	<i>pheR</i>
Fluoro(4)phenylalanine resistance	<i>pheS</i>
Fluoro(4)phenylalanine resistance	<i>pheU</i>
Fluorophenylalanine resistance	<i>aroF</i>
Fluorophenylalanine resistance	<i>aroG</i>
Fluorophenylalanine resistance	<i>aroP</i>
Fluorophenylalanine resistance	<i>tyrA</i>
Fluoro(5)tryptophan resistance	<i>aroP</i>
Fluoro(6)tryptophan resistance	<i>trp</i> (generic)
Fluorotyrosine resistance	<i>tyrR</i>
Fluorotyrosine resistance	<i>tyrS</i>
Fluoro(5)uracil + fluoro(5)uridine resistance	<i>guaB</i>
Fluoro(5)uracil + 5'-AMP resistance in <i>upp</i>	<i>ushA</i>
Fluoro(5)uracil + 5-fluorouridine resistance in <i>udp</i>	<i>pyrH</i>
Fluoro(5)uracil + nucleotide resistance	<i>ompF</i>
Fluoro(5)uracil + nucleotide resistance	<i>ompR</i>
Fluoro(5)uracil + adenosine resistance	<i>udp</i>
Fluorouracil + adenosine resistance in <i>upp deoD xapR</i> (Con)	<i>xapA</i>
Fluoro(5)uracil + adenosine resistance in <i>upp, phoS</i> , or <i>phoT</i>	<i>phoA</i>
Fluoro(5)uracil + adenosine resistance in <i>upp, phoS</i> , or <i>phoT</i>	<i>phoB</i>
Fluoro(5)uracil and 3'-AMP resistance	<i>cpdB</i>
Fluoro(5)uracil + 5'-AMP + 3'-AMP resistance	<i>crp</i>
Fluoro(5)uracil + carbamylaspartate resistance	<i>ubiF</i>
Fluoro(5)uracil resistance	<i>upp</i>
Fluorouracil resistance	<i>nupC</i>
Fluorouracil resistance	<i>nupG</i>
Fluorouracil resistance	<i>pyrH</i>
Fluorouracil resistance	<i>rpoB</i>
Fluoro(5)uridine + uracil resistance	<i>udk</i>
Fluoro(5)uridine resistance	<i>udhA</i>
Fluoro(5)uridine resistance in <i>upp</i>	<i>udk</i>
Fluorouridine resistance	<i>pyrH</i>
Fluorouridine resistance	<i>nupC</i>
Fluorouridine resistance	<i>nupG</i>
Fosfomycin resistance due to increased gene dosage	<i>murZ</i>
Fosfomycin + fructose-6-phosphate resistance	<i>pgi</i>
Fosfomycin resistance	<i>crp</i>
Fosfomycin resistance	<i>cyaA</i>
Fosfomycin resistance	<i>glpT</i>
Fosfomycin resistance	<i>hipA</i>
Fosfomycin resistance	<i>mrb</i>
Fosfomycin resistance	<i>ptsI</i>
Fosfomycin resistance	<i>uhpT</i>
Fucitol resistance in galactitol-utilizing strains	<i>gatACD</i>

Selection purpose and technique	Mutant gene
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglA</i>
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglB</i>
Fucose + arabinose-supported growth in <i>galP</i>	<i>mglC</i>
Fucose resistance (arabinose as C source)	<i>araC</i>
Fusaric acid resistance of Tn10 insertion mutants	<i>tet</i>
Fusidic acid resistance	<i>fusA</i>
Galactose resistance in <i>gale</i>	<i>galK</i>
Galactose resistance in <i>galT</i>	<i>galK</i>
Galactose resistance in <i>galU</i>	<i>gal</i> operon
Galactose resistance in <i>galU</i>	<i>galK</i>
Galactose resistance in <i>galT^{K+E+}/galU galT^{K+E+}</i> merodiploid	<i>galR</i>
Galactose utilization in presence of thiomethylglucoside	<i>gal</i> operon
Gentamicin resistance	<i>rplF</i>
Gentamicin resistance	<i>ubif</i>
Globomicin resistance	<i>dnaE</i>
Globomicin resistance	<i>lpp</i>
Glucarate (D) resistance in <i>ppc</i>	<i>garA</i>
Glucose + gluconate-independent motility	<i>pts</i> (general)
Glucose-resistant satisfaction of <i>trp</i> by indole + 5-methyltryptophan	<i>tna</i>
Glutamate (D) resistance in <i>gltS</i> (increased)	<i>gltS</i>
Glutamine (D) resistance	<i>glnP</i>
Glutamyl(γ)hydrazide resistance	<i>glnF</i>
Glutamyl(γ)hydrazide resistance	<i>glnH</i>
Glutamyl(γ)hydrazide resistance	<i>glnP</i>
Glutamyl(γ)methyl ester resistance	<i>gltX</i>
Glutamyl(γ)methyl ester resistance	<i>meJ</i>
Glutamyl(γ)methyl ester resistance	<i>metK</i>
Glyceraldehyde (DL) 3-phosphate resistance	<i>glpT</i>
Glyceraldehyde (L) 3-phosphate resistance in <i>uhp</i> (Con)	<i>uhpT</i>
Glyceraldehyde (L) resistance	<i>glpF</i>
Glyceraldehyde (L) resistance	<i>glpK</i>
Glycerol 3-phosphorothioate resistance	<i>glpT</i>
Glycine tolerance	<i>qmeACDE</i>
Glycylglycyl-N-phosphonoacetylornithine resistance	<i>argR</i>
Glycylleucine resistance	<i>ilvA</i>
Glycylleucine resistance	<i>ilvB</i>
Glycylleucine resistance	<i>ilvH</i>
Glycylleucine resistance	<i>ilvI</i>
Glycylleucine resistance	<i>oppA</i>
Glycylleucine resistance in <i>ilv</i>	<i>gleR</i>
Glycylglycyl histidinol phosphate ester resistance	<i>oppA</i>
Glycylglycyl-N-phosphonoacetylornithine resistance	<i>oppA</i>
Glyphosate resistance	<i>aroA</i>
Hexuronate resistance in <i>eda</i>	<i>uxaBC</i>
Hexuronate resistance in <i>eda</i>	<i>uxuAB</i>
Homocysteic acid resistance	<i>gltS</i>
Hydrazino (α) imidazole propionic acid resistance	<i>argT</i>
Hydrazino (α) imidazole propionic acid resistance	<i>hisG</i>
Hydrazino (α) imidazole propionic acid resistance	<i>hisJ</i>
Hydrazino (α) imidazole propionic acid resistance	<i>hisQ</i>
Hydrazino (α) imidazole propionic acid resistance in <i>dhuA</i>	<i>hisP</i>
Hydroxy (β) norvaline resistance	<i>metL</i>
Hydroxyaspartate resistance	<i>pan</i>
Hydroxybutylphosphonate resistance in <i>uhp</i> (Con)	<i>uhpT</i>
Hydroxyurea resistance	<i>nrdA</i>

Selection purpose and technique	Mutant gene
Hydroxyurea resistance	<i>nrdB</i>
Indole acrylic acid resistance	<i>aroT</i>
Indolmycin resistance	<i>trpS</i>
Indospicine resistance	<i>argR</i>
Iodoacetylglucosamine resistance	<i>nagA</i>
Iodoacetylglucosamine resistance	<i>nagB</i>
Iodoacetylglucosamine resistance	<i>nagE</i>
Isoniazid resistance	<i>pdx</i>
Kanamycin resistance	<i>atpA–atpE</i>
Kanamycin resistance	<i>cpxA</i>
Kanamycin resistance	<i>ecfB</i>
Kanamycin resistance	<i>hemA</i>
Kanamycin resistance	<i>hemB</i>
Kanamycin resistance	<i>hemL</i>
Kanamycin resistance	<i>topA</i>
Kasugamycin resistance	<i>ksgA</i>
Kasugamycin resistance	<i>ksgB</i>
Kasugamycin resistance	<i>ksgC</i>
Kasugamycin resistance	<i>ksgD</i>
Kasugamycin resistance	<i>rplK</i>
Kasugamycin resistance	<i>rplB</i>
Kasugamycin resistance	<i>rpsN</i>
Kasugamycin resistance	<i>rpsM</i>
Kasugamycin resistance	<i>rpsR</i>
Kasugamycin resistance and dependence	<i>rpsI</i>
Keto(2)butyrate resistance	<i>ilvA</i>
Kirromycin resistance	<i>tufAB</i>
Lambda cII phage + rifampin coresistance	<i>rpoB</i>
Lambda phage + nalidixic acid resistance	<i>crp</i>
Lambda phage + nalidixic acid resistance	<i>cyaA</i>
Levallorphan resistance	<i>lev</i>
Lincomycin resistance	<i>linB</i>
Lincomycin resistance	<i>rplN</i>
Lincomycin resistance	<i>rplO</i>
Lincomycin resistance	<i>rpsG</i>
Lithium-resistant use of proline as C source	<i>putP</i>
Lysine hydroxamate resistance	<i>lysC</i>
Mecillinam resistance (see beta-lactam resistance)	<i>alaS</i>
Mecillinam resistance	<i>argS</i>
Mecillinam resistance	<i>crp</i>
Mecillinam resistance	<i>cyaA</i>
Mecillinam resistance	<i>envB</i>
Mecillinam resistance	<i>mrdA</i>
Mecillinam resistance	<i>mrdB</i>
Mecillinam resistance	<i>mreB</i>
Mecillinam resistance	<i>mreC</i>
Mecillinam resistance	<i>mreD</i>
Menadionine resistance	<i>marA</i>
Mercaptopurine resistance in <i>gpt</i>	<i>hpt</i>
Methionine sulfoximine + methyl(α)methionine resistance	<i>metJ</i>
Methionine sulfoximine resistance	<i>asm</i>
Methionine sulfoximine resistance	<i>glnP</i>
Methionine sulfoximine resistance	<i>metP</i>
Methionine sulfoximine resistance in <i>glnG</i>	<i>glnA</i>
Methylammonium resistance	<i>glnA</i>
Methyl(3)anthranilate resistance	<i>trpE</i>
Methyl(3)anthranilate resistance	<i>aroG</i>

Selection purpose and technique	Mutant gene
Methyl(α)glutamate resistance in <i>gltS</i> (increased)	<i>gltS</i>
Methylglucoside(α)-resistant utilization of lactose	<i>lacI</i> O
Methylglucoside(α)-resistant utilization of maltose	<i>malE</i>
Methylglucoside(α)-resistant utilization of maltose	<i>malF</i>
Methylglucoside(α)-resistant utilization of maltose	<i>malG</i>
Methylglucoside(α)-resistant utilization of maltose	<i>malK</i>
Methylglucoside(α)-resistant utilization of mannitol + lactose	<i>ptsG</i>
Methylglucoside(α) resistance	<i>ptsG</i>
Methylglucoside(α)-resistant utilization of glycerol in $\Delta ptsHI$	<i>crr</i>
Methylglucoside(α)-resistant utilization of lactose in <i>ptsH</i>	<i>lacI</i> , operator
Methylglucoside(α)-resistant utilization of melibiose	<i>mel</i>
Methylglyoxal resistance	<i>gsh</i>
Methyl(2)histidine resistance + aminotriazole resistance	<i>hisR</i>
Methyl methanesulfonate resistance in <i>lon</i>	<i>sulA</i>
Methyl methanesulfonate resistance in <i>lon</i>	<i>ftsZ</i>
Methyl(α)methionine resistance	<i>metA</i>
Methyl(α)methionine resistance	<i>metD</i> (<i>metP</i>)
Methyl(α)methionine resistance	<i>metK</i>
Methyl(6)purine resistance	<i>apt</i>
Methyl(6)purine + hypoxanthine resistance	<i>purA</i>
Methyl(<i>o</i>)threonine resistance	<i>brnQ</i>
Methyl(4)tryptophan resistance in <i>aroP</i>	<i>aroT</i>
Methyl(5)tryptophan resistance	<i>mtr</i>
Methyl(5)tryptophan resistance	<i>aroP</i>
Methyl(5)tryptophan resistance	<i>trp</i> (generic)
Methyl(5)tryptophan resistance	<i>trpE</i>
Methyl(5)tryptophan resistance	<i>trpR</i>
Methyl(5)tryptophan + thierylalanine resistance	<i>aroP</i>
Methyl viologen resistance	<i>mvrA</i>
Methyl viologen resistance (multicopy)	<i>mvrC</i>
Methyl viologen resistance	<i>gor</i>
Metronidazole resistance	<i>nar</i> (general)
Microcin B17 resistance	<i>sbmA</i>
Microcin E492 resistance	<i>semA</i>
Mitomycin C resistance of <i>lexA</i> (Con)	<i>lexA</i>
Mocimycin resistance	<i>tufA,B</i>
Nalidixic acid resistance	<i>hisU</i>
Nalidixic acid resistance	<i>icdE</i>
Nalidixic acid tolerance	<i>slob</i>
Nalidixic acid resistance	<i>gyrA</i>
Nalidixic acid resistance	<i>gyrB</i>
Nalidixic acid resistance	<i>nalB</i>
Nalidixic acid resistance	<i>nalD</i>
Nalidixic acid resistance	<i>purB</i>
Nalidixic acid resistance due to gene dosage	<i>emrB</i>
Neamine resistance	<i>rpsL</i>
Neamine resistance	<i>rpsQ</i>
Neamine resistance	<i>neaB</i>
Negamycin resistance	<i>prfB</i>
Neomycin resistance	<i>atpA-atpE</i>
Neomycin resistance	<i>ecfB</i>
Neomycin resistance	<i>hemA</i>
Neomycin resistance	<i>hemC</i>
Neomycin resistance	<i>hemD</i>
Neomycin resistance	<i>hemE</i>
Neomycin resistance	<i>hemG</i>
Neomycin resistance	<i>metC</i> (<i>ecfA</i>)
Neomycin resistance	<i>topA</i>
Neomycin resistance	<i>ubi</i> (generic)

Selection purpose and technique	Mutant gene
Neutrophil granule protein resistance	<i>pmrA</i>
Nitro(4)pyridine <i>N</i> -oxide resistance	<i>proA</i>
Nitro(4)pyridine <i>N</i> -oxide resistance	<i>proB</i>
Nitro(<i>o</i>)-phenyl galactoside resistance	<i>lacZ</i>
Nitro(<i>o</i>)-phenylthiogalactoside resistance	<i>lacY</i>
Nitro(<i>o</i>)-phenylthiogalactoside resistance in <i>lacI</i> (Con) or <i>lacO</i> (Con)	<i>lacI</i> , operator
Nitrofurantoin resistance	<i>nfnA</i>
Nitrofurantoin resistance	<i>nfnB</i>
Nitrofurantoin resistance in <i>lon</i>	<i>sulA</i>
Nitrofurantoin resistance in <i>lon</i>	<i>ftsZ</i>
Nitrofuranzone resistance	<i>nfsA</i>
Nitrofuranzone resistance	<i>nfsB</i>
Nitrosoguanidine resistance	<i>ada</i>
Nitrosoguanidine resistance	<i>gsh</i> (generic)
Norfloxacin resistance	<i>hipQ</i>
Norleucine resistance	<i>metJ</i>
Norleucine resistance	<i>metK</i>
Norleucine resistance	<i>nol</i>
Norleucylglycyl glycine resistance	<i>oppA</i>
Novobiocin resistance	<i>cysB</i>
Novobiocin resistance	<i>cysE</i>
Novobiocin resistance	<i>gyrB</i>
Novobiocin resistance	<i>nov</i>
Novobiocin resistance	<i>ompA</i>
Oxolinic acid resistance	<i>gyrA</i>
Paromycin resistance or dependence	<i>rpsL</i>
Pentachlorophenol resistance	<i>atpA-atpE</i>
Peten(4)oate resistance in <i>atoC</i> (Con)	<i>atoC</i>
Pentylpantothenamide resistance	<i>pan</i>
Peptide (toxic, valine containing) resistance	<i>pepA</i>
Peptide (toxic, valine containing) resistance	<i>pepD</i>
Peptide (toxic, valine containing) resistance	<i>pepN</i>
Peptide (toxic, valine containing) resistance	<i>pepQ</i>
Peroxide (organic) resistance	<i>oxyR</i>
Phaseolotoxin resistance	<i>oppA</i>
Phenethyl alcohol resistance	<i>dnaB</i>
Phenethyl alcohol resistance	<i>dnaP</i>
Phenethyl alcohol resistance	<i>seCA</i>
Phenethylgalactoside resistance	<i>lacY</i>
Phenethylgalactoside resistance	<i>lacZ</i>
Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	<i>hist</i>
Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	<i>prfA</i>
Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	<i>rpsL</i>
Phenyl galactoside resistance of <i>lacI</i> ^q / <i>lacP lacI</i> (nonsense) <i>supL</i>	<i>lysS</i>
Phenyl galactoside resistance of <i>lacI</i> ^q / <i>lacP lacI</i> (nonsense) <i>supL</i>	<i>strM</i>
Phenyl galactoside resistance of <i>lacI</i> ^q / <i>lacP lacI</i> (nonsense) <i>supL</i>	<i>trmE</i>
Phenyl galactoside resistance	<i>lacY</i>
Phenyl galactoside resistance	<i>lacZ</i>
Phenylalanylleucine resistance	<i>ilvB</i>
Phenylalanylleucine resistance	<i>ilvH</i>
Phenylalanylleucine resistance	<i>ilvI</i>
Plasmid maintenance	<i>polA</i>
Polymyxin resistance	<i>pmrA</i>
Promethazine resistance	<i>lon</i>
Pseudomonic acid resistance	<i>ileS</i>
Psicofuranine resistance	<i>guaAB</i>

Selection purpose and technique	Mutant gene
Psoralen + UV irradiation resistance	<i>puvA</i>
Pyrithiamine resistance	<i>thi</i>
Quinaldic acid resistance of Tn10 insertion mutants	<i>tet</i>
Quinolone resistance	<i>gyrA</i>
Ribitol resistance in <i>araC</i> (Con)	<i>araB</i>
Ribitol resistance in <i>araC</i> (Con)	<i>araC</i>
Rifampin + kasugamycin dependence	<i>ridA</i>
Rifampin dependence	<i>ridB</i>
Rifampin resistance	<i>crp</i>
Rifampin resistance	<i>cyaA</i>
Rifampin resistance	<i>rpoB</i>
Rifampin resistance in <i>rpoB</i> ⁺ / <i>rpoB</i> (<i>rif</i>) diploids	<i>rpoB</i>
Salicylate resistance	<i>pan</i>
Serine (D) resistance	<i>cycA</i>
Serine + methionine + glycine resistance in <i>relA</i>	<i>glyA</i>
Serine hydroxamate resistance	<i>serA</i>
Serine hydroxamate resistance	<i>sers</i>
Serine resistance	<i>sbaA</i>
Serine resistance	<i>thrA</i>
Serine resistance in <i>relA</i>	<i>crp</i>
Serine resistance in <i>relA</i>	<i>cyaA</i>
Serine resistance in <i>relA</i>	<i>relA</i>
Serine resistance in <i>relA</i>	<i>rpoB</i>
Serine resistance in <i>relA</i>	<i>rpoC</i>
Showdomycin resistance	<i>nupC</i>
Showdomycin resistance	<i>pnp</i>
Siderophore–beta-lactam conjugate resistance	<i>cirA</i>
Sorbitol + xylitol resistance	<i>srlA</i>
Sorbose (L) resistance	<i>fruA</i>
Sorbose resistance <i>ptsG</i>	
Spectinomycin resistance	<i>rpsE</i>
Spectinomycin resistance	<i>rrn</i>
Spectinomycin resistance	<i>spcB</i>
Spectinomycin resistance and sucrose dependence	<i>rpsC</i>
Spectinomycin resistance and sucrose dependence	<i>rpsD</i>
Spectinomycin resistance and sucrose dependence	<i>rpSE</i>
Streptolydigin resistance	<i>rpoB</i>
Streptomycin + cAMP resistance	<i>crp</i>
Streptomycin resistance	<i>hem</i> (generic)
Streptomycin resistance	<i>rpsL</i>
Streptomycin resistance	<i>strB</i>
Streptomycin resistance	<i>strC</i>
Streptomycin resistance	<i>strM</i>
Streptomycin resistance	<i>ubiF</i>
Streptomycin resistance	<i>mut</i> (generic)
Streptomycin resistance	<i>topA</i>
Streptovaricin resistance	<i>rpoB</i>
Streptozotocin resistance	<i>fba</i>
Streptozotocin resistance	<i>galT</i>
Streptozotocin resistance	<i>manA</i>
Streptozotocin resistance	<i>nagA</i>
Streptozotocin resistance	<i>nagE</i>
Streptozotocin resistance	<i>pfkA</i>
Streptozotocin resistance	<i>ptsI</i>
Streptozotocin resistance	<i>glpD</i>
Sulfanilamide + hypoxanthine resistance	<i>hpt</i>
Sulfanilamide + hypoxanthine resistance	<i>pspABCDE</i>
Sulfanilamide resistance	<i>folP</i>

Selection purpose and technique	Mutant gene
Sulfanilamide resistance	<i>gpt</i>
Sulfometuron methyl + valine resistance	<i>ilv</i> structural genes
Sulfometuron methyl + valine resistance	<i>ilvG</i>
Sulfonamide resistance	<i>fola</i>
Sulfonamide resistance	<i>pab</i>
Tartrate resistance	<i>dct</i>
Tetracycline resistance	<i>cmlA</i>
Tetracycline resistance	<i>marA</i>
Tetracycline resistance	<i>ompF</i>
Thiaisoleucine resistance	<i>ileS</i>
Thiaisoleucine resistance	<i>ilvU</i>
Thialysine resistance	<i>thrA</i>
Thiazolealanine resistance	<i>hisG</i>
Thiazolealanine resistance	<i>hisR</i>
Thienylalanine resistance	<i>aroP</i>
Thienylalanine resistance	<i>aroG</i>
Thiodigalactoside resistance	<i>lacY</i>
Thio(5)glucose resistance	<i>crr</i>
Thiolactomycin resistance	<i>emrB</i>
Thiolactomycin resistance (due to gene dosage)	<i>fadB</i>
Thiolactomycin resistance (due to gene dosage)	<i>emrB</i>
Thiolutin resistance	<i>tlnA</i>
Thiomaltose resistance	<i>lamB</i>
Thiomaltose resistance	<i>malE</i>
Thiomaltose resistance	<i>malF</i>
Thiomaltose resistance	<i>malG</i>
Thiomaltose resistance	<i>malK</i>
Thiomaltose resistance	<i>malT</i>
Thiomethylgalactoside-independent utilization of galactose in <i>galR</i> (Con)	<i>galR</i>
Thiopeptin resistance	<i>rplE</i>
Thiosine resistance	<i>argP</i>
Thymidine resistance in <i>deoC</i>	<i>deoA</i>
Thymidine resistance in <i>deoC</i>	<i>deoB</i>
Thymineless death prevention by low thymine levels in <i>thyA</i>	<i>deoB</i>
Thymineless death prevention by low thymine levels in <i>thyA</i>	<i>deoC</i>
Thymineless death resistance in <i>thyA</i>	<i>recF</i>
Thymineless death resistance in <i>thyA</i>	<i>recJ</i>
Thymineless death resistance in <i>thyA</i>	<i>recO</i>
Thymineless death resistance in <i>thyA</i>	<i>recQ</i>
Thymineless death resistance in <i>thyA</i>	<i>alaS</i>
Thymineless death resistance in <i>thyA</i>	<i>pheS</i>
Thymineless death resistance in <i>thyA</i>	<i>valS</i>
Tiamulin resistance	<i>rplC</i>
Tiamulin resistance	<i>rplD</i>
Triazole resistance	<i>cysB</i>
Triazole resistance	<i>cysE</i>
Triazole resistance	<i>cysG</i>
Triazole resistance	<i>trzA</i>
Triazole resistance in <i>cysM</i>	<i>cysB</i>
Triazole resistance in <i>cysM</i>	<i>cysE</i>
Triazolealanine + aminotriazole resistance	<i>gyrA</i>
Triazolealanine + aminotriazole resistance	<i>gyrB</i>
Triazolealanine + aminotriazole resistance	<i>his</i> structural genes
Triazolealanine + aminotriazole resistance	<i>hisR</i>

Selection purpose and technique	Mutant gene
Triazolealanine + aminotriazole resistance	<i>hisS</i>
Triazolealanine + aminotriazole resistance	<i>hist</i>
Triazolealanine + aminotriazole resistance	<i>hisU</i>
Triazolealanine + aminotriazole resistance	<i>hisW</i>
Trifluorocitrate resistance	<i>tct</i>
Trifluoroleucine resistance	<i>ftrB</i>
Trifluoroleucine resistance	<i>ileR</i>
Trifluoroleucine resistance	<i>leuA</i>
Trifluoroleucine resistance	<i>leuJ</i>
Trifluoroleucine resistance	<i>leu</i> (generic)
Trifluoroleucine resistance	<i>leuS</i>
Trilysine resistance	<i>oppA</i>
Trimethoprim resistance	<i>folA</i>
Trimethoprim resistance	<i>thyA</i>
Triornithine resistance	<i>oppA</i>
Triornithine resistance in <i>opp</i>	<i>tpp</i>
Tripeptide (toxic amino acid containing) resistance	<i>oppAE</i>
Tripeptide (toxic amino acid containing) resistance	<i>tppA</i>
Tripeptide (toxic amino acid containing) resistance	<i>tppB</i>
Tryptophan analog resistance	<i>aroH</i>
Uncoupler resistances	<i>atpA-atpE</i>
Uridine resistance of <i>thyA</i> <i>deoB</i>	<i>deoR</i>
Valine resistance	<i>ilv</i> structural genes
Valine resistance	<i>ilvB</i>
Valine resistance	<i>ilvF</i>
Valine resistance	<i>ilvG</i>
Valine resistance	<i>ilvH</i>
Valine resistance	<i>ilvI</i>
Valine resistance	<i>ilvJ</i>
Valine resistance	<i>ilvG</i>
Valine resistance	<i>ilvH</i>
Valine resistance	<i>ilvJ</i>
Valine resistance	<i>ilvK</i>
Valine resistance	<i>brnQ</i>
Vinylglycolate resistance	<i>dd</i>
Vinylglycolate resistance	<i>lct</i>
Xylitol resistance	<i>fruA</i>
Xylose resistance in <i>fda</i>	<i>xyLE</i>
Xylose (D) + cAMP resistance	<i>cxm</i>
Resistance to biological agents	
9NA phage resistance	<i>pmi</i>
9NA phage resistance in <i>galE</i>	<i>kdsA</i>
Bf23 phage resistance	<i>btuB</i>
C21 phage resistance	<i>rfaD</i>
Chi phage resistance	<i>fliC</i> (<i>hag</i>)
Chi phage resistance	<i>motA</i>
Chi phage resistance	<i>motB</i>
ES18 phage resistance	<i>fhuA</i>
ES18 phage resistance	<i>prbA,B</i>
ES18 phage resistance	<i>sidK</i>
ES18 phage resistance	<i>tonB</i>
Felix O phage resistance	<i>galE</i>
Felix O phage resistance	<i>galU</i>
Felix O phage resistance	<i>rfaC,D,E,F,H</i>
Filamentous phage tolerance	<i>tolR</i>
Filamentous phage tolerance	<i>tolQ</i>
HK009 phage resistance	<i>prh</i>
HK068 phage resistance	<i>prk</i>
Host range phage (from <i>Serratia marcescens</i>) resistance	<i>ompC</i>
K10 phage resistance	<i>lamB</i>

Selection purpose and technique	Mutant gene
K3 phage resistance	<i>ompA</i>
Lambda + 434 phage resistance	<i>mopA</i>
Lambda + 434 phage resistance	<i>mopB</i>
Lambda cII + rifampin coresistance	<i>rpoB</i>
Lambda mutant infection resistance	<i>gyrB (hisW)</i>
Lambda mutant phage infection, survival of	<i>himA</i>
Lambda mutant phage resistance	<i>hfIC</i>
Lambda mutant phage resistance	<i>hfIK</i>
Lambda mutant phage resistance	<i>hfIX</i>
Lambda mutant prophage induction, survival of	<i>grpD</i>
Lambda mutant prophage induction, survival of	<i>grpE</i>
Lambda phage + nalidixic acid resistance	<i>cpr</i>
Lambda phage + nalidixic acid resistance	<i>cyaA</i>
Lambda phage + 434 phage cross-resistance	<i>rpoB</i>
Lambda phage gamma mutant resistance	<i>polA</i>
Lambda phage induction, resistance to	<i>dnaJ</i>
Lambda phage induction, resistance to	<i>dnaK</i>
Lambda phage resistance	<i>envZ</i>
Lambda phage resistance	<i>gprAB</i>
Lambda phage resistance	<i>lamB</i>
Lambda phage resistance	<i>malK</i>
Lambda phage resistance	<i>matT</i>
Lambda phage resistance	<i>rap</i>
Lambda phage resistance with maltose and arabinose as C sources	<i>cpr</i>
Lambda phage resistance with maltose and arabinose as C sources	<i>cyaA</i>
Lambda prophage induction deficiency during thymine deprivation	<i>recA</i>
Lambda prophage induction, resistance to	<i>rpsJ</i>
Lambda prophage induction, resistance to	<i>rpsM</i>
Lambda prophage induction, survival of	<i>nusA</i>
Lambda prophage induction, survival of	<i>nusB</i>
Lambda <i>sus N7 nin-5</i> resistance in P2 lysogen	<i>rho</i>
Lambda <i>vir</i> resistance after infection with heteromodified lambda <i>cI857</i>	<i>hsd</i>
Lambdoid phage resistance	<i>nusB</i>
Lambdoid phage mixture coinfection resistance	<i>dnaB</i>
Lambdoid phage mixture coinfection resistance	<i>dnaJ</i>
Lambdoid phage mixture coinfection resistance	<i>dnaK</i>
Lambda <i>cI71</i> resistance	<i>rpoD</i>
Lambda <i>Nmar</i> mutant phage resistance	<i>rpoB</i>
Male-specific phage resistance	<i>arcA (fexA)</i>
Me1 phage resistance	<i>envZ</i>
Me1 phage resistance	<i>ompC</i>
Me1 phage resistance	<i>ompF</i>
Me1 phage resistance	<i>ompR</i>
Mu phage lytic growth resistance	<i>himA</i>
Mu phage lytic growth resistance	<i>himD</i>
Mu prophage induction, survival of	<i>himA</i>
Mu prophage induction, survival of	<i>himD</i>
N4 phage resistance	<i>manXYZ</i>
Ox2 phage resistance	<i>ompA</i>
P1 phage resistance	<i>galE</i>
P1 phage resistance	<i>galU</i>
P1 phage resistance	<i>lpcA</i>
P1 phage resistance	<i>rfaD</i>
P1 phage specialized transduction of drug resistance to <i>Salmonella</i> sp.	<i>sspA</i>
P2 <i>vir1</i> phage resistance	<i>rpoA</i>
P2 phage + lambda phage coinfection resistance	<i>dnaJ</i>
P2 phage + lambda phage coinfection resistance	<i>dnaK</i>
P2 phage resistance	<i>rep</i>
P22 phage resistance	<i>galE</i>
P22 phage resistance	<i>pml</i>
P221 phage resistance	<i>praAB</i>
PH105 phage resistance	<i>ompB (ompR of E. coli)</i>
PH105 phage resistance	<i>ompC</i>

Selection purpose and technique	Mutant gene
PH105 phage resistance	<i>ompF</i>
PH105 phage resistance	<i>praAB</i>
PH51 phage resistance	<i>ompB</i> (<i>ompR</i> of <i>E. coli</i>)
PH51 phage resistance	<i>ompC</i>
PH51 phage resistance	<i>ompF</i>
PH51 phage resistance	<i>praAB</i>
PH51 phage resistance	<i>prdB</i>
φX174 phage resistance	<i>phxB</i>
φ80 phage resistance	<i>fhuA</i>
φ80 phage resistance	<i>tonB</i>
Q phage resistance	<i>cpxA</i> (<i>ecfB</i> , <i>ssd</i> , <i>eup</i>)
T-even phage resistance	<i>ompA</i>
T1 phage (UV irradiated) resistance	<i>phr</i>
T1 phage resistance	<i>fhuA</i>
T1 phage resistance	<i>tonB</i>
T2 phage resistance in <i>ompF</i> ⁺ or <i>ompF</i>	<i>fadL</i>
T3 phage resistance	<i>lpcA</i>
T4 mutant phage resistance	<i>lit</i>
T4 phage <i>lig</i> mutant nibbling of colonies yielding <i>lig</i> -overproducing strain	<i>lig</i>
T4 phage <i>lig</i> mutant resistance from <i>lig</i> -overproducing strain	<i>lig</i>
T4 phage resistance	<i>lpcA</i>
T4 phage resistance	<i>lpcB</i>
T4 phage resistance	<i>mopA</i>
T4 phage resistance	<i>mopB</i>
T4 phage resistance	<i>rho</i>
T4 phage resistance	<i>tabC</i>
T4 phage resistance	<i>lit</i>
T4 phage (uracil containing) resistance	<i>ung</i>
T5 phage resistance	<i>fhuA</i>
T6 phage resistance	<i>crp</i>
T6 phage resistance	<i>cyaA</i>
T6 phage resistance	<i>tsx</i>
T7 phage gene 1.2 mutant resistance	<i>optA</i>
T7 phage gene 2 resistance	<i>rpoC</i>
T7 phage resistance	<i>grom</i>
T7 phage resistance	<i>lpcA</i>
T7 phage resistance	<i>lpcB</i>
T7 phage resistance	<i>rpoB</i>
T7 phage resistance	<i>trxA</i>
TC45 phage resistance	<i>phoB</i>
TC45 phage resistance	<i>phoE</i>
TC45 phage resistance	<i>phoR</i>
TC45 phage resistance	<i>phoS</i>
TC45 phage resistance	<i>phoT</i>
TC45 phage resistance	<i>pstABC</i>
TP1 phage resistance	<i>envZ</i>
TuIa phage resistance	<i>envZ</i>
TuIa phage resistance	<i>ompC</i>
TuIa phage resistance	<i>ompF</i>
TuIa phage resistance	<i>ompR</i>
TuIa phage resistance	<i>tolQAB</i>
TuIb phage resistance	<i>ompF</i>
TuII* phage resistance	<i>ompA</i>
U3 phage + K3 phage coresistance	<i>rfaP</i>
U3 phage resistance	<i>galE</i>
U3 phage resistance	<i>galU</i>
U3 phage resistance	<i>pgi</i>
U3 phage resistance	<i>pgm</i>

Selection purpose and technique	Mutant gene
U3 phage resistance	<i>rfa</i> (general)
UV-irradiated lytic phage resistance	<i>uvrA</i>
UV-irradiated lytic phage resistance	<i>uvrB</i>
UV-irradiated lytic phage resistance	<i>uvrC</i>
UV-irradiated lytic phage resistance	<i>uvrD</i>
Resistance to physical extremes	
Cold resistance in <i>rpsE</i> cold-sensitive mutants	<i>rpsB</i>
Cold-resistant growth	<i>crg</i>
Filter retention	<i>fts</i> (generic)
Freeze-thaw resistance	<i>envZ</i>
Gamma irradiation resistance	<i>garA</i>
Gamma irradiation resistance	<i>garB</i>
Growth at 42°C in <i>his</i> -overexpressing strain	<i>his</i> structural genes
Near-UV irradiation resistance	<i>nuvA</i>
Near-UV irradiation resistance	<i>nuvC</i>
Near-UV irradiation resistance	<i>relA</i>
Osmotolerance	<i>crp</i>
Osmotolerance	<i>cyaA</i>
Osmotolerance	<i>osmB</i>
Osmotolerance	<i>proA</i>
Osmotolerance	<i>proB</i>
Phage (UV-irradiated T1) resistance	<i>phr</i>
Psoralen + UV irradiation resistance	<i>puvA</i>
Temperature resistance in <i>rpoD</i> (Ts)	<i>rpoH</i>
Thermotolerance	<i>gyrA</i>
UV light resistance	<i>crp</i>
UV light resistance	<i>cyaA</i>
UV light resistance	<i>envB</i>
UV light resistance	<i>relA</i>
UV irradiation resistance in <i>lon</i>	<i>sula</i>
UV irradiation resistance in <i>lon</i>	<i>ftsZ</i>
UV light + bromodeoxyuridine resistance	<i>tdk</i>
UV light + bromodeoxyuridine resistance	<i>ung</i>
UV light + psoralen resistance	<i>puvA</i>
UV-irradiated lytic phage resistance	<i>uvrA</i>
UV-irradiated lytic phage resistance	<i>uvrB</i>
UV-irradiated lytic phage resistance	<i>uvrC</i>
UV-irradiated lytic phage resistance	<i>uvrD</i>
Movement	
Migration in a chemical gradient	<i>che</i>
Static cultivation (prolonged)	<i>fliC</i>

^aReferences to selections and species used in selections can be found in Table 2. Note that a single selection can give rise to mutations in several distinct genes. Abbreviations: cAMP, cyclic AMP; DAP, diaminopimelate; IS, insertion sequence; CCCP, carbonyl cyanide m-chlorophenylhydrazone, an uncoupling agent. Abbreviations following gene names: (Con), constitutive; (Ts), heat sensitive.

TABLE 2 Genes for which selections exist in *E.coli* and *S. typhimurium*

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>ackA</i>	E, S	Fluoroacetate resistance	96, 281, 463, 797	L
<i>ada</i>	E	Nitrosoguanidine resistance	693	
<i>add</i>	E	Deoxyadenosine + hypoxanthine satisfaction of <i>purB</i> requirement	370	L
<i>add</i>	S	Deoxyadenosine (low) satisfaction of <i>purA</i> requirement	326	L
<i>adhCE</i>	E	Chloracetaldehyde resistance	157	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>adhCE</i>	E	Chlorethanol resistance	157	
<i>adhE</i>	E	Allyl alcohol resistance	476	L
<i>adh</i>	E	Ethanol as C source	132	C
<i>alaS</i>	E	Thymineless death resistance in <i>thyA</i>	394	S
<i>alaS</i>	E	Mecillinam resistance (beta-lactam resistance)	802	S
<i>ampC</i>	E	Ampicillin resistance	139, 570	D
<i>ampC</i>	E	Ampicillin resistance	210, 212, 362	C
<i>amtAB</i>	S	Aminotriazole resistance	828	
<i>apeA</i>	E, S	N-Acetyl-L-phenylalanine-β-naphthyl ester hydrolysis	421, 516	L
<i>apt</i>	E	6-Methylpurine resistance	60	L
<i>apt</i>	E	Adenine resistance in <i>hpt gpt</i>	462	
<i>apt</i>	E	2,6-Diaminopurine resistance in <i>pnp</i>	470	L
<i>apt</i>	E, S	2,6-Diaminopurine resistance	107, 390	L
<i>araB</i>	E	Ribitol resistance from <i>araC</i> (Con)	396	L
<i>araC</i>	E	Fucose resistance (arabinose as C source)	67	C
<i>araC</i>	E	Ribitol resistance from <i>araC</i> (Con)	396	L
<i>arcA</i>	E	Male-specific phage resistance; also called <i>fexA</i>	110, 651, 711	L
<i>argA</i>	E	Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	153	L
<i>argB</i>	E	<i>N</i> -Acetylhistidine + ornithine satisfaction of <i>his</i>	50	C
<i>argB</i>	E	Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	153	L
<i>argC</i>	E	<i>N</i> -Acetylhistidine + ornithine satisfaction of <i>his</i>	50	C
<i>argC</i>	E	Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	153	L
<i>argD</i>	E, S	Proline-independent growth of Δ <i>proAB</i>	62, 403	L
<i>argD</i>	E	Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>)	153	L
<i>argE</i>	E	<i>N</i> -Acetylhistidine + ornithine satisfaction of <i>his</i>	50	C
<i>argE</i>	E	Acetylnorvaline resistance in <i>argR</i> (Con)	402	L
<i>argH</i>	E	<i>N</i> -Acetylhistidine + ornithine satisfaction of <i>his</i>	50	C
<i>argP</i>	E	Canavanine resistance	483, 655	L
<i>argP</i>	E	Thiosine resistance	293, 716	L
<i>argP</i>	E	Canavanine + thiouracil resistance	605	L
<i>argR</i>	E, S	Arginine-resistant, proline-independent growth of Δ <i>pro</i>	62, 403	C
<i>argR</i>	E	Acetylhistidine satisfaction of <i>his</i>	49, 50, 403	C
<i>argR</i>	E	Acetylmethionine satisfaction of <i>met</i>	402	C
<i>argR</i>	E	Indospicine resistance	454	C
<i>argR</i>	E	Canavanine resistance	482, 523	C
<i>argR</i>	E	Glycylglycyl- <i>N</i> -phosphonoacetylornithine resistance	604	C
<i>argR</i>	E	Canavanine + azauracil resistance	605	C
<i>argR</i>	E	Canavanine + thiouracil resistance	605	C
<i>argR</i>	E	Acetylnorvaline resistance in <i>argR</i> (Con)	402	
<i>argS</i>	E	Canavanine resistance	322	S
<i>argS</i>	E	Mecillinam resistance (beta-lactam resistance)	802	S
<i>argT</i>	S	Hydrazino (α) imidazole propionic acid resistance	432, 433	
<i>aroA</i>	E, S	Glyphosate resistance	512, 731; Comai ^d	C, D
<i>aroF</i>	E	Amino(4)phenylalanine resistance	504	C
<i>aroF</i>	S	Fluoro(4)phenylalanine resistance	270, 729	C
<i>aroG</i>	E, S	Methyl(3)anthranilate resistance	307	FBI, S
<i>aroG</i>	E	Thienylalanine resistance	215	FBI, S
<i>aroG</i>	E	Fluorophenylalanine resistance	351	FBI, S
<i>aroH</i>	E	Tryptophan analog resistance	637	FBI, S
<i>aroP</i>	E, S	Methyl(5)tryptophan resistance	12, 94, 288, 303, 393, 437–439	L, C
<i>aroP</i>	E, S	Fluoro(5)tryptophan resistance	12, 94, 288, 303, 393, 437–439	L
<i>aroP</i>	E, S	Azaserine resistance	12, 94, 288, 303,	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
			393, 437–439, 836, 837	
<i>aroP</i>	E, S	Thienylalanine resistance	12, 94, 288, 303, 393, 437–439	L
<i>aroP</i>	E, S	Fluorophenylalanine resistance	12, 94, 288, 303, 393, 437–439	L
<i>aroP</i>	E, S	Azaleucine resistance	12, 94, 288, 303, 393, 437–439	L
<i>aroP</i>	E, S	Methyl(5)tryptophan + thienylalanine resistance	12, 94, 288, 303, 393, 437–439	L
<i>aroT</i>	E, S	Indole acrylic acid resistance	769	L
<i>aroT</i>	E	Methyl(4)tryptophan resistance in <i>aroP</i>	594	L
<i>asm</i>	S	Methionine sulfoxamine resistance	188	
<i>atoB</i>	S	Dinitropyrene resistance	590	L
<i>atoC</i>	E	Butyrate as C source in <i>fadR</i> (Con)	602	C
<i>atoC</i>	E	Valerate as C source in <i>fadR</i> (Con)	602	C
<i>atoC</i>	E	Penten(4)oate resistance in <i>atoC</i> (Con)	669	L
<i>atpA-atpE</i>	E	Uncoupler resistances, including DCCD	225, 226, 229, 355, 537	L
<i>atpA-atpE</i>	E	Tributyl tin resistance	355	
<i>atpA-atpE</i>	E	CCCP resistance	355	
<i>atpA-atpE</i>	E	Pentachlorophenol resistance	355	
<i>atpA-atpE</i>	E	Auroventin resistance	451, 685, 818	L
<i>atpA-atpE</i>	E	Kanamycin resistance	768	L
<i>atpA-atpE</i>	E	Neomycin resistance	392	L
<i>atpA-atpE</i>	E	Azide resistance	355	
<i>atr</i>	S	Acid resistance	233	
<i>azaAB</i>	E	Azaserine resistance	836	
<i>azl</i>	E	Azaleucine resistance	610	
<i>bglBC</i>	E	Arbutin as C source	523, 616, 640	
<i>bglBC</i>	E	Salicin as C source	523, 616, 640	
<i>bglT</i>	E	Methyl(β)glucoside as C source	686	C
<i>bio operon</i>	E	Dehydrobiotin resistance	206	
<i>bioP</i>	E	Dehydrobiotin resistance	206	L
<i>birA</i>	E	Dehydrobiotin resistance	206, 597	
<i>brnQ</i>	E	Methyl(<i>o</i>)threonine resistance	278	L
<i>brnQ</i>	E	Valine resistance	277	L
<i>btuB</i>	E	Colicin E3 tolerance	46, 47, 109, 284, 388, 620	
<i>btuB</i>	E, S	Bf23 phage resistance	46, 47, 109, 284, 388, 528, 620	
<i>bymA</i>	E	Maltose utilization in <i>malT</i>	327	
<i>cbt</i>	E	Chloroacetate(β) resistance	68	L
<i>cbt</i>	E	Colicin B tolerance	623	L
<i>cbt</i>	E	Colicin D tolerance	623	L
<i>cdd</i>	E	Aza(5)-2'-deoxycytidine resistance	196	L
<i>cdd</i>	E, S	Fluoro(5)deoxycytidine resistance	53, 579	L
<i>celABCDF</i>	E	Cellobiose as C source	426	
<i>cet</i>	E	Colicin E2 tolerance	201	
<i>che</i>	S	Migration in a chemotaxis gradient	34	
<i>chlABDEG</i>	E, S	Chlorate resistance	2, 121, 122, 228, 266, 523, 743, 744	L
<i>chlABDE</i>	E	Lactate + fumarate as anaerobic energy source	436	L
<i>chlC</i>	S	Chlorate resistance	45	L
<i>chlE</i>	E	Lactate + nitrate as anaerobic energy source	799	
<i>chlE</i>	E	Biotin sulfoxide utilization in <i>chl bio</i>	180	
<i>cirA</i>	E	Colicin I resistance	77, 93, 620	L
<i>cirA</i>	E	Siderophore–beta-lactam conjugate resistance	93	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>cit</i>	E	Citrate as C source	290	
<i>cls</i>	E	Dihydroxy(3,4)butyl-1-phosphonate resistance	345	L
<i>cmlA</i>	E	Chloramphenicol resistance	48	
<i>cmlA</i>	E	Tetracycline resistance	523, 638	
<i>coaA</i>	E	Coenzyme A feedback resistance	789, 790	FBI, S
<i>codA(cod)</i>	E, S	Fluoro(5)cytosine resistance	4, 54	L
<i>corABCD</i>	E, S	Cobalt resistance	262, 600, 817	
<i>corABCD</i>	E	Manganese resistance	600	
<i>corABCD</i>	E	Nickel resistance	817	
<i>cpd</i>	S	Succinate as improved C source	8, 530	L
<i>cpd</i>	S	Citrate as C source in presence of low cAMP	8	L
<i>cpdB</i>	E	Fluorouracil(5) and 3'-AMP resistance	51	L
<i>cpxA</i>	E	Amikacin resistance	629	
<i>cpxA</i>	E	Colicin A tolerance	629	
<i>cpxA</i>	E	Kanamycin resistance	768	
<i>cpxA</i>	E	Q phage resistance	508, 711	
<i>cpxA</i>	E	Serine (L) as C source	567	
<i>crg</i>	E	Cold-resistant growth	398	
<i>crp</i>	S	Fosfomycin resistance	10	L
<i>crp</i>	E	Serine (L) resistance in <i>relA</i>	167	L
<i>crp</i>	E	Lambda phage + nalidixic acid resistance	429	L
<i>crp</i>	E	Streptomycin + cAMP resistance	31	L
<i>crp</i>	E	Lambda phage resistance with maltose and arabinose as C sources	92, 766	L
<i>crp</i>	E	cAMP + glucose 6-phosphate resistance	1a	L
<i>crp</i>	E	cAMP + glucose 6-phosphate + D-xylose + L-arabinose resistance	1a	L
<i>crp</i>	E	Fluorouracil(5) + 5'-AMP + 3'-AMP resistance	52	L
<i>crp</i>	E	Osmotolerance	282	L
<i>crp</i>	E	Beta-lactam resistance	362	L
<i>crp</i>	E	Mecillinam resistance	25, 168, 857	L
<i>crp</i>	E	UV light resistance	627	L
<i>crp</i>	E	Rifampin resistance	413	L
<i>crp</i>	E	T6 phage resistance	6	L
<i>crr</i>	E	Thio(5)glucose resistance	419	L
<i>crr</i>	S	Methylglucoside(α)-resistant utilization of glycerol in <i>ptsHI</i>	563	L
<i>cxm</i>	E	Xylose (D) + cAMP resistance	1a	L
<i>cyaA</i>	E	Lambda phage resistance with maltose and arabinose as C sources	92	L
<i>cyaA</i>	E	Lambda phage + nalidixic acid resistance	429	L
<i>cyaA</i>	E	Serine (L) resistance in <i>relA</i>	167	L
<i>cyaA</i>	S	Fosfomycin resistance	10	L
<i>cyaA</i>	E	Osmotolerance	282	L
<i>cyaA</i>	E	Beta-lactam resistance	362	L
<i>cyaA</i>	E	Mecillinam resistance	25, 168, 857	L
<i>cyaA</i>	E	UV light resistance	627	L
<i>cyaA</i>	E	Rifampin resistance	413	L
<i>cyaA</i>	E	T6 phage resistance	6	L
<i>cycA</i>	E	Cycloserine (D) resistance	150, 646, 813	L
<i>cycA</i>	E	Serine (D) resistance	689	L
<i>cysA</i>	S	Chromate resistance	581	L
<i>cysA</i>	E	Selenate resistance	728	L
<i>cysA</i>	S	Azaserine resistance	340, 689	L
<i>cysB</i>	S	Chromate resistance	340	L
<i>cysB</i>	S	Azide resistance	227	C
<i>cysB</i>	S	Selenate resistance	339	L
<i>cysB</i>	E	Novobiocin resistance	631	L
<i>cysB</i>	S	Triazole resistance	227	C
<i>cysB</i>	S	Azaserine resistance	340	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>cysC</i>	S	Azaserine resistance	340	L
<i>cysC</i>	S	Chromate resistance	581	L
<i>cysD</i>	S	Azaserine resistance	340	L
<i>cysD</i>	S	Chromate resistance	581	L
<i>cysE</i>	S	Triazole resistance in <i>cysM</i>	717, 825	C
<i>cysE</i>	S	Triazole resistance	341	C
<i>cysE</i>	E	Novobiocin resistance	631	L
<i>cysG</i>	S	Azaserine resistance	340	L
<i>cysH</i>	S	Azaserine resistance	340	L
<i>cysH</i>	S	Chromate resistance	581	L
<i>cysI</i>	S	Azaserine resistance	340	L
<i>cysI</i>	S	Chromate resistance	581	L
<i>cysJ</i>	S	Azaserine resistance	340	L
<i>cysJ</i>	S	Chromate resistance	581	L
<i>cysK</i>	S, E	Azaserine resistance	340, 827	L
<i>cysK</i>	S	Azide resistance	147, 227	L
<i>cysK</i>	E	Selenate resistance	230	L
<i>cysK</i>	E, S	Triazole resistance	147, 227, 826, 827	L, C
<i>cysK</i>	E	Selenite resistance	230	L
<i>cysL</i>	S	Selenate resistance	673, 674	
<i>cysL</i>	S	Chromate + selenate resistance	338	
<i>cysM</i>	S	Azaserine resistance	340	L
<i>cytR</i>	E	Uridine as C source, improved utilization	546	
<i>dadA</i>	E, S	Chloro(β)-D-alanine resistance	832	L
<i>dadA</i>	E, S	D-Amino acid satisfaction of amino acid auxotrophy	428, 831	C
<i>dcm</i>	E	Aza(5)cytidine resistance	247	L
<i>dct</i>	E	Fluoro(3)malate resistance	401	L
<i>dct</i>	E	Tartrate resistance	687	L
<i>dct</i>	S	Malate (L) as improved C source	745	D
<i>deoA</i>	E	Deoxyadenosine + fluorouracil resistance in <i>upp</i>	3	L
<i>deoA</i>	E	Thymidine resistance in <i>deoC</i>	3	
<i>deoB</i>	E	Thymidine resistance in <i>deoC</i>	3, 651	L
<i>deoB</i>	E, S	Thymineless death prevention by low thymine levels in <i>thyA</i>	71, 471	
<i>deoC</i>	E	Thymineless death prevention by low thymine levels in <i>thyA</i>	325, 471, 651	L
<i>deoD</i>	E	Deoxy(2)adenosine resistance in <i>deoC</i>	651	L
<i>deoD</i>	E	Deoxyadenosine + fluorouracil resistance in <i>upp</i>	3	L
<i>deoR</i>	E	Inosine as improved C source	546	C
<i>deoR</i>	S	Diamino(2,6)purine satisfaction of purine auxotrophy	251	
<i>deoR</i>	S	Uridine resistance in <i>thyA deoB</i>	71	
<i>dgd</i>	E	Arabitol (D) as C source in <i>fuc</i>	849	
<i>dgoR</i>	E	Keto(2)-3-deoxygalactonate as C source	144	C
<i>dgsA</i>	E	Glucosamine as anaerobic C source in <i>ptsG</i>	652	L
<i>dhuA</i>	E, S	Histidine (D) satisfaction of <i>his</i> auxotrophs	422, 428, 546	
<i>dhuA</i>	S	Azaserine + tryptophan resistance	432	
<i>dld</i>	E	Vinylglycolate resistance	696	
<i>dml</i>	S	Malate (D) as C source	737	
<i>dnaB</i>	E	Lambdoid phage mixture coinfection resistance	259	
<i>dnaB</i>	E	Phenethyl alcohol resistance	494	
<i>dnaE</i>	E	Acriflavin (acridine) resistance	553–555	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>dnaE</i>	E	Globomycin resistance	668	S
<i>dnaJ</i>	E	Lambda phage induction, resistance to	667	S
<i>dnaJ</i>	E	Lambdoid phage mixture coinfection resistance	257, 259	S
<i>dnaJ</i>	E	P2 phage + lambda phage coinfection resistance	753	S
<i>dnaK</i>	E	Lambda phage induction, resistance to	667	S
<i>dnaK</i>	E	Lambdoid phage mixture coinfection resistance	257, 259	S
<i>dnaK</i>	E	P2 phage + lambda phage coinfection resistance	753	S
<i>dnaP</i>	E	Phenethyl alcohol resistance	809	
<i>dor</i>	S	Drug-resistant gene maintenance	814	
<i>dppA</i>	E, S	Bacilysin resistance	1	L
<i>dppA</i>	E, S	Bialaphos resistance	1	L
<i>dppA</i>	E, S	Valine-containing dipeptide resistance	1	L
<i>dppA</i>	E	Lysyl-2-aminoxypropionate resistance	603	L
<i>dppA</i>	E	Glycylleucine resistance	269	L
<i>dppA</i>	E	Phenylalanylleucine resistance	269	L
<i>dppA</i>	E	Glycylvaline resistance in <i>opp</i>	178	L
<i>dsdA</i>	E	Sucrose as C source	5	L
<i>dsdC</i>	E	Sucrose as C source	5	
<i>ebgA</i>	E	Lactose utilization in $\Delta lacZ$	118	Q
<i>ecfB</i>	E	Serine (L) as C source	567, 768	
<i>ecfB</i>	E	Kanamycin resistance	567, 768	
<i>ecfB</i>	E	Neomycin resistance	608	
<i>ecfB</i>	E	Colicin K resistance	608	
<i>edd</i>	E	Gluconate as C source in <i>eda</i>	239, 240	L
<i>emrB</i>	E	CCCP resistance due to gene dosage	472	D
<i>emrB</i>	E	Nalidixic acid resistance due to gene dosage	472	D
<i>emrB</i>	E	Thiolactomycin resistance due to gene dosage	250	D
<i>emrB</i>	E	Thiolactomycin resistance	250	
<i>envB</i>	E, S	Mecillinam resistance	359, 587	
<i>envB</i>	E	UV light resistance	24	
<i>envM</i>	E, S	Diazoborine resistance	63	S
<i>envZ</i>	E	Ampicillin resistance	362, 363	
<i>envZ</i>	E	Colicin L tolerance	812	
<i>envZ</i>	E	Lambda phage resistance	812	
<i>envZ</i>	E	Me1 phage resistance	801	
<i>envZ</i>	E	TPI phage resistance	812	
<i>envZ</i>	E	TuIa phage resistance	801	
<i>envZ</i>	E	Freeze-thaw resistance	112	
<i>envZ</i>	E	Colicin (multiple) resistance	626	
<i>eryC</i>	E	Erythromycin resistance	599	
<i>eryD</i>	E	Erythromycin resistance	830	
<i>exbB</i>	E	Albomycin resistance	205	
<i>exbB</i>	E	Colicin I resistance	283, 624	
<i>exbB</i>	E	Colicin (other) resistance	283, 624	
<i>exbC</i>	E	Colicin B resistance	624	
<i>exbC</i>	E	Colicin I resistance	283, 624	
<i>exbC</i>	E	Colicin (other) resistance	283, 624	
<i>exuR</i>	E	Aldohexuronate resistance in <i>eda</i>	612	
<i>exuR</i>	E	Hexuronate as C course in noninducible <i>exuR eda</i>	612	C
<i>exuT</i>	E	Aldohexuronate resistance in <i>eda</i>	612	L
<i>fadB</i>	E	Thiolactomycin resistance (due to gene dosage)	778	D
<i>fadL</i>	E	T2 phage resistance in <i>ompF^r</i> or <i>ompF</i>	70, 534	L
<i>fadR</i>	E	Decanoate as C source	713	L
<i>fba</i>	E	Streptozotocin resistance	456	L
<i>fepABCDG</i>	E	Colicin B resistance	623, 624	L
<i>fepABDCG</i>	E	Colicin D resistance	623	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>fhuA</i>	E, S	Albomycin resistance	87, 387, 388, 478, 479	S
<i>fhuA</i>	S	ES18 phage resistance	87, 478, 479	S
<i>fhuA</i>	E	T1 phage resistance	93, 409; Lin et al. ^e	S, L
<i>fhuA</i>	E	T5 phage resistance	93, 151, 387; Lin et al. ^e	L
<i>fhuA</i>	E	Φ80 phage resistance	151, 387, 409; Lin et al. ^e	L, S
<i>fhuA</i>	E	Colicin M resistance	151, 387, 409	L, S
<i>fhuA</i>	E	Beta-lactam conjugate resistance	93	L
<i>fhuB</i>	E	Albomycin resistance	618	L
<i>fliC</i>	E, S	Chi phage resistance	347, 349, 416, 417, 513, 710	
<i>fliC</i>	S	Prolonged static cultivation	249	
<i>flrB</i>	S	Trifluoroleucine resistance	115, 117	
<i>folA</i>	E	Sulfonamide resistance	607, 697	S, D
<i>folA</i>	S	Trimethoprim resistance	405, 654, 718, 719	S, D
<i>folP</i>	E	Sulfonamide resistance	756	S
<i>fruA</i>	E	Deoxy(2)glucose-independent fructose utilization	11	
<i>fruA</i>	E	Xylitol resistance	614, 639	L
<i>fruA</i>	E	Sorbose (L) resistance	715	L
<i>fts</i> (generic)	E	Filter retention	55	
<i>ftsZ</i>	E	UV irradiation resistance in <i>lon</i>	373	
<i>ftsZ</i>	E	Methyl methanesulfonate resistance in <i>lon</i>	373	
<i>ftsZ</i>	E	Nitrofurantoin resistance in <i>lon</i>	252	
<i>fucA</i>	E	Propanediol as C source	287	
<i>fucA</i>	E	Ethyleneglycol as C source in propanediol utilizer	79	
<i>fucA</i>	E	Fucose (L) as C source in propanediol utilizer	287	
<i>fucA</i>	E	Xylitol as C source in propanediol utilizer	848	
<i>fucA</i>	E	Arabinose (D) as C source	450	
<i>fur</i>	E	Manganese resistance	300	C
<i>fusA</i>	E	Fusidic acid resistance	65, 434, 695, 761	S
<i>gabC</i>	E	Aminobutyrate as N source	197	
<i>gadS</i>	E	Glutamate as C source	292	L
<i>gal</i> operon	E	Galactose utilization in the presence of thiomethylglucoside	636	D
<i>gal</i> operon	S	Deoxy(2)galactose resistance	9, 552	L
<i>gal</i> operon	E	Galactose resistance in <i>galU</i>	664	L
<i>galC</i>	S	Glucose as C source in $\Delta ptsHI$	613	
<i>galE</i>	E, S	P1 phage infection of <i>Salmonella</i> sp. monitored by drug resistance	527	L
<i>galE</i>	E	U3 phage resistance	816	L
<i>galE</i>	S	Deoxy(2)galactose resistance	408	L
<i>galE</i>	S	Felix O phage resistance	334, 527, 591, 833	L
<i>galE</i>	S	P22 phage resistance	334, 527, 591, 833	L
<i>galK</i>	S	Deoxy(2)galactose resistance	408	L
<i>galK</i>	E, S	Galactose resistance in <i>galE</i>	569, 752	L
<i>galK</i>	E	Galactose resistance in <i>galT</i>	859	L
<i>galK</i>	E	Galactose resistance in <i>galU</i>	664	L
<i>galP</i>	S	Deoxy(2)galactose resistance	552	L
<i>galR</i>	E	Thiomethylgalactoside-independent utilization of galactose in <i>galR</i> (Con)	108	
<i>galR</i>	S	Glucose utilization in $\Delta ptsHI$	613	
<i>galR</i>	E	Galactose resistance in <i>galT^{K+E+}/galT^{K+E+} galU</i>	664	
<i>galT</i>	E	Streptozotocin resistance	456	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>galU</i>	E	Ampicillin resistance	212	L
<i>galU</i>	E	P1 phage resistance	242	L
<i>galU</i>	E	U3 phage resistance	816	L
<i>galU</i>	S	Felix O phage resistance	334	L
<i>garA</i>	S	Gamma irradiation resistance	346	
<i>garA</i>	E	Glucarate (D) resistance in <i>ppc</i>	647	L
<i>garB</i>	S	Gamma irradiation resistance	346	
<i>gatACD</i>	E	Fucitol resistance in galactitol-utilizing strains	184	L
<i>gatACD</i>	E	Deoxy(2)galactitol resistance in galactitol-utilizing strains	184	L
<i>gatACD</i>	E	Arabitol utilization	466, 845	
<i>gatACD</i>	E	Ribitol utilization	466, 845	
<i>gatACD</i>	E	Arbitol (D) resistance	639	L
<i>gleR</i>	S	Glycylleucine resistance in <i>ilv</i>	580	
<i>glnA</i>	S	Histidine(D) + glycylglutamine satisfaction of <i>his</i> auxotrophs	819	L
<i>glnA</i>	E	Methylammonium resistance	694	S
<i>glnA</i>	E	Methionine sulfoxamine resistance in <i>glnG</i>	592	C
<i>glnA</i>	S	Glutamyl(γ)hydrazide resistance	518; Miller ^f	S
<i>glnF</i>	S	Glutamyl(γ)hydrazide resistance	433	L
<i>glnH</i>	S	Glutamyl(γ)hydrazide resistance	433	L
<i>glnP</i>	E	Glutamine as C source	433, 501, 820	
<i>glnP</i>	E, S	Methionine sulfoxamine resistance	37, 501	L
<i>glnP</i>	E	Glutamyl(γ)hydrazide resistance	501, 821	L
<i>glnP</i>	E	Glutamine (D) resistance	501	L
<i>glnV</i>	E	Caffeine resistance	185	S
<i>glpD</i>	E	Streptozotocin resistance	456	L
<i>glpF</i>	E	Glyceraldehyde (L) resistance	762	L
<i>glpK</i>	E	Glyceraldehyde (L) resistance	762	L
<i>glpK</i>	E, S	Methyl(α)glucoside-resistant glycerol utilization in <i>ptsI</i>	64, 665	
<i>glpT</i>	E, S	Fosfomycin resistance	10, 29, 313, 707, 800	L
<i>glpT</i>	E	Glyceraldehyde (DL) 3-phosphate resistance	762	L
<i>glpT</i>	E	Arsenate resistance	838	L
<i>glpT</i>	E	Dihydroxybutyl phosphonate resistance	285, 453	L
<i>glpT</i>	E	Fluorohydroxyacetone phosphate resistance	515	L
<i>glpT</i>	E	Chlorohydroxyacetone phosphate resistance	515	L
<i>glpT</i>	E	Glycerol 3-phosphothioate resistance	295	L
<i>gltA</i>	E	Improved growth in <i>icd</i>	435	L
<i>gltH</i>	E	Glutamate as C source	496, 497, 687	
<i>gltR</i>	E	Glutamate as C source at 42°C	497	
<i>gltS</i>	E	Glutamate as C source	496, 687	Q
<i>gltS</i>	E	Glutamate as C source	496, 497, 687	
<i>gltS</i>	E	Glutamate (D) resistance in <i>gltS</i> (increased)	525, 716	L
<i>gltS</i>	E	Methyl(α)glutamate resistance in <i>gltS</i> (increased)	391, 525, 716	L
<i>gltS</i>	E	Homocysteic acid resistance	213	L
<i>gltX</i>	E	Glutamyl- γ -methyl ester resistance	425	
<i>glyA</i>	E	Serine + methionine + glycine resistance in <i>relA</i>	783	
<i>gntM</i>	E	Glycerol + gluconate as C source in <i>eda</i>	217	L
<i>gntR</i>	E	Acetate + gluconate as C source in <i>ppc</i>	39	
<i>gntS</i>	E	Acetate + gluconate as C source in <i>ppc</i>	39	L
<i>gor</i>	E	Methyl viologen tolerance	430	L
<i>gprAB</i>	E	Lambda phage resistance	578, 670	
<i>gpt</i>	S	Aza(8)guanine resistance	272, 764	L
<i>gpt</i>	E	Sulfanilamide resistance in presence of guanine	97	L
<i>groM</i>	E	T7 phage resistance	427	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>grpD</i>	E	Lambda mutant prophage induction, survival of	667	
<i>grpE</i>	E	Lambda mutant prophage induction, survival of	667	
<i>gsh</i> (generic)	E	Nitrosoguanidine resistance	693	L
<i>gsh</i> (generic)	E	Methylglyoxal resistance	548	
<i>gshAB</i>	E, S	Selenite resistance	423	L
<i>guaAB</i>	E	Psicofuranine resistance	779	
<i>guaB</i>	S	Fluoro(5)uracil + fluoro(5)uridine resistance	367	L
<i>gurBCD</i>	E	Glycerol + methylglucuronide a C source in <i>eda</i>	572	L
<i>gyrA</i>	E, S	Triazolealanine + aminotriazole resistance	660	S
<i>gyrA</i>	E, S	Nalidixic acid resistance	200, 298	S
<i>gyrA</i>	E	Quinolone resistance	860	S
<i>gyrA</i>	E	Oxolinic acid resistance	734	S
<i>gyrA</i>	E	Glucosides (β) as C source	194	
<i>gyrA</i>	S	Thermotolerance	200	
<i>gyrB</i>	S	Triazolealanine + aminotriazole resistance	660	S
<i>gyrB</i>	E	Aminotriazole resistance in <i>relA</i>	772	S
<i>gyrB</i>	E	Novobiocin resistance	255	S
<i>gyrB</i>	E	Coumermycin resistance	181, 255, 593	D, S
<i>gyrB</i>	E	Chlorobiocin resistance	589	
<i>gyrB</i>	E	Glucosides (β) as C source	194	
<i>gyrB</i>	E	Lambda mutant infection resistance	521	
<i>gyrB</i>	E	Nalidixic acid resistance	333, 855	S
<i>hem</i> (generic)	E	Streptomycin resistance	57	L
<i>hemA</i>	E	Kanamycin resistance	585	L
<i>hemA</i>	E, S	Neomycin resistance	683	L
<i>hemB</i>	E	Kanamycin resistance	585	L
<i>hemB</i>	E	Kanamycin-resistant, hemin-supported growth of <i>hemA</i>	507	L
<i>hemB</i>	E	Colicin "K-type" tolerance	83	
<i>hemC</i>	S	Neomycin resistance	682	L
<i>hemD</i>	S	Neomycin resistance	681	L
<i>hemE</i>	S	Neomycin resistance	189, 680	L
<i>hemBCF</i>	E	Plate method	506	L
<i>hemG</i>	E	Neomycin resistance	679	L
<i>hemL</i>	E	Kanamycin resistance	350	L
<i>hflC</i>	E	Lambda mutant phage resistance	56	
<i>hflK</i>	E	Lambda mutant phage resistance	56	
<i>hflX</i>	E	Lambda mutant phage resistance	56	
<i>himA</i>	E	Mu prophage induction, survival of	520, 522	
<i>himA</i>	E	Mu phage lytic growth resistance	81	
<i>himA</i>	E	Lambda mutant phage infection, survival of	519, 521	
<i>himA</i> (<i>himC</i>)	E	Lambda mutant phage resistance	519, 521	
<i>himD</i>	E	Mu prophage induction, survival of	520, 522	
<i>himD</i>	E	Mu phage lytic growth resistance	81	
<i>hipA</i>	E	Cycloserine resistance	541	
<i>hipA</i>	E	Ampicillin resistance	541	
<i>hipA</i>	E	Fosfomycin resistance	541	
<i>hipQ</i>	E	Norfloxacin resistance	842	
<i>hipQ</i>	E	Ampicillin resistance	842	
<i>his</i> structural genes	E, S	Triazolealanine + aminotriazole resistance	98, 126, 658	C, Q
<i>his</i> structural genes	S	Aminotriazole resistance	20, 21	D
<i>his</i> structural genes	S	Growth at 42°C in <i>his</i> -overexpressing strain	804	Q
<i>his</i> structural genes	S	Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C	374, 375	Q
<i>his</i> structural genes	S	Histidine (D) satisfaction of <i>his</i> auxotroph requirement	374, 375	Q

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>hisG</i>	E, S	Thiazolealanine resistance	540, 698, 824	S, FBI
<i>hisG</i>	S	Hydrazino (α) imidazole propionic acid resistance	699	S, FBI
<i>hisG</i>	S	Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C	374, 375	L
<i>hisG</i>	S	Histidine (D) satisfaction of <i>his</i> auxotroph requirement	374, 375	L
<i>hisG</i>	E	Histidine-resistant adenine \rightarrow guanine nucleotide conversion in <i>deoD purF add</i>	33	S, FBI
<i>hisJ</i>	S	Hydrazino (α) imidazole propionic acid resistance	13, 15	L
<i>hisJ</i>	S	Azaserine + tryptophan resistance in <i>dhuA</i>	15, 432	
<i>hisP</i>	S	Hydrazino (α) imidazole propionic acid resistance in <i>dhuA</i>	14, 15	L
<i>hisP</i>	S	Arginine as N source	13, 15, 432	D
<i>hisQ</i>	S	Hydrazino (α) imidazole propionic acid resistance	13, 15	L
<i>hisR</i>	S	Triazolealanine + aminotriazole resistance	658	Q
<i>hisR</i>	S	Thiazolealanine resistance	706	Q
<i>hisR</i>	S	Methyl(2)histidine resistance + aminotriazole resistance	658	Q
<i>hisS</i>	S	Triazolealanine + aminotriazole resistance	658	S
<i>hisS</i>	S	Thiazolealanine resistance	657	S
<i>hisT</i>	E, S	Triazolealanine + aminotriazole resistance	98, 148, 658, 705, 784	L
<i>hisT</i>	E	Azaleucine resistance	98, 784	L
<i>hisT</i>	E	Serine resistance	98, 784	L
<i>hisT</i>	S	Amino(3)tyrosine resistance	148, 658, 705	L
<i>hisT</i>	S	Thialysine resistance	148, 658, 705	L
<i>hisT</i>	S	Trifluoroleucine resistance	148, 658, 705	L
<i>hisT</i>	S	Norleucine resistance	148, 658, 705	L
<i>hisT</i>	S	Hydroxy (β) leucine resistance	148, 658, 705	L
<i>hisT</i>	E	Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	747	
<i>hisU</i>	S, E	Triazolealanine + aminotriazole resistance	23, 660	
<i>hisU</i>	S	Nalidixic acid resistance	593, 660	
<i>hisW</i>	S, E	Triazolealanine + aminotriazole resistance	23	
<i>hisW</i>	S	Coumermycin resistance	593, 660	
<i>hpt</i>	E	Mercapto(6)purine resistance in <i>gpt</i>	371	
<i>hpt</i>	E	Sulfanilamide + hypoxanthine resistance	97	L
<i>hsd</i>	E	Lambda <i>vir</i> resistance after infection with heteromodified lambda cI857	183	L
<i>hsd</i>	S	Lactose utilization after conjugation of <i>F'lac</i> into <i>Salmonella</i> sp.	103	L
<i>hut</i>	S	Histidine as sole N or C source	509	
<i>icdE</i>	E, S	Nalidixic acid resistance	91, 311	L
<i>iclR</i>	E	Butyrate or valerate as better C source	602	C
<i>iclR</i>	E	Glucose or glycerol as C source in <i>ppc</i>	488	
<i>ileR</i>	E	Trifluoroleucine resistance	412	
<i>ileS</i>	E	Pseudomonic acid resistance	858	S
<i>ileS</i>	E	Thiaisoleucine resistance	757	S
<i>ilv structural genes</i>	S	Sulfometuron methyl + valine resistance	Epelbaum et al. ⁸	C
<i>ilv structural genes</i>	E	Aminobutyrate resistance	633, 780	C
<i>ilv structural genes</i>	E	Valine resistance	268	C
<i>ilv structural genes</i>	S	Cyclopentane glycine resistance	586	C
<i>ilvA</i>	S	Cyclopentane glycine resistance	586	S, FBI
<i>ilvA</i>	E	Glycylleucine resistance	806	S, FBI

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>ilvA</i>	S	Threonine as sole N source	106	S, FBI
<i>ilvA</i>	E	Growth on minimal medium of <i>ilvA</i> ⁺ (multicopy) <i>ilvDC</i> <i>hisT</i> overcoming 2-ketobutyrate accumulation	231	L
<i>ilvB</i>	E	Aminobutyrate resistance	633, 780	S, FBI
<i>ilvB</i>	E	Valine resistance	633, 755	S, FBI
<i>ilvB</i>	E	Glyclleucine resistance	269	S
<i>ilvB</i>	E	Phenylalanylleucine resistance	269	S
<i>ilvF</i>	E	Valine resistance	174, 610	G
<i>ilvG</i>	E, S	Sulfometuron methyl + valine resistance	441, 851; Epelbaum et al. ^g	S, Q
<i>ilvG</i>	E	Valine resistance	221, 448, 720	G
<i>ilvH</i>	E	Aminobutyrate resistance	633, 780	S, FBI
<i>ilvH</i>	E	Valine resistance	633, 755	S, FBI
<i>ilvH</i>	E	Glyclleucine resistance	269	S
<i>ilvH</i>	E	Phenylalanylleucine resistance	269	S
<i>ilvI</i>	E	Aminobutyrate resistance	633, 780	S
<i>ilvI</i>	E	Valine resistance	633, 755	
<i>ilvI</i>	E	Glyclleucine resistance	269	
<i>ilvI</i>	E	Phenylalanylleucine resistance	269	
<i>ilvJ</i>	E	Valine resistance	174, 361, 649	G
<i>ilvU</i>	E	Thiaisoleucine resistance	222	
<i>kdgR</i>	E	Keto(2)-3-deoxygluconate as C source	377, 615	C
<i>kdsA</i>	S	9NA phage resistance in <i>galE</i>	452, 641	
<i>ksgA</i>	E	Kasugamycin resistance	312, 726, 793	L
<i>ksgB</i>	E	Kasugamycin resistance	238, 726	
<i>ksgC</i>	E	Kasugamycin resistance	861	
<i>ksgD</i>	E	Kasugamycin resistance	238	
<i>lac</i>	E	Growth in lactose-limited chemostats	330	D
<i>lacI</i> , operator	E	Methyl(α)glucoside-resistant utilization of lactose in <i>ptsH</i>	665	C
<i>lacI</i> , operator	E	Raffinose as C source	459	C
<i>lacI</i> , operator	E	Neolactose as C source	459	C
<i>lacI</i> , operator	E	Phenyl galactoside as C source	523	C
<i>lacI</i> , operator	E	Lactobionic acid as C source	440	C
<i>lacI</i> , operator	E	Lactitol as C source	457	C
<i>lacI</i> , operator	E	Melibiose as C source	475	C
<i>lacI</i> , operator	E	Melibiose as C source and acetyl(<i>N</i>)lactonate as N source	475	C
<i>lacI</i> , operator	E	Lactobionic acid as C source	474	
<i>lacI</i> , operator	E	Acetyl(<i>N</i>)lactonate as N source	474	Q
<i>lacI</i> , operator	E	Nitro(<i>o</i>)-phenylthiogalactoside resistance in <i>lacI</i> (Con) or <i>lacO</i> (Con)	543, 571	Q
<i>lacI</i> , operator	E	Methyl(α)glucoside-resistant lactose utilization	406	C
<i>lacY</i>	E	Nitro(<i>o</i>)-phenylthiogalactoside resistance	523, 543, 721	L
<i>lacY</i>	E	Phenyl galactoside resistance	376	L
<i>lacY</i>	E	Phenethyllyl galactoside resistance	376	L
<i>lacY</i>	E	Arabinose (L) growth in the presence of <i>lac</i> operon inducer	812	L
<i>lacY</i>	E	Thiodigalactoside resistance	241	
<i>lacZ</i>	E	Lactobionic acid as C source	440	D
<i>lacZ</i>	E	Phenyl galactoside resistance	376, 500	L
<i>lacZ</i>	E	Phenethyllyl galactoside resistance	376, 500	L
<i>lacZ</i>	E	Nitro(<i>o</i>)-phenyl galactoside resistance	376, 500	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>lamB</i>	E	Lambda phage resistance	88, 134, 135, 253, 644, 766	L, S
<i>lamB</i>	E	K10 phage resistance	644	
<i>lamB</i>	E	Thio(5)maltose resistance	223	L
<i>lct</i>	E	Vinylglycolate resistance	696	
<i>leuA</i>	S	Trifluoroleucine resistance	115	FBI, S
<i>leuJ</i>	E	Trifluoroleucine resistance	575	
<i>leu</i>	S	Trifluoroleucine resistance	115, 116	C
(structural genes)				
<i>leuS</i>	S, E	Azaleucine resistance	477, 514	S
<i>leuS</i>	S	Trifluoroleucine resistance	7	S
<i>leuW</i>	E	Calmodulin inhibitor resistance	129	S
<i>lev</i>	E	Levallorphan resistance	164	
<i>lexA</i>	E	Mitomycin C resistance of <i>recA</i> (SOS-induced) <i>sfi</i> <i>lexA3</i> (Con)	538	L
<i>lig</i>	E	T4 phage <i>lig</i> mutant nibbling of colonies yielding <i>lig</i> overproducer	254	Q
<i>lig</i>	E	T4 phage <i>lig</i> mutant resistance from <i>lig</i> overproducer	254	L
<i>linB</i>	E	Lincomycin resistance	26, 343	
<i>lit</i>	E	T4 mutant phage resistance	143	
<i>livG</i>	E	Azaleucine resistance	303, 561	L
<i>livH</i>	E	Valine resistance in <i>leu</i>	17, 595	L
<i>livH</i>	E	Azaleucine resistance	561	L
<i>livJ</i>	E	Valine resistance in <i>leu</i>	17, 595	L
<i>livK</i>	E	Valine resistance in <i>leu</i>	17, 595	L
<i>lon</i>	E, S	Chlorpromazine resistance	198, 529	L
<i>lon</i>	E	Promethazine resistance	529	L
<i>lpp</i>	E	Globomycin resistance	140, 344, 854, 868	L
<i>lpcA</i>	E	T3 phage resistance	792	L
<i>lpcA</i>	E	T4 phage resistance	792	L
<i>lpcA</i>	E	T7 phage resistance	792	L
<i>lpcA</i>	E	P1 phage resistance	40, 41	
<i>lpcB</i>	E	T4 phage resistance	760	
<i>lpcB</i>	E	T7 phage resistance	760	
<i>lrp</i>	E	Leucine (D) satisfaction of <i>leu</i> auxotrophs	18, 428	
<i>lysC</i>	E	Aminoethylcysteine (thialysine) resistance	82, 765	S, FBI
<i>lysC</i>	E	Lysine hydroxamate resistance	82, 765	S, FBI
<i>lysP</i>	E	Aminoethylcysteine (thialysine) resistance	611, 736	L
<i>lysS</i>	E	Aminoethylcysteine (thialysine) resistance	323	S
<i>lysS</i>	E	Phenyl galactoside resistance of <i>lacI</i> ^q <i>lacI</i> (nonsense) <i>lacP supL</i>	748	
<i>lyt</i>	E	Beta-lactam tolerance	700	
<i>mac</i>	E	Erythromycin growth dependence	725	
<i>malE</i>	E, S	Methylglucoside(α)-resistant utilization of maltose	665	
<i>malE</i>	E	Thio(5)maltose resistance	223	L
<i>malF</i>	E, S	Methylglucoside(α)-resistant utilization of maltose	665	
<i>malF</i>	E	Thio(5)maltose resistance	223	L
<i>malG</i>	E, S	Methylglucoside(α)-resistant utilization of maltose	665	
<i>malG</i>	E	Thio(5)maltose resistance	223	L
<i>malK</i>	E	Lambda phage resistance	766	L
<i>malK</i>	E, S	Methylglucoside(α)-resistant utilization of maltose	177, 665	
<i>malK</i>	E	Thio(5)maltose resistance	223	L
<i>malP</i>	E	Maltose as C source in <i>malT</i>	327	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>malQ</i>	E	Maltose as C source in <i>malT</i>	327	
<i>malT</i>	E	Lambda phage resistance	766	L
<i>malT</i>	E	Thiomaltose resistance	223	L
<i>manA</i>	E	Streptozotocin resistance	456	
<i>manC</i>	E	Lyxose (D) as C source	738	
<i>manXYZ</i>	E	Phage N4 resistance	410	
<i>manXYZ</i>	E	Deoxyglucose resistance	158, 379	L
<i>marA</i>	E	Menadionine resistance	274	
<i>marA</i>	E	Chloramphenicol resistance	286	
<i>marA</i>	E	Tetracycline resistance	286, 329	
<i>mbrABCD</i>	E	Camphor resistance	776, 777	
<i>mDOB</i>	E	Arbutin resistance in <i>dkg</i>	360	L
<i>mel</i> (generic)	E	Raffinose as C source in <i>lacI</i>	459	
<i>mel</i> (generic)	S	Methylglucoside(α)-resistant utilization of melibiose	665	
<i>melB</i>	E	Deoxy(2)glucose-resistant utilization of melibiose	431	S
<i>melB</i>	E	Lithium-resistant utilization of melibiose	397	S
<i>metA</i>	S	Methyl(α)methionine resistance	127, 447	FBI, S
<i>metC</i> (<i>ecfA?</i>)	E	Neomycin resistance	464	
<i>metC</i> (<i>ecfA?</i>)	E	Colicin K resistance	465	
<i>metC</i> (<i>ecfA?</i>)	E	Chloro(β)alanine resistance	832	
<i>metG</i>	E	Ethionine resistance	28	S
<i>metJ</i>	E, S	Ethionine resistance	447	
<i>metJ</i>	E	Glutamyl- γ -methyl ester resistance	425	S
<i>metJ</i>	E, S	Norleucine resistance	128	
<i>metJ</i>	E	Methionine sulfoximine + methyl(α)methionine resistance	386	S
<i>metK</i>	E, S	Ethionine resistance	275, 289, 447, 735	S
<i>metK</i>	E	Glutamyl- γ -methyl ester resistance	425	S
<i>metK</i>	E, S	Norleucine resistance	128, 447, 735	S
<i>metK</i>	S	Methyl(α)methionine resistance	447, 735	S
<i>metL</i>	E	Hydroxy (β) norvaline resistance	138	S, FBI
<i>metPD</i>	E, S	Methyl(α)methionine resistance	37, 38, 386	L
<i>metPD</i>	E, S	Methionine sulfoximine resistance	37, 38, 386	L
<i>mglA</i>	E	Fucose + arabinose-supported growth in <i>galP</i>	209, 613	
<i>mglB</i>	E	Fucose + arabinose-supported growth in <i>galP</i>	209, 613	
<i>mglC</i>	E	Fucose + arabinose-supported growth in <i>galP</i>	209, 613	
<i>mglD</i>	E	Methyl- β -galactoside-supported growth	645	C
<i>mng</i>	E	Manganese resistance	708	
<i>mopA</i> (<i>groEL</i>)	E	T4 phage resistance	258	S
<i>mopA</i> (<i>groEL</i>)	E	Lambda + 434 phage resistance	258	S
<i>mopB</i> (<i>groES</i>)	E	T4 phage resistance	258	S
<i>mopB</i> (<i>groES</i>)	E	Lambda + 434 phage resistance	258	S
<i>motAB</i>	E	Chi phage resistance	349, 709, 710	
<i>mrb</i>	E	Fosfomycin resistance	800	
<i>mrdA</i>	E	Mecillinam resistance	759	
<i>mrdB</i>	E	Mecillinam resistance	358, 502, 759	
<i>mrcBCD</i>	E	Mecillinam resistance	582, 807	
<i>mtLA</i>	E	Arabinitol (D) resistance	614	L
<i>mtLC</i>	E	Mannitol (limiting) as C source	722	C
<i>mtr</i>	E	Methyl(5)tryptophan resistance	305, 320, 523	L
<i>murZ</i>	E	Fosfomycin resistance due to increased gene dosage	499	D

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>mut</i> (generic)	E	Streptomycin resistance	309	
<i>mut</i> (generic)	E	Azaserine resistance	703	
<i>mut</i> (generic)	E	Chemostat growth	152	
<i>mutH</i>	E	Amino(2)purine resistance in <i>dam</i>	267	L
<i>mutL</i>	E	Amino(2)purine resistance in <i>dam</i>	267	L
<i>mutS</i>	E	Amino(2)purine resistance in <i>dam</i>	267	L
<i>mvrC</i>	E	Methyl viologen resistance	532	D
<i>nadB</i>	S	Amino(6)nicotinamide resistance	142, 336	S
<i>nadD</i>	S	Amino(6)nicotinamide resistance	336, 337	L
<i>nagA</i>	E	Streptozotocin resistance	456	L
<i>nagA</i>	E	Iodoacetylglucosamine resistance	823	L
<i>nagB</i>	E	Iodoacetylglucosamine resistance	823	L
<i>nagE</i>	E	Streptozotocin resistance	456	L
<i>nagE</i>	E	Iodoacetylglucosamine resistance	823	L
<i>nagE</i>	E	Deoxy(2)-2-iodoacetamideoglucose resistance	379	L
<i>nalB</i>	E	Nalidixic acid resistance	298	
<i>nalD</i>	E	Nalidixic acid resistance	333	
<i>nar</i> (general)	E	Metronidazole resistance	677	L
<i>narC</i>	E	Chlorate resistance	266, 280	L
<i>narG</i>	E	Chlorate resistance	739	L
<i>narH</i>	E	Chlorate resistance	739	L
<i>ndk</i>	S	Aza(8)guanine resistance	264, 650	
<i>neaB</i>	E, S	Neamine resistance	119, 182, 495	
<i>nek</i>	E	Aminoglycoside resistance	27, 342	
<i>nfnA</i>	E	Nitrofurantoin resistance	684	
<i>nfnB</i>	E	Nitrofurantoin resistance	684	
<i>nfsA</i>	E	Nitrofuranzone resistance	90, 505	
<i>nfsB</i>	E	Nitrofuranzone resistance	90, 505	
<i>nhaA</i>	E	Lithium resistance (multicopy)	628	D
<i>nol</i>	S	Norleucine resistance	324	
<i>nov</i>	E	Novobiocin resistance	630	
<i>nrdA</i>	E	Hydroxyurea resistance	609	D
<i>nrdB</i>	E	Hydroxyurea resistance	609	D
<i>nupC</i>	E	Showdomycin resistance	415, 545	L
<i>nupC</i>	E	Fluorouracil resistance	544	L
<i>nupC</i>	E	Fluorodeoxyuridine resistance	545	L
<i>nupC</i>	E	Fluoruridine resistance	544	L
<i>nupC</i>	E	Fluorodeoxycytidine resistance	544	L
<i>nupG</i>	E	Fluorouracil resistance	544	L
<i>nupG</i>	E	Fluorodeoxyuridine resistance	545	L
<i>nupG</i>	E	Fluorouridine resistance	544	L
<i>nupG</i>	E	Fluorodeoxycytidine resistance	544	L
<i>nusA</i>	E	Lambda prophage induction, survival of	244	
<i>nusB</i>	E	Lambda prophage induction, survival of	245, 260	
<i>nusB</i>	E	Lambdoid phage resistance	260	
<i>nuvA</i>	E, S	Near-UV irradiation resistance	424, 468, 767	L
<i>nuvC</i>	E	Near-UV irradiation resistance	663	
<i>ompA</i>	E	K3 phage resistance	306, 489, 491, 493	L
<i>ompA</i>	E	T-even-like phage resistance	199, 533, 535	S
<i>ompA</i>	E	TuII* phage resistance	171, 314, 493	L
<i>ompA</i>	E	Ox2 phage resistance	199, 493, 642	
<i>ompA</i>	E	Bacteriocin JF246 resistance	124, 491	
<i>ompA</i>	S	Bacteriocin 4-59 resistance	741	L
<i>ompA</i>	E	Colicin K tolerance	491	
<i>ompA</i>	E	Colicin L tolerance	491	
<i>ompA</i>	E	Chelator resistance	493	
<i>ompA</i>	E	Novobiocin resistance	493	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>ompB</i>	S	PH51 phage resistance	372	
<i>ompB</i>	S	PH105 phage resistance	372	
<i>ompC</i>	E	Me1 phage resistance	791, 801	L
<i>ompC</i>	E	Tula phage resistance	801	L
<i>ompC</i>	S	PH51 phage resistance	372	L
<i>ompC</i>	S	PH105 phage resistance	372	L
<i>ompC</i>	E	Host range <i>Serratia marcescens</i> phage resistance	702	
<i>ompD</i>	S	PH51 phage resistance	741	L
<i>ompD</i>	S	Bacteriocin 4-59 resistance	741	L
<i>ompF</i>	E	Beta-lactam (ampicillin, cefoxitin) resistance	362, 363	L
<i>ompF</i>	E	Chloramphenicol resistance	235, 523	L
<i>ompF</i>	E	Tetracycline resistance	235, 523	L
<i>ompF</i>	E	Fluoro(5)uracil + nucleotide resistance	52	L
<i>ompF</i>	E	Colicin A tolerance	125, 235	
<i>ompF</i>	E	Cloacin DF13 resistance	846	L
<i>ompF</i>	E	Colicin L tolerance	235, 291	L
<i>ompF</i>	E	Colicin K tolerance	235	L
<i>ompF</i>	E	Colicin E2 tolerance	235	
<i>ompF</i>	E	Colicin E3 tolerance	235	
<i>ompF</i>	E	Me1 phage resistance	801	L
<i>ompF</i>	E	Tula phage resistance	801	L
<i>ompF</i>	E	TuIb phage resistance	237	
<i>ompF</i>	S	PH51 phage resistance	372	L
<i>ompF</i>	S	PH105 phage resistance	372	L
<i>ompF</i>	E	Copper resistance in <i>ompC</i>	480	
<i>ompR</i>	E	Me1 phage resistance	801	
<i>ompR</i>	E	TuIa phage resistance	801	
<i>ompR</i>	E	Copper resistance	52, 625	
<i>ompR</i>	E	Beta-lactam (ampicillin, cefoxitin) resistance	362, 363	L
<i>ompR</i>	E	Chloramphenicol resistance	625	
<i>ompR</i>	E	Fluoro(5)uracil + nucleotide resistance	52	
<i>oppA</i>	E, S	Triornithine resistance	43, 317	L
<i>oppA</i>	E	Glycylleucine resistance	806	L
<i>oppA</i>	E	Alanyl-2-aminopropionate resistance	603	L
<i>oppA</i>	E, S	Tritysine resistance	317	L
<i>oppA</i>	E, S	Norleucylglycyl glycine resistance	317	L
<i>oppA</i>	S	Glycylglycyl histidinol phosphate ester resistance	317	L
<i>oppA</i>	E, S	Phaseolotoxin resistance	733	L
<i>oppA</i>	E	Tripeptide (toxic amino acid containing) resistance	604	L
<i>oppA</i>	E	Glycylglycyl-N-S-(phosphonoacetyl)-L-ornithine resistance	604	L
<i>oppE</i>	E	Tripeptide (toxic amino acid containing) resistance	22	L
<i>optA</i>	E	T7 phage gene 1.2 mutant resistance	666	
<i>osmB</i>	E	Osmotolerance	384	L
<i>osmZ</i>	E	Arbutin as C source	179	
<i>osmZ</i>	E	Salicin as C source	179	
<i>oxyR</i>	E, S	Peroxide resistance	131	C
<i>pab</i>	E	Sulfonamide resistance	97	C
<i>pan</i>	E	Salicylate resistance	481	C
<i>pan</i>	E	Hydroxyaspartate resistance	701	C
<i>pan</i>	E	Pentylpantothenamide resistance	136	C
<i>pdx</i>	E	Isoniazid resistance	186	C
<i>pepA</i>	S	Alafosfalin resistance	263	L
<i>pepA</i>	E, S	Peptide (toxic, valine containing) resistance in <i>pepN</i>	517	L
<i>pepD</i>	E, S	Peptide (toxic, valine containing) resistance in <i>pepN</i> <i>pepA</i>	517	L
<i>pepN</i>	E, S	Albomycin resistance	86	L
<i>pepN</i>	E, S	Peptide (toxic, valine containing) resistance	517	L
<i>pepN</i>	E, S	Indicator plate	445	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>pepQ</i>	E, S	Peptide (toxic, valine containing) resistance	517	L
<i>pfkA</i>	E	Streptozotocin resistance	456	L
<i>pgi</i>	E	U3 phage resistance	816	L
<i>pgi</i>	E	Fosfomycin + fructose-6-phosphate resistance	243	L
<i>pgm</i>	E	U3 phage resistance	816	L
<i>pheA</i>	E	Fluoro(4)phenylalanine resistance	351, 564	C, FBI
<i>pheR</i>	S	Fluoro(4)phenylalanine resistance	271	C
<i>pheS</i>	E	Fluoro(4)phenylalanine resistance	78, 218, 395	S
<i>pheS</i>	E	Thymineless death resistance in <i>thyA</i>	394	S
<i>pheU</i>	S	Fluoro(4)phenylalanine resistance	729	
<i>pho</i>	S	Glycerol(β)-phosphate as C source in the presence of high phosphate	407	C
<i>phoA</i>	E	Fluoro(5)uracil + adenosine resistance in <i>upp</i> , <i>phoS</i> , or <i>phoT</i>	315	
<i>phoA</i>	E	Glycerol(β)-phosphate as C source in the presence of high phosphate	773	C
<i>phoA</i>	E	Glycerol(β)-phosphate resistance in <i>glpD</i>	678	
<i>phoB</i>	E	Tellurite resistance	770	
<i>phoB</i>	E	TC45 phage resistance	771	L
<i>phoB</i>	E	Fluoro(5)uracil + adenosine resistance in <i>upp</i> , <i>phoS</i> , or <i>phoT</i>	316	
<i>phoE</i>	E	Acid resistance	659	D
<i>phoE</i>	E	TC45 phage resistance	420, 771	S, L
<i>phoR</i>	E	Arsenate resistance	852	
<i>phoR</i>	E	Glycerol(β)-phosphate as C source in the presence of high phosphate	204, 838	
<i>phoR</i>	E	TC45 phage resistance	621	S
<i>phoS</i>	E	Arsenate resistance	852	
<i>phoS</i>	E	Glycerol(β)-phosphate as C source in the presence of high phosphate	204, 838	
<i>phoS</i>	E	TC45 phage resistance	621	S
<i>phoT</i>	E	Arsenate resistance	852	
<i>phoT</i>	E	Glycerol(β)-phosphate as C source in the presence of high phosphate	204, 838	
<i>phoT</i>	E	TC45 phage resistance	621	S
<i>phr</i>	E	T1 phage (UV irradiated) resistance	332	L
<i>phxB</i>	E	ϕ X174 phage resistance	547	L
<i>pit</i>	E	Arsenate resistance	59, 727	L
<i>pldA</i>	E	Actinomycin D resistance in the presence of EDTA	301, 805	L
<i>pmi</i>	S	P22 phage resistance	656, 833	L
<i>pmi</i>	S	9NA phage resistance	656, 833	L
<i>pmrA</i>	E, S	Polymyxin resistance	219, 297, 485, 785–788	
<i>pmrA</i>	S	Neutrophil granule protein resistance	219	
<i>pncA</i>	E, S	Amino(6)nicotinamide resistance	234, 455, 822	L
<i>pncA</i>	E	Nicotinamide as sole N source	598	Q
<i>pncB</i>	E, S	Amino(6)nicotinamide resistance	234, 455	L
<i>pncB</i>	E, S	Amino(6)nicotinate resistance	234, 455	L
<i>pncX</i>	S	Amino(6)nicotinamide resistance	336	
<i>pnp</i>	E	Showdomycin resistance	58	
<i>polA</i>	E	Lambda γ mutant phage resistance	867	L
<i>praA,B</i>	S	P221 phage resistance	576, 674	L
<i>praA,B</i>	S	PH51 phage resistance	576	L
<i>praA,B</i>	S	PH105 phage resistance	576	L
<i>prbA,B</i>	S	ES18 phage resistance	674	

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>prdB</i>	S	PH51 phage resistance	674	
<i>prfA</i>	E	Phenylgalactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	747	
<i>prfB</i>	E	Negamycin resistance	145	
<i>prh</i>	S	HK009 phage resistance	674	
<i>prk</i>	S	HK068 phage resistance	674	
<i>proAB</i>	S	Osmotolerance	155	
<i>proA</i>	E	Nitro(4)pyridine <i>N</i> -oxide resistance	62, 222, 321	L
<i>proB</i>	E, S	Dehydroproline resistance	62, 155, 635	FBI, S
<i>proB</i>	E	Nitro(4)pyridine <i>N</i> -oxide resistance	62, 222, 321	
<i>proB</i>	E, S	Azetidine carboxylate resistance	62, 155, 635	FBI, S
<i>proP</i>	E, S	Dehydroproline resistance in <i>putA putP</i>	156, 732	L
<i>proU</i>	S	Dehydroproline + azetidine carboxylate resistance at high osmolarity in <i>putA putP</i>	156	L
<i>prp</i>	E	Propionate as C source	400	Q
<i>pspABCDE</i>	E	Sulfanilamide + hypoxanthine resistance	97	
<i>pss</i>	E	Ethanol resistance	133	
<i>pss</i>	E	Dimethyl sulfoxide resistance	133	
<i>pstABC5</i>	E	Arsenate resistance	727, 838	L
<i>pstABC5</i>	E	TC45 phage resistance	621	S
<i>pta</i>	S	Fluoroacetate resistance	96, 281, 463, 797	
<i>pts</i> (general)	E	Glucose + gluconate-independent motility	30	
<i>ptsG</i>	E	Methyl(α)-glucoside resistance	102, 104	
<i>ptsG</i>	E	Sorbose resistance	715	L
<i>ptsG</i>	E, S	Deoxy(2)glucose-independent utilization of fructose	418, 510	L
<i>ptsG</i>	E, S	Deoxy(3)-3-fluoroglucose-independent utilization of fructose	418, 510	L
<i>ptsG</i>	E	Methyl(α)-glucoside-independent lactose + mannitol utilization	80	L
<i>ptsG</i>	E	Glucosamine as C source	379	
<i>ptsG</i>	E	Mannose as C source	379	
<i>ptsHI</i>	E, S	Deoxy(3)-3-fluoroglucose-independent utilization of lactate	510	L
<i>ptsHI</i>	E, S	Fosfomycin resistance	146, 800	L
<i>ptsHI</i>	E	Streptozotocin resistance	16; Freitag ^h	L
<i>ptsI</i>	E	Ampicillin resistance	212	
<i>ptsI</i>	S	Deoxy(3)-3-fluoroglucose resistance	510	L
<i>purA</i>	E	Methyl(6)purine + hypoxanthine resistance	60	
<i>purB</i>	E	Nalidixic acid resistance	310	L
<i>purR</i>	E	Adenine resistance in <i>hpt gpt</i>	461, 462	
<i>putA</i>	E, S	Azetidine carboxylic acid resistance	511, 635, 775	L
<i>putAP</i>	S	Baikain resistance in constitutive background	187	L
<i>putA</i>	S	Proline as N source with glucose as C source	566	
<i>putP</i>	E, S	Dehydroproline resistance	193, 511, 635, 732, 775, 843	L
<i>putP</i>	E, S	Azetidine carboxylic acid resistance	193, 511, 635, 775, 843	L
<i>putP</i>	S	Lithium-resistant proline utilization as C source	551	S
<i>puvA</i>	E	Psoralen + UV irradiation resistance	328	C
<i>pyrB</i>	S	Arginine-independent growth of <i>pyrH</i> in the presence of uracil	366	L
<i>pyrC</i>	S	Arginine-independent growth of <i>pyrH</i> in the presence of uracil	366	L
<i>pyrD</i>	S	Arginine-independent growth of <i>pyrH</i> in the presence of uracil	366	L
<i>pyrF</i>	E	Fluoro(5)orotic acid resistance	74	L
<i>pyrH</i>	S	Fluoro(5)orotic acid resistance	865	C
<i>pyrH</i>	S	Fluorouracil resistance	385	C
<i>pyrH</i>	S	Fluorouridine resistance	385	C

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>pyrH</i>	E	Fluoro(5)uracil + 5-fluorouridine resistance in <i>udp</i>	606	
<i>qmeACDE</i>	E	Glycine tolerance	829	
<i>rap</i>	E	Lambda phage resistance	279	
<i>recA</i>	E	Lambda prophage induction deficiency during thymine deprivation	190	
<i>recF</i>	E	Thymineless death resistance in <i>thyA</i>	558	
<i>recJ</i>	E	Thymineless death resistance in <i>thyA</i>	558	
<i>recO</i>	E	Thymineless death resistance in <i>thyA</i>	558	
<i>recQ</i>	E	Thymineless death resistance in <i>thyA</i>	557	
<i>relA</i>	E	UV (near) irradiation resistance	632	
<i>relA</i>	E	Serine resistance in <i>relA</i>	167	L
<i>rep</i>	E	P2 phage resistance	113	
<i>rfa</i> (general)	E, S	U3 and FO phage resistance	35, 484, 486, 588, 833	
<i>rfa</i> (general)	E, S	Ampicillin resistance	212, 550, 562	
<i>rfa</i> (general)	S	Hemin satisfaction of <i>hemA</i> auxotrophy	364	
<i>rfa</i> (general)	S	Cephalothin resistance	562	
<i>rfa</i> (general)	S	Bacitracin resistance	562	
<i>rfaCDEF</i>	S	FO phage resistance	676	
<i>rfaD</i>	E	C21 phage resistance	141	
<i>rfaD</i>	E	P1 phage resistance	141	
<i>rfaH</i>	S	FO phage resistance	458, 675	
<i>rfaP</i>	E	U3 phage + K3 phage coresistance	601	
<i>rfb</i>	S	DCCD resistance in <i>rfa</i>	833	
<i>rho</i>	E	T4 phage resistance	740	
<i>rho</i>	E	Lambda <i>sus N7 nin-5</i> resistance in P2 lysogen	352, 353	
<i>rho</i>	E, S	Polarity suppression of <i>gal</i> leader insertion	169, 331	
<i>ridA</i>	E	Rifampin + kasugamycin dependence	162	
<i>ridB</i>	E	Rifampin dependence	160	
<i>rplC</i>	E	Tiamulin resistance	73	
<i>rplD</i>	E	Erythromycin resistance	725, 840	S
<i>rplE</i>	E	Thiopeptin resistance	467	
<i>rplF</i>	E	Gentamicin resistance	101	S
<i>rplK</i>	E	Kasugamycin resistance	159	
<i>rplK</i>	E	DAP starvation of $\Delta(mal-asd)$ in the presence of serine, methionine, and glycine	165	
<i>rplN</i>	E	Kasugamycin resistance	159	
<i>rplN</i>	E	Lincomycin resistance	343	
<i>rplO</i>	E	Lincomycin resistance	343	
<i>rplV</i>	E	Erythromycin resistance	840	
<i>rpoA</i>	E	P2 <i>virI</i> phage resistance	754	S
<i>rpoB</i>	E	Lambda cII + rifampin coresistance	296	S
<i>rpoB</i>	E	Streptovaricin resistance	863	S
<i>rpoB</i>	E	Rifampin resistance	216, 359, 369	S
<i>rpoB</i>	E	Streptolydigin resistance	357, 469, 688	S
<i>rpoB</i>	S	Fluorouracil resistance	368	S
<i>rpoB</i>	E	Lambda phage + 434 phage cross-resistance	256	S
<i>rpoB</i>	E	Lambda <i>Nmar</i> mutant phage resistance	261	S
<i>rpoB</i>	E	Serine resistance in <i>relA</i>	784	S
<i>rpoB</i>	E	Rifampin resistance in <i>rpoB</i> ⁺ / <i>rpoB</i> (<i>rif</i>) merodiploids	36	L
<i>rpoB</i>	E	T7 phage resistance	690	S
<i>rpoC</i>	E	T7 phage gene 2 resistance	100	
<i>rpoD</i>	E	Lambda cI71 resistance	556	
<i>rpoD</i>	E	Arabinose (L) as C source in <i>cya</i> or <i>crp</i>	712	S
<i>rpoH</i>	E	Temperature resistance in <i>rpoD</i> (Ts)	577	S
<i>rpsB</i>	E	Kasugamycin resistance	583, 861	S

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>rpsB</i>	E	Cold resistance in <i>rpsE</i> cold-sensitive mutants	559	
<i>rpsC</i>	E	Spectinomycin resistance and sucrose dependence	195	S
<i>rpsD</i>	E	Spectinomycin resistance and sucrose dependence	195	S
<i>rpsD</i>	E	Streptomycin independence of streptomycin-dependent <i>rpsL</i>	304	
<i>rpsE</i>	E	Spectinomycin resistance and sucrose dependence	195, 526	S
<i>rpsE</i>	E, S	Spectinomycin resistance	172, 495, 634, 672, 853	S
<i>rpsE</i>	E	Streptomycin independence of streptomycin-dependent <i>rpsL</i>	304	
<i>rpsG</i>	E	Lincomycin resistance	343	S
<i>rpsI</i>	E	Kasugamycin resistance and dependence	161, 163	S
<i>rpsJ</i>	E	Lambda prophage induction, resistance to	170, 246	S
<i>rpsL</i>	E, S	Streptomycin resistance	89, 495, 853	S
<i>rpsL</i>	E	Neamine dependence	798	
<i>rpsL</i>	E	Paromomycin resistance or dependence	853	S
<i>rpsL</i>	E	Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>	747	
<i>rpsM</i>	E	Kasugamycin resistance	159	
<i>rpsQ</i>	E	Neamine resistance	76, 119	S
<i>rpsR</i>	E	Kasugamycin resistance	159	
<i>rrn</i>	E	Erythromycin resistance	704	S
<i>rrn</i>	E	Chloramphenicol resistance	704	S
<i>rrn</i>	E	Spectinomycin resistance	704	S
<i>sbaA</i>	E	Serine resistance	166	
<i>sbmA</i>	E	Microcin B17 resistance	446	
<i>sdh</i>	E	Succinate-independent growth in <i>lpd</i>	154	
<i>secA</i>	E, S	Azide resistance	227, 232, 584, 808, 864	
<i>secA</i>	E	Phenethyl alcohol resistance	808, 864	
<i>semA</i>	E	Microcin E492 resistance	622	
<i>serA</i>	E	Serine hydroxamate resistance	774	FBI, S
<i>serS</i>	E	Serine hydroxamate resistance	774	S
<i>sidCF</i>	S	Albomycin resistance	87, 478, 479, 674	
<i>sidK</i>	S	Albomycin resistance	87, 478, 479, 674	
<i>sidK</i>	S	ES18 phage resistance	87, 478, 479, 674	
<i>sloB</i>	E	Nalidixic acid tolerance	473	
<i>sloB</i>	E	Amidinopenicillin tolerance	473	
<i>sorAT</i>	E	Sorbose (L) as C source in crosses with wild strains	844	
<i>spcB</i>	S	Spectinomycin resistance	853	
<i>srlA</i>	E	Sorbitol + xylitol resistance	639	L
<i>srlD</i>	E	Fructose as C source in <i>ptsF</i> or <i>ptsM</i>	378	
<i>sspA</i>	E	P1 phage resistance	835	L
<i>strB</i>	S	Streptomycin resistance	273, 853	
<i>strC</i>	S	Streptomycin resistance	648	
<i>strM</i>	E	Streptomycin resistance	671	
<i>strM</i>	E	Phenyl galactoside resistance of <i>lacI</i> ^q <i>lacI</i> (nonsense) <i>lacP supL</i>	748	
<i>sulA</i>	E	UV irradiation resistance in <i>lon</i>	373	L
<i>sulA</i>	E	Methyl methanesulfonate resistance in <i>lon</i>	373	L
<i>sulA</i>	E	Nitrofurantoin resistance in <i>lon</i>	252	L
<i>tabC</i>	E	T4 phage resistance	258	
<i>tct</i>	S	Fluorocitrate resistance	724	
<i>tct</i>	S	Trifluorocitrate resistance	723	L
<i>tct</i>	S	2-Fluoro-L-erythrocitrate resistance	32	L
<i>tdk</i>	E, S	Azidothymidine resistance	207	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>tdk</i>	S	Fluorodeoxyuridine + uracil resistance in <i>deoA</i>	54	
<i>tdk</i>	E	Fluoro(5)deoxyuridine resistance	749	L
<i>tdk</i>	E	Bromo(5)deoxyuridine + UV irradiation resistance	319, 348	L
“ <i>tet</i> ”	E, S	Fusaric acid resistance	72, 487	L
“ <i>tet</i> ”	S	Quinaldic acid resistance	72	L
<i>thdA</i>	E	Dapsone resistance	383	
<i>thi</i>	E	Pyrithiamine resistance	399	C
<i>thrA</i>	E, S	Thialysine resistance	365	S, FBI
<i>thrA</i>	E	Serine resistance	294	S, FBI
<i>thrABC</i>	E	Amino(2)-hydroxy(3)-pentoate resistance	847	D
<i>thrS</i>	E	Borrelidin resistance	248, 276, 560, 596	S, Q
<i>thyA</i>	E, S	Aminopterin resistance	66, 123, 325, 730	L
<i>thyA</i>	E	Trimethoprim resistance	66, 730	L
<i>tinA (tlr)</i>	E, S	Thiolutin resistance	381, 382, 714	
<i>tmk</i>	E	Dideoxy(2',3')thymidine resistance	176	S
<i>tnaA</i>	E	Tryptophan-supported growth at 13°C	568	C
<i>tma</i>	E	Indole + methyl(5)tryptophan-supported, glucose-resistant growth in Δtrp	862	
<i>tol</i>	E	Bacteriocin tolerance	85, 120, 173, 236	
<i>tolQAB</i>	E	Colicin E1 resistance	449	
<i>tolQAB</i>	E	Tula phage resistance	449	
<i>tolB</i>	E	Colicin E resistance	19	L
<i>tolB</i>	E	Azaleucine resistance	19	L
<i>tolC</i>	E	Colicin E1 tolerance	536, 653	L
<i>tolD</i>	E	Colicin E2 and E3 tolerance	210	
<i>tolD</i>	E	Ampicillin resistance	105, 210	
<i>tolE</i>	E	Colicin E2 and E3 tolerance	210, 211	
<i>tolE</i>	E	Ampicillin resistance	210, 211	
<i>tolI</i>	E	Colicin Ia and Ib tolerance	120	
<i>tolJ</i>	E	Colicin L, A, and S4 tolerance	173	
<i>tolM</i>	E	Colicin M tolerance	302	
<i>tolQ</i>	E	Colicin group A tolerance	84a, 750	
<i>tolQ</i>	E	Filamentous phage tolerance	84a, 750	
<i>tolR</i>	E	Colicin group A tolerance	84a, 750	
<i>tolR</i>	E	Filamentous phage tolerance	84a, 750, 751	
<i>tolZ</i>	E	Colicin E2, E3, D, 1a, and 1b tolerance	503	
<i>tonB</i>	S	ES18 phage resistance	149, 741	
<i>tonB</i>	E	T1 phage resistance	46	
<i>tonB</i>	E	φ80 phage resistance	46	
<i>tonB</i>	E	Colicin B resistance	46, 623	
<i>tonB</i>	E, S	Albomycin resistance	85, 505, 741	
<i>tonB</i>	E	Colicin M resistance	85, 523	
<i>tonB</i>	S	Bacteriocin 4-59 resistance	741	
<i>tonB</i>	E	Cephalosporin E-0702 resistance	815	
<i>topA</i>	S	Kanamycin resistance	202	
<i>topA</i>	S	Neomycin resistance	202	
<i>topA</i>	S	Streptomycin resistance	202	
<i>tpp</i>	E	Alafosfalin resistance	603	L
<i>tpp</i>	E	Triornithine resistance in <i>opp</i>	44	L
<i>tppA</i>	S	Tripeptide (toxic) resistance	263	
<i>tppB</i>	S	Tripeptide (toxic) resistance	263	
<i>trmE?</i>	E	Phenyl galactoside resistance of <i>lacI^q</i> <i>lacI</i> (nonsense) <i>lacP supL</i>	748	
<i>trp</i> (generic)	E, S	Fluoro(6)tryptophan resistance	42, 318	C

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>trp</i> (generic)	E, S	Methyl(5)tryptophan resistance	42, 318	C
<i>trpE</i>	E, S	Methyl(5)tryptophan resistance	114, 539	S, FBI
<i>trpE</i>	E	Methyl(3)anthranilate resistance	308	S, FBI
<i>trpR</i>	E, S	Methyl(5)tryptophan resistance	42, 137, 523, 746	
<i>trpR</i>	E	Chuangxinmycin resistance	850	
<i>trpS</i>	E	Indolmycin resistance	75	D
<i>trxA</i>	E	T7 phage resistance	498	L
<i>trzA</i>	S	Triazole resistance	339	
<i>tsx</i>	E	T6 phage resistance	99, 299, 490, 492, 620	L, S
<i>tsx</i>	E	Colicin K resistance	99, 299, 490, 492, 620	L, S
<i>tsx</i>	E	Albicidin resistance	69	
<i>tufAB</i>	E	Kirromycin resistance	220, 356, 763, 795	
<i>tufAB</i>	E, S	Mocimycin resistance	335, 794	
<i>tyn</i>	S	Tyramine as N source	549	
<i>tyrA</i>	E, S	Fluorophenylalanine resistance	270, 729	C
<i>tyrA</i>	E	Amino(4)phenylalanine resistance	504	C
<i>tyrR</i>	E, S	Amino(4)phenylalanine resistance	95, 504, 811	
<i>tyrR</i>	E	Fluorotyrosine resistance	130	
<i>tyrR</i>	S	Fluoro(4)phenylalanine resistance	729	
<i>tyrS</i>	E	Fluorotyrosine resistance	662	S
<i>ubi</i> (generic)	E	Neomycin resistance	265	L
<i>ubiF</i>	S	Fluoro(5)uracil + carbamylaspartate resistance	404, 866	L
<i>ubiF</i>	E	Gentamicin resistance	542	
<i>ubiF</i>	E	Streptomycin resistance	542	
<i>udhA</i>	S	Fluoro(5)uridine resistance	834	L
<i>udk</i>	E	Fluoro(5)uridine + uracil resistance	380	L
<i>udk</i>	E	Fluoro(5)uridine resistance in <i>upp</i>	565	L
<i>udp</i>	E	Fluoro(5)uracil + adenosine resistance	606, 617	L
<i>ugpAB</i>	E	Fluorohydroxyacetone phosphate resistance	515	L
<i>ugpAB</i>	E	Dihydroxybutylphosphonate resistance in <i>glpT</i>	691, 692	L
<i>ugpAB</i>	E	Glycerol-3-phosphate as C source in <i>glpT</i>	691	C
<i>uhpR</i>	E	Glucosamine 6-phosphate as C source	191	C
<i>uhpR</i>	S	Glucose 1-phosphate as C source	192	C
<i>uhpR</i>	E	Fructose 1-phosphate as C source	224	C
<i>uhpT</i>	E	Chloro-3-hydroxyacetone resistance in <i>uhp</i> (Con)	515	L
<i>uhpT</i>	E	Fluoro-3-hydroxyacetone resistance in <i>uhp</i> (Con)	515	L
<i>uhpT</i>	E	Dihydroxybutylphosphonate resistance in <i>uhp</i> (Con)	285	L
<i>uhpT</i>	E	Hydroxybutylphosphonate resistance in <i>uhp</i> (Con)	285	L
<i>uhpT</i>	E	Deoxydihydroxyphosphonyl methyl fructose resistance	285	L
<i>uhpT</i>	E	L-Glyceraldehyde-3-phosphate resistance in <i>uhp</i> (Con)	285	L
<i>uhpT</i>	E	Fosfomycin resistance	230, 389, 800	L
<i>uhpT</i>	E	Deoxy(2)glucose-6-phosphate resistance	214	L
<i>uidA</i>	E	Galacturonide as C source	742	C
<i>uidA</i>	E	Methylgalacturonide as C source	573	C
<i>uidA</i>	E	Methylglucuronide + glycerol-supported growth in <i>eda</i>	572	L
<i>uidR</i>	E	Galacturonide as C source	742	C
<i>uidR</i>	E	Methylgalacturonide as C source	573	C
<i>ung</i>	E	Bromodeoxyuridine + UV light resistance	856	L
<i>ung</i>	E	T4 phage (uracil containing) resistance	203	L
<i>upp</i>	E, S	Fluoro(5)uracil resistance	53, 605, 617	L
<i>upp</i>	E	Aza(6)uracil resistance	605, 617	L

Gene	Organism ^a	Selection ^b	Reference(s)	Alteration ^c
<i>upp</i>	E	Canavanine + aza(6)uracil resistance	605, 617	L
<i>ushA</i>	E	Fluoro(5)uracil + 5'-AMP resistance in <i>upp</i>	52	L
<i>uvrA</i>	E	UV-irradiated lytic phage resistance	332	
<i>uvrB</i>	E	UV-irradiated lytic phage resistance	332	
<i>uvrC</i>	E	UV-irradiated lytic phage resistance	332	
<i>uvrD</i>	E	UV-irradiated lytic phage resistance	332	
<i>uxaBC</i>	E	Hexuronate resistance in <i>eda</i>	742	L
<i>uxuAB</i>	E	Hexuronate resistance in <i>eda</i>	742	L
<i>uxuR</i>	E	Methylgalacturonide as C source	574	C
<i>valS</i>	E	Thymineless death resistance in <i>thyA</i>	394	S
<i>xapA</i>	E	Fluoro(5)uracil + adenosine resistance in <i>upp deoD</i> <i>xapR</i> (Con)	111	L
<i>xapR</i>	E	Adenosine as C source in <i>upp deoD</i>	111	C
<i>xapR</i>	E	Inosine as C source in <i>upp deoD</i>	111	C
<i>xylE</i>	E	Xylose resistance in <i>fda</i>	175	L

^aE, *E. coli*; S, *S. typhimurium*.

^bAbbreviations: DCCD, N,N'-dicyclohexylcarbodiimide; CCCP, carbonyl cyanide m-chlorophenylhydrazone; cAMP, cyclic AMP; DAP, diaminopimelic acid; (Con), constitutive; (Ts), heat sensitive.

^cS, structure; FBI, site of feedback inhibition; D, increased gene dosage; C, constitutive gene expression; Q, altered amount of gene product; G, gain of function; L, loss of function.

^dL. Comai, U.S. Patent 4,535,060, 1988; L. Comai, European patent application 389066, 1984.

^eN. S. C. Lin, D. T. Palmer, and H. I. Miller, European patent application EP 85-308408 and U.S. patent application 84-673955, 1986.

^fE. S. Miller, thesis, Purdue University, West Lafayette, Ind., 1984.

^gS. Epelbaum, Z. Barak, R. LaRossa, and D. Chipman, unpublished data.

^hC. S. Freitag, Ph.D. thesis, North Carolina State University, Raleigh, 1982.

TABLE 3 Selectable genes grouped by metabolic function^a

I. Intermediary metabolism
A. Degradation
<i>aceE, aceF, ackA, araA, araB, araC, atoB, atoC, dadA, dgd, dgoR, dsdA, dsdC, edd, exuR, fadB, fadL, fadR, fba, fucA, galK, galR, garA, garB, gatC, gatD, hut, kdgR, lacA, lacI, lacZ, malP, malQ, malT, manC, melA, mtlC, pfkA, pgi, pgm, phoA, prp, pta, putA, sorA, sorT, srlD, thdA, tnaA, udp, uidA, uidR, uxaB, uxaC, uxuA, uxuB, uxuR, xapA, xapR</i>
B. Central intermediary metabolism
<i>gabC, gadA, gnd, icdE, iclR, lpdA, metK, zwf</i>
C. Respiration (aerobic and anaerobic)
<i>chl, chlA, chlB, chlC, chlD, chlE, cydA, cydB, glpD, glpR, narC, narG, narH, sdHABCD</i>
D. Fermentation
<i>adhE, dld, frdABCD, hyb, hyc, hyd, hyp, lctD</i>
E. ATP-proton motive force interconversion
<i>atpA-I</i>
F. Broad regulatory functions
<i>arcA, cpxA, crp, cyaA, cytR, envZ, fur, lexA, lon, ompR, oxyR, phoB, phoR, relA, rpoD, sspA</i>
II. Biosynthesis of small molecules
A. Amino acids
1. Glutamate family, nitrogen assimilation
<i>argA, argB, argC, argD, argR, glnA, gltH, proA, proB, proC</i>
2. Aspartate family, pyruvate family
<i>asd, azl, ileR, ilvA, ilvB, ilvH, ilvI, leuA, leuJ, leuO, lrp, lysA, lysC, metA, metC, metJ, metL, thrA, thrB, thrC</i>
3. Glycine-serine family, sulfur metabolism
<i>cysB, cysE, cysG, cysK, cysL, cysM, glyA, sbaA, serA</i>
4. Aromatic amino acid family
<i>aroA, aroF, aroG, aroH, pheA, pheR, trp, trpE, trpR, tyrA</i>
5. Histidine
<i>his, hisG</i>
B. Nucleotides
1. Purine ribonucleotides
<i>guaA, guaB, purA, purB, purR</i>
2. Pyrimidine ribonucleotides
<i>carA, pyrB, pyrC, pyrD, pyrF, pyrH</i>
3. 2'-Deoxyribonucleotides
<i>dcd, dut, ndk, nrdA, nrdB, thyA, tmk</i>
4. Salvage and interconversions
<i>apt, cdd, codA, cpdB, deoA, deoB, deoC, deoD, deoR, gpt, hpt, optA, spoT, tdk, upp</i>
C. Sugars and sugar nucleotides
<i>galE, galT, manA, nagA, nagB, nagR, rfbA, rfbB, rfbD, ushA</i>
D. Cofactors, prosthetic groups, electron carriers
1. Biotin
<i>bioA, bioB, bioC, bioD, bioF, bioH, birA</i>
2. Folic acid
<i>folA, pabA, pabB</i>
3. Pantothenate
<i>coaA</i>
4. Pyridoxine
<i>pdxA, pdxB</i>
5. Pyridine nucleotides
<i>nadA, nadB, nadC, nadD, pncA, pncB, pncH, pncX</i>
6. Thiamine
<i>thiA</i>
7. Thioredoxin, glutaredoxin, and glutathione
<i>gor, gshA, gshB, trxA</i>
8. Menaquinone and ubiquinones
<i>ubiF</i>
9. Heme and porphyrins
<i>hemA, hemB, hemE, hemF, hemG, hemH, hemL</i>
E. Fatty acids and lipids
<i>clsA, glpK, pldA, pssA</i>
III. Macromolecular metabolism
A. Synthesis and modification

1. Ribosomal proteins and their modification
ksgC, rplC, rplD, rplE, rplF, rplK, rplN, rplO, rplT, rplV, rpsB, rpsD, rpsE, rpsG, rpsI, rpsJ, rpsL, rpsM, rpsQ
2. tRNAs and their modification, aminoacyl-tRNA synthetases
alaS, argS, glnV, hemM, hisR, hisT, ileS, ilvU, leuS, leuW, lysS, metG, miaA, nuaA, nuaC, pheS, pheU, serS, thrS, trmE, trpS, tyrS, valS
3. RNA synthesis and modification and DNA transcription
nusA, nusB, nusG, pnp, rho, ridA, rpoA, rpoB, rpoC
4. DNA (replication, restriction-modification, recombination, and repair)
dcm, dnaB, dnaE, dnaG, dnaJ, dnaK, gyrA, gyrB, himA, himD, lig, mcrC, msp, mutA, mutC, mutH, mutL, mutS, mutY, phr, polA, recA, recF, recJ, recO, recQ, rep, sbcB, topA, ung, uvrA, uvrB, uvrC, uvrD
5. Proteins (translation and modification)
fusA, prfA, prfB, tufA, tufB
6. Polysaccharides (cytoplasmic)
glgA, glgB, glgC

B. Degradation of macromolecules

1. DNA
hsdR, mcrA, mcrB
2. Proteins
pepA, pepD, pepN, pepQ, sulA

IV. Cell structure

- A. Membrane components
mvrC, ompA, phoE, qmeA, qmeC, qmeD, qmeE
- B. Murein sacculus
hipA, hipQ, lpp, mrbA, mrdA, mreB, mreC, mreD, murZ
- C. Surface polysaccharides and antigens
kdsA, lpcA, rfaB, rfaC, rfaH, rfaP
- D. Surface structures
fliC

V. Cellular processes

- A. Transport-binding proteins
araF, argP, argT, aroP, aroT, bioP, brnQ, btuB, bymA, cadB, cbt, codB, corA, corB, crr, cycA, cysA, dctA, dctB, dgsA, dppA, exbB, exbC, fepA, fepB, fepD, fepG, fhuA, fhuB, fhuA, galP, gatA, glnP, glpF, glpT, gltR, gltS, gntS, hisJ, hisM, hisP, hisQ, lacY, livG, livH, livJ, livK, lysP, malE, malF, malG, malK, manX, manY, manZ, mdoB, melB, metD, mgID, mtlA, mtr, nagE, nhaA, nupC, nupG, oppA, oppE, panF, pit, proP, proU, pstA, pstB, pstC, pstS, ptsG, ptsH, ptsI, putP, srlA, tct, tonB, tpp, tsx, tyrR, udhA, ugpA, ugpB, uhpA, uhpB, uhpC, uhpT, xyIE
- B. Cell division
envB, ftsY, ftsZ, mbrA, mbrB, mbrC
- C. Chemotaxis and mobility
che, mglA, mglB, mglC, motA, motB
- D. Protein secretion
lspA, secA
- E. Osmotic adaptation
envM, ompC, ompF, osmB

VI. Other functions

- A. Cryptic genes
bglB, bglT, celA, celB, celC, celD, celF, citA, ebgA, ebgC, ebgR, ilvF, ilvG, ilvM, ilvJ
- B. Phage-related functions and prophages
grpA, grpB, grpD, grpE, groM, hflC, hflK, hflX, lamB, lit, mopA, mopB, phxB, pmi, pmrA, praAB, prbAB, prdB, prh, rap, tabC
- C. Colicin-related functions
cet, cirA, tolA, tolB, tolC, tolD, tolE, tolI, tolJ, tolM, tolQ, tolR, tolZ
- D. Drug or analog sensitivity
ampC, ampD, ampE, azaA, azaB, can, cmlA, eryC, eryD, ksgA, ksgB, ksgD, lev, linB, lytA, marA, mbrD, mng, mvrA, nalB, nalD, neaB, nek, nfnA, nfnB, nfsA, nfsB, nol, nov, pmrA, puvA, ridB, sbmA, semA, sloB, spcB, strB, strC, strM, tet, tlnA, trzA
- E. Radiation sensitivity
garA, garB
- F. Adaptations to atypical conditions
crg

^aReferences to selections and species used in selections are given in Table 2.

FUTURE DIRECTIONS

Inhibitory conditions will continue to be important genetic tools with which to probe *E. coli* and *S. typhimurium* physiology. The study of mutants hypersensitive to environmental insults, alluded to earlier, is a most fertile area for exploitation. In addition, bacteriophage-resistant mutations have recently been of prime importance in defining pathway-assisted protein folding in the cell (531). Vigorous investigation of several such ill-defined mutants may reveal other new challenges to our orthodoxies. Relatively few natural product inhibitors of essential amino acid and cofactor biosynthetic pathways are identified (Table 1). Searches for such products and molecular biological definition of their modes of action may contribute both to our understanding of the establishment of microbial niches and to the development of a bioagrichemical industry akin to the antibiotic industry. These possibilities, and several others, portend an integrative understanding of biology emanating from the continued detailed study of the selectable phenotypes in *E. coli* and *S. typhimurium*.

ACKNOWLEDGMENTS

I thank past and present members of the DuPont Microbial Genetics laboratory for their patience as I labored on this chapter. Dana Smulski of DuPont helped to ensure the accuracy of the references. I am grateful to Carol Perrotto of DuPont for her conduct of computerized literature searches. My training in the laboratories of Phil Hartman, Dieter Söll, Brooks Low, and Dale Kaiser convinced me that judicious genetic analysis of inhibitor action is a field worthy of extended study. R. T. Vinopal's compilation of selectable phenotypes was an invaluable starting point for this effort.

LITERATURE CITED

1. **Abouhamad, W. N., M. Manson, M. M. Gibson, and C. F. Higgins.** 1991. Peptide transport and chemotaxis in *Escherichia coli* and *Salmonella typhimurium*: characterization of the dipeptide permease *dpp* and the dipeptide-binding protein. *Mol. Microbiol.* **5**:1035–1048.
- 1a. **Ackerman, R. S., N. R. Cozzarelli, and W. Epstein.** 1974. Accumulation of toxic concentrations of methylglyoxal by *Escherichia coli* K-12. *J. Bacteriol.* **119**:357–362.
2. **Adhya, S., P. Cleary, and A. Campbell.** 1968. A deletion analysis of prophage lambda and adjacent genetic regions. *Proc. Natl. Acad. Sci. USA* **61**:956–962.
3. **Ahmad, S. I., and R. H. Pritchard.** 1969. A map of four genes specifying enzymes involved in catabolism of nucleosides and deoxynucleosides in *Escherichia coli*. *Mol. Gen. Genet.* **104**:351–359.
4. **Ahmad, S. I., and R. H. Pritchard.** 1972. Location of the gene specifying cytosine deaminase in *Escherichia coli*. *Mol. Gen. Genet.* **118**:323–325.
5. **Alaeddinoglu, N. C., and H. P. Charles.** 1979. Transfer of a gene for sucrose utilization into *Escherichia coli* K12, and consequent failure of expression of genes for D-serine utilization. *J. Gen. Microbiol.* **110**:47–59.
6. **Alderman, E. M., S. S. Dills, T. Melton, and W. J. Dobrogosz.** 1979. Cyclic AMP regulation of the bacteriophage T6 colicin K receptor in *Escherichia coli*. *J. Bacteriol.* **140**:369–376.
7. **Alexander, R. R., J. M. Calvo, and M. Freundlich.** 1971. Mutants of *Salmonella typhimurium* with an altered leucyl-transfer ribonucleic acid synthetase. *J. Bacteriol.* **106**:213–220.
8. **Alper, M. D., and B. N. Ames.** 1975. Cyclic 3',5'-adenosine monophosphate phosphodiesterase mutants of *Salmonella typhimurium*. *J. Bacteriol.* **122**:1081–1090.
9. **Alper, M. D., and B. N. Ames.** 1975. Positive selection of mutants with deletions of the *gal-chl* region of the *Salmonella* chromosome as a screening procedure for mutagens that cause deletions. *J. Bacteriol.* **121**:259–266.
10. **Alper, M. D., and B. N. Ames.** 1978. Transport of antibiotics and metabolite analogs by systems under cyclic AMP control: positive selection of *Salmonella typhimurium* *cya* and *crp* mutants. *J. Bacteriol.* **133**:149–157.

11. **Amaral, D., and H. L. Kornberg.** 1975. Regulation of fructose uptake by glucose in *Escherichia coli*. *J. Gen. Microbiol.* **90**:157–168.
12. **Ames, G. F.-L.** 1964. Uptake of amino acids by *Salmonella typhimurium*. *Arch. Biochem. Biophys.* **104**:1–18.
13. **Ames, G. F.-L., D. P. Biek, and E. N. Spudich.** 1978. Duplications of histidine transport genes in *Salmonella typhimurium* and their use for the selection of deletion mutants. *J. Bacteriol.* **136**:1094–1108.
14. **Ames, G. F.-L., and J. Lever.** 1970. Components of histidine transport: histidine-binding proteins and *hisP* protein. *Proc. Natl. Acad. Sci. USA* **66**:1096–1103.
15. **Ames, G. F.-L., K. D. Noel, H. Tabor, E. N. Spudich, K. Nikaido, J. Afong, and F. Ardesir.** 1977. Fine-structure map of the histidine transport genes in *Salmonella typhimurium*. *J. Bacteriol.* **129**:1289–1297.
16. **Ammer, J., M. Brennenstuhl, P. Schindler, J.-V. Holtje, and H. Zahner.** 1979. Phosphorylation of streptozotocin during uptake via the phosphoenolpyruvate:sugar phosphotransferase system in *Escherichia coli*. *Antimicrob. Agents Chemother.* **16**:801–807.
17. **Anderson, J. J., and D. L. Oxender.** 1977. *Escherichia coli* transport mutants lacking binding protein and other components of the branched-chain amino acid transport systems. *J. Bacteriol.* **130**:384–392.
18. **Anderson, J. J., S. C. Quay, and D. L. Oxender.** 1976. Mapping of two loci affecting the regulation of branched-chain amino acid transport in *Escherichia coli* K-12. *J. Bacteriol.* **126**:80–90.
19. **Anderson, J. J., J. M. Wilson, and D. L. Oxender.** 1979. Defective transport and other phenotypes of a periplasmic “leaky” mutant of *Escherichia coli* K-12. *J. Bacteriol.* **140**:351–358.
20. **Anderson, R. P., and J. R. Roth.** 1977. Tandem genetic duplications in phage and bacteria. *Annu. Rev. Microbiol.* **31**:473–505.
21. **Anderson, R. P., and J. R. Roth.** 1978. Tandem genetic duplications in *Salmonella typhimurium*: amplification of the histidine operon. *J. Mol. Biol.* **126**:53–71.
22. **Andrews, J. C., and S. A. Short.** 1985. Genetic analysis of *Escherichia coli* oligopeptide transport mutants. *J. Bacteriol.* **161**:484–492.
23. **Anton, D.** 1968. Histidine regulatory mutants in *Salmonella typhimurium*. V. Two new classes of histidine regulatory mutants. *J. Mol. Biol.* **33**:533–546.
24. **Anton, D. N.** 1981. *envB* mutations confer UV sensitivity to *Salmonella typhimurium* and UV resistance to *Escherichia coli*. *Mol. Gen. Genet.* **181**:150–152.
25. **Aono, R., M. Yamasaki, and G. Tamura.** 1979. High and selective resistance to meillinam in adenylate cyclase-deficient or cyclic adenosine 3',5'-monophosphate receptor protein-deficient mutants of *Escherichia coli*. *J. Bacteriol.* **137**:839–845.
26. **Apirion, D.** 1967. Three genes that affect *Escherichia coli* ribosomes. *J. Mol. Biol.* **30**:255–275.
27. **Apirion, D., and D. Schlessinger.** 1968. Coresistance to neomycin and kanamycin by mutations in an *Escherichia coli* locus that affects ribosomes. *J. Bacteriol.* **96**:768–776.
28. **Archibald, E. R., and L. S. Williams.** 1973. Regulation of methionyl-transfer ribonucleic acid synthetase formation in *Escherichia coli* and *Salmonella typhimurium*. *J. Bacteriol.* **114**:1007–1013.
29. **Argast, M., D. Luttko, T. J. Silhavy, and W. Boos.** 1978. A second transport system for *sn*-glycerol-3-phosphate in *Escherichia coli*. *J. Bacteriol.* **136**:1070–1083.
30. **Armstrong, G. D., and H. Yamazaki.** 1977. Isolation and characterization of catabolite repression resistant mutants of *Escherichia coli*. *Can. J. Microbiol.* **23**:1384–1393.
31. **Artman, M., and S. Werthamer.** 1979. Use of streptomycin and cyclic adenosine 5'-monophosphate in the isolation of mutants deficient in CAP protein. *J. Bacteriol.* **120**:542–544.
32. **Ashton, D. M., G. D. Sweet, J. M. Somers, and W. W. Kay.** 1980. Citrate transport in *Salmonella typhimurium*: studies with 2-fluoro-L-erythro-citrate as a substrate. *Can. J. Biochem.* **58**:797–803.
33. **Astvatsatryan, G. V., A. F. Lysenkov, Y. V. Smirnov, R. and R. S. Shakulov.** 1988. Mutants of *Escherichia coli* with impaired feedback inhibition of histidine biosynthesis. *Genetika* **24**:1928–1934.

34. **Aswad, D., and D. E. Koshland, Jr.** 1975. Isolation, characterization and complementation of *Salmonella typhimurium* chemotaxis mutants. *J. Mol. Biol.* **97**:225–235.
35. **Austin, E. A., J. F. Graves, L. A. Hite, C. T. Parker, and C. A. Schnaitman.** 1990. Genetic analysis of lipopolysaccharide core biosynthesis by *Escherichia coli* K-12 insertion mutagenesis of the *rfa* locus. *J. Bacteriol.* **172**:5312–5325.
36. **Austin, S., and J. Scaife.** 1970. A new method for selecting RNA polymerase mutants. *J. Mol. Biol.* **49**:263–267.
37. **Ayling, P. D.** 1981. Methionine sulfoxide is transported by high-affinity methionine and glutamine transport systems in *Salmonella typhimurium*. *J. Bacteriol.* **148**:514–520.
38. **Ayling, P. D., and E. S. Bridgeland.** 1972. Methionine transport in wild-type and transport-defective mutants of *Salmonella typhimurium*. *J. Gen. Microbiol.* **73**:127–141.
39. **Bachi, B., and H. L. Kornberg.** 1975. Genes involved in the uptake and catabolism of gluconate by *Escherichia coli*. *J. Gen. Microbiol.* **90**:321–335.
40. **Bachmann, B. J.** 1983. Linkage map of *Escherichia coli* K-12, edition 7. *Microbiol. Rev.* **47**:180–230.
41. **Bachmann, B. J.** 1990. Linkage map of *Escherichia coli* K-12, edition 8. *Microbiol. Rev.* **54**:130–197.
42. **Balbinder, E., R. Callahan III, P. P. McCann, J. C. Cordero, A. R. Weber, A. M. Smith, and F. Angelosanto.** 1970. Regulatory mutants of the tryptophan operon of *Salmonella typhimurium*. *Genetics* **66**:31–53.
43. **Barak, Z., and C. Gilvarg.** 1974. Triornithine-resistant strains of *Escherichia coli*. Isolation, definition, and genetic studies. *J. Biol. Chem.* **249**:143–148.
44. **Barak, Z., and C. Gilvarg.** 1975. Specialized peptide transport system in *Escherichia coli*. *J. Bacteriol.* **122**:1200–1207.
45. **Barrett, E. L., and D. L. Riggs.** 1982. Evidence for a second nitrate reductase activity that is distinct from the respiratory enzyme in *Salmonella typhimurium*. *J. Bacteriol.* **150**:563–571.
46. **Bassford, P. J., Jr., C. Bradbeer, R. J. Kadner, and C. A. Schnaitman.** 1976. Transport of vitamin B₁₂ in *tonB* mutants of *Escherichia coli*. *J. Bacteriol.* **128**:242–247.
47. **Bassford, P. J., Jr., R. J. Kadner, and C. A. Schnaitman.** 1977. Biosynthesis of the outer membrane receptor for vitamin B₁₂, E colicins, and bacteriophage BF23 by *Escherichia coli*: kinetics of phenotypic expression after the introduction of *bfe*⁺ and *bfe* alleles. *J. Bacteriol.* **129**:265–275.
48. **Baughman, G. A., and S. R. Fahnestock.** 1979. Chloramphenicol resistance mutation in *Escherichia coli* which maps in the major ribosomal protein gene cluster. *J. Bacteriol.* **137**:1315–1323.
49. **Baumberg, S.** 1970. Acetylhistidine as substrate for acetylornithinase: a new system for the selection of arginine regulation mutants in *Escherichia coli*. *Mol. Gen. Genet.* **106**:162–173.
50. **Baumberg, S.** 1976. Genetic control of arginine metabolism in prokaryotes, p. 369–389. In K. D. MacDonald (ed.), *Second International Symposium on the Genetics of Industrial Microorganisms*. Academic Press (Inc.), London.
51. **Beacham, I. R., and S. Garrett.** 1980. Isolation of *Escherichia coli* mutants (*cpdB*) deficient in periplasmic 2':3'-cyclic phosphodiesterase and genetic mapping of the *cpdB* locus. *J. Gen. Microbiol.* **119**:31–34.
52. **Beacham, I. R., R. Kahana, L. Levy, and E. Yagil.** 1973. Mutants of *Escherichia coli* K-12 “cryptic” or deficient in 5'-nucleotidase (uridine diphosphate-sugar hydrolase) and 3'-nucleotidase (cyclic phosphodiesterase) activity. *J. Bacteriol.* **116**:957–964.
53. **Beck, C. F., and J. L. Ingraham.** 1971. Location on the chromosome of *Salmonella typhimurium* of genes governing pyrimidine metabolism. *Mol. Gen. Genet.* **111**:303–316.
54. **Beck, C. F., J. L. Ingraham, and J. Neuhard.** 1972. Location on the chromosome of *Salmonella typhimurium* of genes governing pyrimidine metabolism. II. Uridine kinase, cytosine deaminase, and thymidine kinase. *Mol. Gen. Genet.* **115**:208–215.
55. **Begg, K. J., G. F. Hatfull, and W. D. Donachie.** 1980. Identification of new genes in a cell envelope-cell division gene cluster of *Escherichia coli*: cell division gene *ftsQ*. *J. Bacteriol.* **144**:435–

56. **Belfort, M., and D. L. Wulff.** 1973. Genetic and biochemical investigation of the *Escherichia coli* mutant *hfl-1* which is lysogenized at high frequency by bacteriophage lambda. *J. Bacteriol.* **115**:299–306.
57. **Beljanski, M., and M. Beljanski.** 1957. Sur la formation d'enzymes respiratoires chez un mutant d'*Escherichia coli* streptomycino-résistant et auxotrophe pour l'hémine. *Ann. Inst. Pasteur (Paris)* **92**:396–412.
58. **Beljanski, M., P. Pourgarel, and M. Beljanski.** 1970. Showdomycine et biosynthèse d'ARN non complémentaires de l'ADN. 1. *Ann. Inst. Pasteur (Paris)* **118**:253–276.
59. **Bennett, R. L., and M. H. Malamy.** 1970. Arsenate resistant mutants of *Escherichia coli* and phosphate transport. *Biochem. Biophys. Res. Commun.* **40**:469–503.
60. **Benson, C. E., S. H. Love, and C. N. Remy.** 1970. Inhibition of de novo purine biosynthesis and interconversion by 6-methyl purine in *Escherichia coli*. *J. Bacteriol.* **101**:872–880.
61. **Berg, C. M.** 1990. The branched chain amino acid transaminase genes and their products in *Escherichia coli*, p. 131–162. In Z. Barak, D. M. Chipman, and J. V. Schoss (ed.), *Biosynthesis of Branched Chain Amino Acids*. VCH Publishers, New York.
62. **Berg, C. M., and J. J. Rossi.** 1974. Proline excretion and indirect suppression in *Escherichia coli* and *Salmonella typhimurium*. *J. Bacteriol.* **118**:928–939.
63. **Bergler, H., G. Hogenauer, and F. Thurnowsky.** 1992. Sequences of the *envM* gene and of two mutated alleles in *Escherichia coli*. *J. Gen. Microbiol.* **138**:2093–2100.
64. **Berman-Kurtz, M., E. C. C. Lin, and D. P. Richey.** 1971. Promoter-like mutant with increased expression of the glycerol kinase operon of *Escherichia coli*. *J. Bacteriol.* **106**:724–731.
65. **Bernardi, A., and P. Leder.** 1970. Protein biosynthesis in *Escherichia coli*: purification and characteristics of a mutant G factor. *J. Biol. Chem.* **245**:4263–4268.
66. **Bertino, J. B., and K. A. Stacey.** 1966. A suggested mechanism for the selective procedure for isolating thymine-requiring mutants of *Escherichia coli*. *Biochem. J.* **101**:32c-33c.
67. **Beverin, S., D. E. Sheppard, and S. S. Park.** 1971. D-Fucose as a gratuitous inducer of the L-arabinose operon in strains of *Escherichia coli* B/r mutant in gene *araC*. *J. Bacteriol.* **107**:79–86.
68. **Bewick, M. A., and T. C. Y. Lo.** 1980. Localization of the dicarboxylate binding protein in the cell envelope of *Escherichia coli* K12. *Can. J. Biochem.* **58**:885–897.
69. **Birch, R. G., J. M. Pemberton, and W. V. S. Basnayake.** 1990. Stable albicidin resistance in *Escherichia coli* involves an altered outer-membrane nucleoside uptake system. *J. Gen. Microbiol.* **136**:51–58.
70. **Black, P. N.** 1988. The *fadL* gene product of *Escherichia coli* is an outer membrane protein required for uptake of long-chain fatty acids and involved in sensitivity in bacteriophage T2. *J. Bacteriol.* **170**:2850–2854.
71. **Blank, J., and P. Hoffee.** 1972. Regulatory mutants of the *deo* regulon in *Salmonella typhimurium*. *Mol. Gen. Genet.* **116**:291–298.
72. **Bochner, B. R., H.-C. Huang, G. L. Schieven, and B. N. Ames.** 1980. Positive selection for loss of tetracycline resistance. *J. Bacteriol.* **143**:926–933.
73. **Böck, A., F. Turnowsky, and G. Hoegenauer.** 1982. Tiamulin resistance mutations in *Escherichia coli*. *J. Bacteriol.* **151**:1253–1256.
74. **Boeke, J. D., F. LaCroute, and G. R. Fink.** 1984. A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. *Mol. Gen. Genet.* **197**:345–346.
75. **Bogosian, G., P. V. Haydock, and R. L. Somerville.** 1983. Indolmycin-mediated inhibition and stimulation of transcription at the *trp* promoter of *Escherichia coli*. *J. Bacteriol.* **153**:1120–1123.
76. **Bollen, A., T. Cabezon, M. De Wilde, R. Villarroel, and A. Herzog.** 1975. Alteration of ribosomal protein S17 by mutation linked to neamine resistance in *Escherichia coli*. I. General properties of *neaA* mutants. *J. Mol. Biol.* **99**:795–806.
77. **Boos, W., C. Bantlow, D. Benner, and E. Roller.** 1983. *cir*, a gene conferring resistance to colicin 1, maps between *mgl* and *fpk* on the *Escherichia coli* chromosome. *Mol. Gen. Genet.* **191**:401–406.

78. **Borg-Oliver, S. A., D. Tarlington, and K. D. Brown.** 1987. Defective regulation of the phenylalanine biosynthetic operon in mutants of the phenylalanyl transfer RNA synthetase operon. *J. Bacteriol.* **169**:1949–1953.
79. **Boronat, A., E. Caballero, and J. Aguilar.** 1983. Experimental evolution of a metabolic pathway for ethylene glycol utilization by *Escherichia coli*. *J. Bacteriol.* **153**:134–139.
80. **Bourd, G. I., R. S. Erlagaeva, T. N. Bolshakova, and V. N. Gershonovitch.** 1975. Glucose catabolite repression in *Escherichia coli* K12 mutants defective in methyl- α -D-glucose transport. *Eur. J. Biochem.* **53**:419–427.
81. **Bourret, R. B., and M. S. Fox.** 1988. Lysogenization of *Escherichia coli* him⁺, himA, and himD hosts by bacteriophage Mu. *J. Bacteriol.* **170**:1672–1682.
82. **Boy, E., and U. C. Patte.** 1972. Multivalent repression of aspartic semialdehyde dehydrogenase in *Escherichia coli* K-12. *J. Bacteriol.* **112**:84–92.
83. **Brana, H., J. Hubacek, D. Michaljanicova, I. Holubova, and K. Cejka.** 1977. Membrane mutation affecting energy-linked functions in *Escherichia coli* K12. *Folia Microbiol.* **22**:198–205.
84. **Branes, L. V., J. M. Somers, and W. W. Kay.** 1981. Hydrophobic peptide auxotrophy in *Salmonella typhimurium*. *J. Bacteriol.* **147**:986–996.
- 84a. **Braun, V.** 1989. The structurally related *exbB* and *tolQ* genes are interchangeable in conferring *tonB*-dependent colicin, bacteriophage, and albolomycin sensitivity. *J. Bacteriol.* **171**: 6387–6390.
85. **Braun, V., J. Frenz, K. Hantke, and K. Schaller.** 1980. Penetration of colicin M into cells of *Escherichia coli*. *J. Bacteriol.* **142**:162–168.
86. **Braun, V., K. Guenthner, K. Hantke, and L. Zimmermann.** 1983. Intracellular activation of albolomycin in *Escherichia coli* and *Salmonella typhimurium*. *J. Bacteriol.* **156**:308–315.
87. **Braun, V., K. Hantke, and W. Stauder.** 1977. Identification of the sid outer membrane receptor protein in *Salmonella typhimurium* SL1024. *Mol. Gen. Genet.* **155**:227–229.
88. **Braun-Breton, C., and M. Hofnung.** 1981. In vivo and in vitro functional alterations of the bacteriophage lambda receptor in *lamB* missense mutants of *Escherichia coli* K-12. *J. Bacteriol.* **148**:845–852.
89. **Breckenridge, L., and L. Gorini.** 1970. Genetic analysis of streptomycin resistance in *Escherichia coli*. *Genetics* **65**:9–25.
90. **Breeze, A. S., and E. E. Obaseiki-Ebor.** 1983. Mutations to nitrofurantoin and nitrofurazone resistance in *Escherichia coli* K12. *J. Gen. Microbiol.* **129**:99–103.
91. **Brenchley, J. E., C. A. Baker, and L. G. Patil.** 1975. Regulation of ammonia assimilatory enzymes in *Salmonella typhimurium*. *J. Bacteriol.* **124**:182–189.
92. **Brickman, E., L. Soll, and J. Beckwith.** 1973. Genetic characterization of mutations which affect catabolite-sensitive operons in *Escherichia coli*, including deletions of the gene for adenyl cyclase. *J. Bacteriol.* **116**:582–587.
93. **Brochu, A., N. Brochu, T. I. Nicas, T. R. Parr, Jr., A. A. Minnick, Jr., E. K. Dolence, J. A. McKee, M. J. Miller, M. C. Lavoie, and F. Malouin.** 1992. Modes of action and inhibitory activities of new siderophore-beta lactam conjugates that use specific iron uptake pathways for entry into bacteria. *Antimicrob. Agents Chemother.* **36**:2166–2175.
94. **Brown, K. D.** 1970. Formation of aromatic amino acid pools in *Escherichia coli* K-12. *J. Bacteriol.* **104**:177–188.
95. **Brown, K. D., and R. L. Somerville.** 1971. Repression of aromatic amino acid biosynthesis in *Escherichia coli* K-12. *J. Bacteriol.* **108**:386–399.
96. **Brown, T. D. K., M. C. Jones-Mortimer, and H. L. Kornberg.** 1977. The enzymic interconversion of acetate and acetyl-coenzyme A in *Escherichia coli*. *J. Gen. Microbiol.* **102**:327–336.
97. **Bruce, I., J. Hardy, and K. A. Stacey.** 1984. Potentiation by purines of the growth-inhibitory effects of sulphonamides on *Escherichia coli* and the location of the gene which mediates this effect. *J. Gen. Microbiol.* **130**:2489–2495.
98. **Bruni, C. B., V. Colantuoni, L. Sbordone, R. Cortese, and F. Blasi.** 1977. Biochemical and regulatory properties of *Escherichia coli* K-12 *hisT* mutants. *J. Bacteriol.* **130**:4–10.

99. **Brunner, D. P., G. S. Graham, and R. W. Treick.** 1982. Exchange of colicin receptor capacity between strains of *Escherichia coli* sensitive or resistant to colicin K-K235. *Arch. Microbiol.* **131**:229–234.
100. **Buchstein, S. R., and D. C. Hinkle.** 1982. Genetic analysis of two bacterial RNA polymerase mutants that inhibit the growth of bacteriophage T7. *Mol. Gen. Genet.* **188**:211–218.
101. **Buckel, P., A. Buchberger, A. Boeck, and H. G. Wittmann.** 1977. Alteration of ribosomal protein L6 in mutants of *Escherichia coli* resistant to gentamicin. *Mol. Gen. Genet.* **158**:47–54.
102. **Buhr, A., G. A. Daniels, and B. Erin.** 1992. The glucose transporter of *Escherichia coli* mutants with impaired translocation activity that retain phosphorylation activity. *J. Biol. Chem.* **267**:3847–3851.
103. **Bullas, L. R., and C. Colson.** 1975. DNA restriction and modification systems in *Salmonella*. III. SP, a *Salmonella potsdam* system allelic to the SB system in *Salmonella typhimurium*. *Mol. Gen. Genet.* **139**:177–188.
104. **Burd, G. I., G. I. Erlagaeva, T. N. Bol'shakova, and V. N. Gershmanovich.** 1974. Separation of the α-methylglucoside transport and phosphorylation system in a mutant of *Escherichia coli* K12 resistant to catabolic repression by glucose. *Dokl. Akad. Nauk SSSR* **215**:1243–1246.
105. **Burman, L. G., and K. Nordstrom.** 1971. Colicin tolerance induced by ampicillin resistance in a strain of *Escherichia coli* K-12. *J. Bacteriol.* **106**:1–13.
106. **Burns, R. O., J. G. Hofler, and G. H. Luginbuhl.** 1979. Threonine deaminase from *Salmonella typhimurium*. Substrate-specific patterns of inhibition in an activation site-deficient form of the enzyme. *J. Biol. Chem.* **254**:1074–1079.
107. **Burton, K.** 1977. Transport of adenine, hypoxanthine and uracil into *Escherichia coli*. *Biochem. J.* **168**:195–204.
108. **Buttin, G.** 1963. Mécanismes régulateurs dans la biosynthèse des enzymes du métabolisme du galactose chez *Escherichia coli* K12. *J. Mol. Biol.* **7**:183–205.
109. **Buxton, R. S.** 1971. Genetic analysis of *Escherichia coli* K-12 mutants resistant to bacteriophage BF23 and the E-group colicins. *Mol. Gen. Genet.* **113**:154–156.
110. **Buxton, R. S., K. Hammer-Jespersen, and T. D. Hansen.** 1978. Insertion of bacteriophage lambda into the *deo* operon of *Escherichia coli* K-12 and isolation of plaque-forming λ *deo*⁺ transducing bacteriophages. *J. Bacteriol.* **136**:668–681.
111. **Buxton, R. S., K. Hammer-Jespersen, and P. Valentin-Hansen.** 1980. A second purine nucleoside phosphorylase in *Escherichia coli* K-12. I. Xanthosine phosphorylase regulatory mutants isolated as secondary-site revertants of a *deoD* mutant. *Mol. Gen. Genet.* **179**:331–340.
112. **Calcott, P. H., and K. N. Calcott.** 1984. Involvement of outer membrane proteins in freeze thaw resistance of *Escherichia coli*. *Can. J. Microbiol.* **30**:339–344.
113. **Calendar, R., B. Lindquist, G. Sironi, and A. J. Clark.** 1970. Characterization of REP[−] mutants and their interaction with P2 phage. *Virology* **40**:72–83.
114. **Caligiuri, M. G., and R. Bauerle.** 1991. Identification of amino acid residues involved in feedback regulation of the anthranilate synthase complex from *Salmonella typhimurium*: evidence for an amino-terminal regulatory site. *J. Biol. Chem.* **266**:8328–8335.
115. **Calvo, J. M., M. Freundlich, and H. E. Umbarger.** 1969. Regulation of branched-chain amino acid biosynthesis in *Salmonella typhimurium*: isolation of regulatory mutants. *J. Bacteriol.* **97**:1272–1282.
116. **Calvo, J. M., P. Margolin, and H. E. Umbarger.** 1969. Operator constitutive mutations in the leucine operon of *Salmonella typhimurium*. *Genetics* **61**:777–787.
117. **Calvo, R. A., and J. M. Calvo.** 1967. Lack of end-product inhibition and repression of leucine synthesis in a strain of *Salmonella typhimurium*. *Science* **156**:1107–1109.
118. **Campbell, J. H., J. Lengyel, and J. Langridge.** 1973. Evolution of a second gene for β-galactosidase in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **70**:1841–1845.
119. **Cannon, M., T. Cabezon, and A. Bollen.** 1979. Mapping of neamine resistance: identification of two genetic loci, *neaA* and *neaB*. *Mol. Gen. Genet.* **130**:321–326.
120. **Cardelli, J., and J. Konisky.** 1974. Isolation and characterization of an *Escherichia coli* mutant

- tolerant to colicins Ia and Ib. *J. Bacteriol.* **119**:379–385.
121. **Casse, F.** 1970. Mapping of the gene *chlB* controlling membrane bound nitrate reductase and formic hydrogen-lyase activities in *Escherichia coli* K-12. *Biochem. Biophys. Res. Commun.* **39**:429–436.
122. **Casse, F., M. C. Pascal, M. Chippaux, and J. Ratouchniak.** 1972. Mapping of the *chlB* gene in *Salmonella typhimurium* LT2. *Mol. Gen. Genet.* **119**:67–70.
123. **Caster, J. H.** 1967. Selection of thymine-requiring strains from *Escherichia coli* on solid medium. *J. Bacteriol.* **94**:1804.
124. **Chai, T., and J. Foulds.** Missing outer membrane protein in *tolG* mutants of *Escherichia coli*. *J. Mol. Biol.* **85**:465–474.
125. **Chai, T.-J., V. Wu, and J. Foulds.** 1982. Colicin A receptor role of two *Escherichia coli* outer membrane proteins (OmpF protein and *btuB* gene product) and lipopolysaccharide. *J. Bacteriol.* **151**:983–988.
126. **Chang, G. W., D. Straus, and B. N. Ames.** 1971. Enriched selection of dominant mutations: histidine operator mutations. *J. Bacteriol.* **107**:578–579.
127. **Chater, K. F., and R. J. Rowbury.** 1970. A genetical study of the feedback-sensitive enzyme of methionine synthesis in *Salmonella typhimurium*. *J. Gen. Microbiol.* **63**:111–120.
128. **Chattopadhyay, M. K., A. K. Ghosh, and S. Sengupta.** 1991. Control of methionine biosynthesis in *Escherichia coli* K12: a closer study with analog resistant mutants. *J. Gen. Microbiol.* **137**:685–691.
129. **Chen, M. X., N. Bouquin, V. Norris, S. Casaregola, S. J. Seror, J. Simone, and I. B. Holland.** A single base change in the acceptor stem of tRNA₃^{Leu} confers resistance upon *Escherichia coli* to the calmodulin inhibitor 48/80. *EMBO J.* **10**:3113–3122.
130. **Chippaux, M., D. Giudici, A. Abou-Jaoude, and M. C. Pascal.** 1978. A mutation leading to the total lack of nitrate reductase activity in *Escherichia coli* K12. *Mol. Gen. Genet.* **160**:225–229.
131. **Christman, M. F., R. W. Morgan, F. S. Jacobson, and B. N. Ames.** 1985. Positive control of a regulon for defenses against oxidative stress and some heat-shock proteins in *Salmonella typhimurium*. *Cell* **41**:753–762.
132. **Clark, D., and J. E. Cronan, Jr.** 1980. *Escherichia coli* mutants with altered control of alcohol dehydrogenase and nitrate reductase. *J. Bacteriol.* **141**:177–183.
133. **Clark, D. P., and J. P. Beard.** 1979. Altered phospholipid composition in mutants of *Escherichia coli* sensitive or resistant to organic solvents. *J. Gen. Microbiol.* **113**:267–279.
134. **Clement, J. M., C. Braun-Breton, E. Lepouce, C. Marchal, D. Perrin, H. Villarroya, and M. Hofnung.** 1982. A system for genetic analysis in gene *lamB*: first results with lambda resistant tight mutants. *Ann. Microbiol.* **133A**:9–20.
135. **Clement, J.-M., E. Lepouce, C. Marchal, and M. Hofnung.** 1983. Genetic study of a membrane protein: DNA sequence alterations due to 17 *lamB* point mutations affecting adsorption of phage lambda. *EMBO J.* **2**:77–80.
136. **Clifton, G., S. R. Bryant, and C. G. Skinner.** 1970. N¹-(substituted) pantothenamides, antimetabolites of pantothenic acid. *Arch. Biochem. Biophys.* **137**:523–528.
137. **Cohen, G., and F. Jacob.** 1959. Sur la répression de la synthèse des enzymes intervenant dans la formation du tryptophane chez *Escherichia coli*. *C.R. Acad. Sci. Ser. D* **248**:3490–3492.
138. **Cohen, G. N., J.-C. Patte, P. Truffa-Bachi, C. Sawas, and M. Doudoroff.** 1965. Repression and end-product inhibition in a branched biosynthetic pathway, p. 243–253. In *Mécanismes de Regulation des Activités Cellulaires chez les Micro-organismes*. Centre National de la Recherche Scientifique, Paris.
139. **Cole, S. T., and J. R Guest.** 1979. Production of a soluble form of fumarate reductase by multiple gene duplications in *Escherichia coli* K12. *Eur. J. Biochem.* **102**:65–71.
140. **Coleman, J., S. Inouye, and M. Inouye.** 1983. Isolation of mutants of the major outer membrane lipoprotein of *Escherichia coli* for the study of its assembly. *Methods Enzymol.* **97**:124–129.
141. **Coleman, W. G., and L. Leive.** 1979. Two mutations which affect the barrier function of the *Escherichia coli* K-12 outer membrane. *J. Bacteriol.* **139**:899–910.

142. **Cookson, B. T., B. M. Olivera, and J. R. Roth.** 1987. Genetic characterization and regulation of the *nadB* locus of *Salmonella typhimurium*. *J. Bacteriol.* **169**:4285–4293.
143. **Cooley, W., K. Sirotkin, R. Green, and L. Snyder.** 1979. A new gene of *Escherichia coli* K-12 whose product participates in T4 bacteriophage late gene expression: interaction of *lit* with the T4-induced polynucleotide 5'-kinase 3'-phosphatase. *J. Bacteriol.* **140**:83–91.
144. **Cooper, R. A.** 1978. The utilization of D-galactonate and D-2-oxo-3-deoxygalactonate by *Escherichia coli* K-12. *Arch. Microbiol.* **118**:199–206.
145. **Corchuelo, M. C., A. Herzog, L. Desmarez, R. Lavalle, and A. Bollen.** 1981. Resistance to the peptide-like antibiotic negamycin in *Escherichia coli*. *Biochem. Biophys. Res. Commun.* **100**:1497–1503.
146. **Cordaro, J. C., T. Melton, J. P. Stratis, M. Atagun, C. Gladding, P. E. Hartman, and S. Roseman.** 1976. Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of *Salmonella typhimurium*. *J. Bacteriol.* **128**:785–793.
147. **Cordaro, J. C., and S. Roseman.** 1972. Deletion mapping of the genes coding for HPr and enzyme I of the phosphoenolpyruvate:sugar phosphotransferase system in *Salmonella typhimurium*. *J. Bacteriol.* **112**:17–29.
148. **Cortese, R., R. Landsberg, R. A. VanderHaar, H. E. Umbarger, and B. N. Ames.** 1974. Pleiotropy of *hisT* mutants blocked in pseudouridine synthesis in tRNA: *leucine* and *isoleucine-valine* operons. *Proc. Natl. Acad. Sci. USA* **71**:1857–1861.
149. **Corwin, L. M., G. R. Fanning, F. Feldman, and P. Margolin.** 1966. Mutation leading to increased sensitivity to chromium ion in *Salmonella typhimurium*. *J. Bacteriol.* **91**:1509–1515.
150. **Cosloy, S. D.** 1973. D-Serine transport system in *Escherichia coli* K-12. *J. Bacteriol.* **114**:679–684.
151. **Coulton, J. W., P. Mason, D. R. Cameron, G. Carmel, R. Jean, and H. N. Rode.** 1986. Protein fusions of β-galactosidase to the ferrichrome-iron receptor of *Escherichia coli* K-12. *J. Bacteriol.* **165**:181–192.
152. **Cox, E. C., and T. C. Gibson.** 1974. Selection for high mutation rates in chemostats. *Genetics* **77**:169–184.
153. **Crabeel, M., D. Charlier, R. Cunin, A. Bogen, N. Glansdorf, and A. Pierard.** 1975. Accumulation of arginine precursors in *Escherichia coli*: effects on growth, enzyme repression, and application to the forward selection of arginine auxotrophs. *J. Bacteriol.* **123**:898–904.
154. **Creaghan, I. T., and J. R. Guest.** 1975. Suppression of the succinate requirement of lipoamide dehydrogenase mutants of *Escherichia coli* by mutations affecting succinate dehydrogenase activity. *J. Gen. Microbiol.* **102**:183–194.
155. **Csonka, L. N.** 1981. Proline over-production results in enhanced osmotolerance in *Salmonella typhimurium*. *Mol. Gen. Genet.* **182**:82–86.
156. **Csonka, L. N.** 1982. A third L-proline permease in *Salmonella typhimurium* which functions in media of elevated osmotic strength. *J. Bacteriol.* **151**:1433–1443.
157. **Cunningham, P. R., and D. P. Clark.** 1986. The use of suicide substrates to select mutants of *Escherichia coli* lacking enzymes of alcohol fermentation. *Mol. Gen. Genet.* **205**:487–493.
158. **Curtis, S. J., and W. Epstein.** 1975. Phosphorylation of D-glucose in *Escherichia coli* mutants defective in glucosephosphotransferase, mannosephosphotransferase, and glucokinase. *J. Bacteriol.* **122**:1189–1199.
159. **Dabbs, E. R.** 1978. Kasugamycin-dependent mutants of *Escherichia coli*. *J. Bacteriol.* **136**:994–1001.
160. **Dabbs, E. R.** 1982. Three additional loci of rifampicin dependence in *Escherichia coli*. *Mol. Gen. Genet.* **187**:519–522.
161. **Dabbs, E. R.** 1983. *Escherichia coli* kasugamycin dependence arising from mutation at the *rpsI* locus. *J. Bacteriol.* **153**:709–715.
162. **Dabbs, E. R., and K. Looman.** 1981. An antibiotic dependent conditional lethal mutant with a lesion affecting transcription and translation. *Mol. Gen. Genet.* **184**:224–229.

163. **Dabbs, E. R., B. Poldermans, H. Bakker, and P. H. Van Knippenberg.** 1980. Biochemical characterization of ribosomes of kasugamycin-dependent mutants of *Escherichia coli*. *FEBS Lett.* **117**:164–166.
164. **Dame, J. B., and B. M. Shapiro.** 1976. Use of polymyxin B, levallorphan, and tetracaine to isolate novel mutants of *Escherichia coli*. *J. Bacteriol.* **127**:961–972.
165. **Danchin, A.** 1977. A new technique for selection of sensitive and auxotrophic mutants of *E. coli*: isolation of a strain sensitive to an excess of one-carbon metabolites. *Mol. Gen. Genet.* **150**:293–299.
166. **Danchin, A., and L. Dondon.** 1980. Serine sensitivity of *Escherichia coli* K-12: partial characterization of a serine resistant mutant that is extremely sensitive to 2-ketobutyrate. *Mol. Gen. Genet.* **178**:155–164.
167. **Daniel, J., and A. Danchin.** 1979. Involvement of cyclic AMP and its receptor protein in the sensitivity of *Escherichia coli* K12 toward serine. *Mol. Gen. Genet.* **176**:343–350.
168. **D'Ari, R., A. Jaffé, P. Bouloc, and A. Robin.** 1988. Cyclic AMP and cell division in *Escherichia coli*. *J. Bacteriol.* **170**:65–70.
169. **Das, A., D. Court, and S. Adhya.** 1976. Isolation and characteristics of conditional-lethal mutants of *Escherichia coli* defective in transcription termination factor rho. *Proc. Natl. Acad. Sci. USA* **73**:1959–1963.
170. **Das, A., B. Ghosh, S. Barik, and K. Wolska.** 1985. Evidence that ribosomal protein S-10 itself is a cellular component necessary for transcription antitermination by phage lambda N protein. *Proc. Natl. Acad. Sci. USA* **82**:4070–4074.
171. **Datta, D. B., B. Arden, and U. Henning.** 1977. Major proteins of the *Escherichia coli* outer cell envelope membrane as bacteriophage receptors. *J. Bacteriol.* **131**:821–829.
172. **Davies, J., P. Anderson, and B. D. Davis.** 1965. Inhibition of protein synthesis by spectinomycin. *Science* **149**:1096–1098.
173. **Davies, J. K., and P. Reeves.** 1975. Genetics of resistance to colicins in *Escherichia coli* K-12: cross-resistance among colicins of group A. *J. Bacteriol.* **123**:102–117.
174. **Davis, E. J., J. M. Blatt, E. K. Henderson, J. J. Whittaker, and J. H. Jackson.** 1977. Valine-sensitive acetohydroxy acid synthetases in *Escherichia coli* K-12: unique regulation modulated by multiple genetic sites. *Mol. Gen. Genet.* **156**:239–249.
175. **Davis, E. O., M. J. Jones-Mortimer, and P. J. F. Henderson.** 1984. Location of a structural gene for xylose proton symport at 91 minutes on the linkage map of *Escherichia coli* K12. *J. Biol. Chem.* **259**:1520–1525.
176. **Daws, T. D., and J. A. Fuchs.** 1984. Isolation and characterization of an *Escherichia coli* mutant deficient in dTMP kinase activity. *J. Bacteriol.* **157**:440–444.
177. **Dean, D. A., J. Reizer, H. Nikaido, and M. H. Saier, Jr.** 1990. Regulation of the maltose transport system of *Escherichia coli* by the glucose-specific enzyme III of the phosphoenolpyruvate-sugar phosphotransferase system. Characterization of inducer exclusion resistant mutants and reconstitution of inducer exclusion in proteoliposomes. *J. Biol. Chem.* **265**:21005–21010.
178. **DeFelice, M., J. Guardiola, A. Lamberti, and M. Iaccarino.** 1973. *Escherichia coli* K-12 mutants altered in the transport systems for oligo- and dipeptides. *J. Bacteriol.* **116**:751–756.
179. **Defez, R., and M. DeFelice.** 1981. Cryptic operon for β-glucoside metabolism in *Escherichia coli* K12: genetic evidence for a regulatory protein. *Genetics* **97**:11–25.
180. **Del Campillo-Campbell, A., and A. Campbell.** 1982. Molybdenum cofactor requirement for biotin sulfoxide reduction in *Escherichia coli*. *J. Bacteriol.* **149**:469–478.
181. **Del Castillo, I., J. L. Vizan, M. Del Carmen Rodriguez-Sainz, and F. Moreno.** 1991. An unusual mechanism for resistance to the antibiotic coumermycin A-1. *Proc. Natl. Acad. Sci. USA* **88**:8860–8864.
182. **Delcuve, G., T. Cabezon, A. Herzog, M. Cannon, and A. Bollen.** 1978. Resistance to the aminoglycoside antibiotic neamine in *Escherichia coli*. A new mutant whose Nea^R phenotype results from the cumulative effects of two distinct mutations. *Biochem. J.* **174**:1–7.
183. **DelGiudice, L.** 1979. Method for isolating restriction- and modification-less mutants of *Escherichia coli* K-12. *J. Bacteriol.* **137**:673–676.

184. **Delidakis, C. E., M. C. Jones-Mortimer, and H. L. Kornberg.** 1982. A mutant inducible for galactitol utilization in *Escherichia coli* K12. *J. Gen. Microbiol.* **128**:601–604.
185. **Delvaux, A. M., and R. Devoret.** 1969. Occurrence of suppressors in caffeine-resistant mutants from *Escherichia coli* K12. *Mutat. Res.* **7**:273–285.
186. **Dempsey, W. B., and L. J. Arcement.** 1971. Identification of the forms of vitamin B₆ present in the culture media of “vitamin B₆ control” mutants. *J. Bacteriol.* **107**:580–582.
187. **Dendinger, S., and W. J. Brill.** 1972. Effect of the proline analogue baikain on proline metabolism in *Salmonella typhimurium*. *J. Bacteriol.* **112**:1134–1141.
188. **Dendinger, S. M., L. G. Patil, and J. E. Brenchley.** 1980. *Salmonella typhimurium* mutants with altered glutamate dehydrogenase and glutamate synthase activities. *J. Bacteriol.* **141**:190–198.
189. **Desrochers, M., L. Peloquin, and A. Sasarman.** 1978. Mapping of the *hemE* locus in *Salmonella typhimurium*. *J. Bacteriol.* **135**:1151–1153.
190. **Devoret, R., and M. Blanco.** 1970. Mutants of *Escherichia coli* K12 λ⁺ noninducible by thymine deprivation. I. Method of isolation and classes of mutants obtained. *Mol. Gen. Genet.* **107**:272–280.
191. **Dietz, G. W., Jr.** 1978. Growth of *Escherichia coli* on glucosamine 6-phosphate; selection of a constitutive hexose phosphate transport system mutant. *Can. J. Microbiol.* **24**:203–208.
192. **Dietz, G. W., and L. A. Heppel.** 1971. Studies on the uptake of hexose phosphates. III. Mechanism of uptake of glucose 1-phosphate in *Escherichia coli*. *J. Biol. Chem.* **246**:2891–2897.
193. **Dila, D. K., and S. R. Maloy.** 1986. Proline transport in *Salmonella typhimurium putP* permease mutants with altered substrate specificity. *J. Bacteriol.* **168**:590–594.
194. **DiNardo, S., K. A. Voelkel, R. Sternglanz, A. E. Reynolds, and A. Wright.** 1982. *Escherichia coli* DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. *Cell* **31**:43–51.
195. **Dombou, M., T. Mizuno, and S. Mizushima.** 1977. Interaction of the cytoplasmic membrane and ribosomes in *Escherichia coli*; altered ribosomal proteins in sucrose-dependent spectinomycin-resistant mutants. *Mol. Gen. Genet.* **155**:53–60.
196. **Doskocil, J., and F. Sorm.** 1970. The mode of action of 5-aza-2'-deoxycytidine in *Escherichia coli*. *Eur. J. Biochem.* **13**:180–187.
197. **Dover, S., and Y. S. Halpern.** 1974. Genetic analysis of the γ-aminobutyrate utilization pathway in *Escherichia coli* K-12. *J. Bacteriol.* **117**:494–501.
198. **Downs, D., L. Waxman, A. L. Goldberg, and J. Roth.** 1986. Isolation and characterization of *lon* mutants in *Salmonella typhimurium*. *J. Bacteriol.* **165**:193–197.
199. **Drexler, K., I. Riede, D. Montag, M.-L. Eschbach, and U. Henning.** 1989. Receptor specificity of the *Escherichia coli* T-even type phage Ox2: mutational alterations in host range mutants. *J. Mol. Biol.* **207**:797–804.
200. **Droffner, M. L., and N. Yamamoto.** 1992. Role of nalidixic acid in isolation of *Salmonella typhimurium* strains capable of growth at 48°C. *Curr. Microbiol.* **25**:257–260.
201. **Drury, L. S., and R. S. Buxton.** 1988. Identification and sequencing of the *Escherichia coli cet* gene which codes for an inner membrane protein, mutation of which causes tolerance to colicin E2. *Mol. Microbiol.* **2**:109–119.
202. **Dubnau, E., and P. Margolin.** 1972. Suppression of promoter mutations by the pleiotrophic *supX* mutations. *Mol. Gen. Genet.* **117**:91–112.
203. **Duncan, B. K., P. A. Rockstroh, and H. R. Warner.** 1978. *Escherichia coli* K-12 mutants deficient in uracil-DNA glycosylase. *J. Bacteriol.* **134**:1039–1045.
204. **Echols, H., A. Garen, S. Garen, and A. Torriani.** 1961. Genetic control of repression of alkaline phosphatase in *E. coli*. *J. Mol. Biol.* **3**:425–438.
205. **Eick-Helmerich, K., and V. Braun.** 1989. Import of biopolymers into *Escherichia coli* nucleotide sequences of the *exbB* and *exbD* genes are homologous to those of the *tolQ* and *tolR* genes, respectively. *J. Bacteriol.* **171**:5117–5126.
206. **Eisenberg, M. A., B. Mee, O. Prakash, and M. R. Eisenberg.** 1975. Properties of α-dehydروبوتين-resistant mutant of *Escherichia coli* K-12. *J. Bacteriol.* **122**:66–72.
207. **Elwell, L. P., R. Ferone, G. A. Freeman, J. A. Fyfe, J. A. Hill, P. H. Ray, C. A. Richards, S. C.**

- Singer, V. B. Knick, J. L. Rideout, and T. P. Zimmerman.** 1987. Antibacterial activity and mechanism of action of 3' azido-3'-deoxythymidine BWA-509U. *Antimicrob. Agents Chemother.* **31**:274–280.
208. **Ely, B., D. B. Fankhauser, and P. E. Hartman.** 1974. A fine structure map of the *Salmonella* histidine operator-promoter. *Genetics* **78**:607–631.
209. **Englesberg, E., J. Irr, J. Power, and N. Lee.** 1965. Positive control of enzyme synthesis by gene C in the L-arabinose system. *J. Bacteriol.* **90**:946–957.
210. **Eriksson-Grennberg, K. G., H. G. Boman, J. A. T. Jansson, and S. Thoren.** 1965. Resistance of *Escherichia coli* to penicillins. I. Genetic study of some ampicillin-resistant mutants. *J. Bacteriol.* **90**:54–62.
211. **Eriksson-Grennberg, K. G., and K. Nordstrom.** 1973. Genetics and physiology of a *tolE* mutant of *Escherichia coli* K-12 and phenotypic suppression of its phenotype by galactose. *J. Bacteriol.* **115**:1219–1222.
212. **Eriksson-Grennberg, K. G., K. Nordstrom, and P. Englund.** 1971. Resistance of *Escherichia coli* to penicillins. IX. Genetics and physiology of class II ampicillin-resistant mutants that are galactose negative or sensitive to bacteriophage C21, or both. *J. Bacteriol.* **108**:1210–1223.
213. **Essenberg, R. C.** 1984. Use of homocysteic acid for selecting mutants at the *gltS* locus of *Escherichia coli* K12. *J. Gen. Microbiol.* **130**:1311–1314.
214. **Essenberg, R. C., and H. L. Kornberg.** 1977. Location of the gene for hexose phosphate transport (*uhp*) on the chromosome of *Escherichia coli*. *J. Gen. Microbiol.* **99**:157–169.
215. **Ezekiel, D. H.** 1965. False feedback inhibition of aromatic amino acid biosynthesis by β-2-thienylalanine. *Biochim. Biophys. Acta* **95**:54–62.
216. **Ezekiel, D., and J. E. Hutchins.** 1968. Mutations affecting RNA polymerase associated with rifampicin resistance in *Escherichia coli*. *Nature* (London) **220**:276–277.
217. **Faik, P., and H. L. Kornberg.** 1973. Isolation and properties of *E. coli* mutants affected in gluconate uptake. *FEBS Lett.* **32**:260–263.
218. **Fangman, W. L., and F. C. Neidhardt.** 1964. Demonstration of an altered aminoacyl ribonucleic acid synthetase in a mutant of *Escherichia coli*. *J. Biol. Chem.* **239**:1839–1843.
219. **Farley, M. M., W. M. Shafer, and J. K. Spitznagel.** 1988. Lipopolysaccharide structure determines ionic and hydrophobic binding of a cationic antimicrobial neutrophil granule protein. *Infect. Immun.* **56**:1589–1592.
220. **Fasano, O., and A. Parmeggiani.** 1981. Altered regulation of the GTPase activity in a kirromycin resistant elongation factor Tu. *Biochemistry* **20**:1361–1366.
221. **Favre, R., A. Wiater, S. Puppo, and M. Iaccarino.** 1976. Expression of a valine resistant acetolactate synthase activity mediated by the *ilvO* and *ilvG* genes of *Escherichia coli* K12. *Mol. Gen. Genet.* **143**:243–252.
222. **Fayerman, J. T., M. C. Vann, L S. Williams, and H. E. Umbarger.** 1979. *ilvU*, a locus in *Escherichia coli* affecting the derepression of isoleucyl-tRNA synthetase and the RPC-5 chromatographic profiles of tRNA^{ile} and tRNA^{val}. *J. Biol. Chem.* **254**:9429–9440.
223. **Ferenci, T.** 1980. Methyl-α-maltoside and 5-thiomaltose: analogs transported by the *Escherichia coli* maltose transport system. *J. Bacteriol.* **144**:7–11.
224. **Ferenci, T., H. L. Kornberg, and J. Smith.** 1971. Isolation and properties of a regulatory mutant in the hexose phosphate transport system of *Escherichia coli*. *FEBS Lett.* **13**:133–136.
225. **Fillingame, R. H.** 1975. Identification of the dicyclohexylcarbodiimide-reactive protein component of the adenosine 5'-triphosphate transducing system of *Escherichia coli*. *J. Bacteriol.* **124**:870–883.
226. **Fillingame, R. H., M. Oldenburg, and D. Fraga.** 1991. Mutation of alanine-24 to serine in subunit C of the *Escherichia coli* F-1 F-O ATP synthase reduces reactivity of aspartyl 61 with dicyclohexylcarbodiimide. *J. Biol. Chem.* **266**:20934–20939.
227. **Filitowicz, M., Z. Ciesla, and T. Kłopotowski.** 1979. Interference of azide with cysteine biosynthesis in *Salmonella typhimurium*. *J. Gen. Microbiol.* **113**:45–55.
228. **Fimmel, A., and B. Haddock.** 1979. Use of *chlC-lac* fusions to determine regulation of gene *chlC*

- in *Escherichia coli* K-12. *J. Bacteriol.* **138**:726–730.
229. **Fimmel, A. L., D. A. Jans, L. Hatch, L. B. James, F. Gibson, and G. B. Cox.** 1985. The F-1 F-0 ATPase of *Escherichia coli* : the substitution of alanine by threonine at position 25 in the C-subunit affects function but not assembly. *Biochim. Biophys. Acta* **808**:252–258.
230. **Fimmel, A. L., and R. E. Loughlin.** 1977. Isolation and characterization of *cysK* mutants of *Escherichia coli*. *J. Gen. Microbiol.* **103**:37–43.
231. **Fisher, K. E., and E. Eisenstein.** 1993. An efficient approach to identify *ilvA* mutations reveals an amino-terminal catalytic domain in biosynthetic threonine deaminase from *Escherichia coli*. *J. Bacteriol.* **175**:6605–6613.
232. **Fortin, T., P. Phoenix, and G. R. Drapeau.** 1990. Mutations conferring resistance to azide in *Escherichia coli* occur primarily in the *secA* gene. *J. Bacteriol.* **172**:6607–6610.
233. **Foster, J. W., and H. K. Hall.** 1990. Adaptive acidification tolerance response of *Salmonella typhimurium*. *J. Bacteriol.* **172**:771–778.
234. **Foster, J. W., D. M. Kinney, and A. G. Moat.** 1979. Pyridine nucleotide cycle of *Salmonella typhimurium*: isolation and characterization of *pncA*, *pncB*, and *pncC* mutants and utilization of exogenous nicotinamide adenine dinucleotide. *J. Bacteriol.* **137**:1165–1175.
235. **Foulds, J.** 1976. *tolF* locus in *Escherichia coli*: chromosomal location and relationship to loci *cmlB* and *tolD*. *J. Bacteriol.* **128**:604–608.
236. **Foulds, J., and C. Barrett.** 1973. Characterization of *Escherichia coli* mutants tolerant to bacteriocin JF246: two new classes of tolerant mutants. *J. Bacteriol.* **116**:885–892.
237. **Foulds, J., and T.-J. Chai.** 1978. New major outer membrane protein found in an *Escherichia coli tolF* mutant resistant to bacteriophage TuIb. *J. Bacteriol.* **133**:1478–1483.
238. **Fouts, K. E., and S. D. Barbour.** 1981. Transductional mapping of *ksgB* and a new Tn5-induced kasugamycin resistance gene, *ksgD*, in *Escherichia coli* K-12. *J. Bacteriol.* **145**:914–919.
239. **Fradkin, J. E., and D. G. Fraenkel.** 1971. 2-Keto-3-deoxygluconate 6-phosphate aldolase mutants of *Escherichia coli*. *J. Bacteriol.* **108**:1277–1283.
240. **Fraenkel, D. G., and S. Banerjee.** 1972. Deletion mapping of *zwf*, the gene for a constitutive enzyme, glucose 6-phosphate dehydrogenase in *Escherichia coli*. *Genetics* **71**:481–489.
241. **Franco, P. J., J. A. Elkema, and R. J. Brooker.** 1989. Isolation and characterization of thiogalactoside resistant mutants of the lactose permease which possess an enhanced recognition for maltose. *J. Biol. Chem.* **264**:15988–15992.
242. **Franklin, N. C.** 1969. Mutation in *galU* gene of *E. coli* blocks phage Pl infection. *Virology* **38**:189–191.
243. **Friedberg, I.** 1972. Localization of phosphoglucose isomerase in *Escherichia coli* and its relation to the induction of the hexose phosphate transport system. *J. Bacteriol.* **112**:1201–1205.
244. **Friedman, D. I.** 1971. A bacterial mutant affecting lambda development, p. 733–738. In A. D. Hershey (ed.), *The Bacteriophage Lambda*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
245. **Friedman, D. I., and M. Baumann.** 1976. Cooperative effects of bacterial mutations affecting λ N gene expression. 1. Isolation and characterization of a *nusB* mutant. *Virology* **73**:119–127.
246. **Friedman, D. I., and M. Gottesman.** 1983. Lytic mode of λ development, p. 21–51. In R. W. Hendrix, J. W. Roberts, F. W. Stahl, and R. A. Weisberg (ed.), *Lambda II*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
247. **Friedman, S.** 1982. Bactericidal effect of 5-azacytidine on *Escherichia coli* carrying EcoRII restriction-modification enzymes. *J. Bacteriol.* **151**:262–268.
248. **Froehler, J., A. Rechenmacher, J. Thomale, G. Nass, and A. Boeck.** 1980. Genetic analysis of mutations causing borrelidin resistance by overproduction of threonyl-transfer ribonucleic acid synthetase. *J. Bacteriol.* **143**:1135–1141.
249. **Fujita, H., S. Yamaguchi, T. Taira, and T. Iino.** 1981. A simple method for the isolation of flagellar shape mutants in *Salmonella*. *J. Gen. Microbiol.* **125**:213–216.
250. **Furukawa, H., J.-T. Tsay, S. Jackowski, Y. Takamura, and C. O. Rock.** 1993. Thiolactomycin resistance in *Escherichia coli* is associated with the multidrug resistance efflux pump encoded by

- emrAB*. *J. Bacteriol.* **175**:3723–3729.
251. **Garber, B. B., and J. S. Gots.** 1980. Utilization of 2,6-diaminopurine by *Salmonella typhimurium*. *J. Bacteriol.* **143**:864–871.
252. **Gayda, R. C., L. T. Yamamoto, and A. Markovitz.** 1976. Second-site mutations in *capR(lon)* strains of *Escherichia coli* K-12 that prevent radiation sensitivity and allow bacteriophage lambda to lysogenize. *J. Bacteriol.* **127**:1208–1216.
253. **Gehring, K., A. Charbit, E. Brissaud, and M. Hofnung.** 1987. Bacteriophage lambda receptor site on the *Escherichia coli* K-12 *lamB* protein. *J. Bacteriol.* **169**:2103–2106.
254. **Gellert, M., and M. L. Bullock.** 1970. DNA ligase mutants of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **67**:1580–1587.
255. **Gellert, M., M. H. O'Dea, T. Itoh, and J.-I. Tomizawa.** 1976. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. *Proc. Natl. Acad. Sci. USA* **73**:4474–4478.
256. **Georgopoulos, C. P.** 1971. Bacterial mutants in which the gene N function of bacteriophage lambda is blocked have an altered RNA polymerase. *Proc. Natl. Acad. Sci. USA* **68**:2977–2981.
257. **Georgopoulos, C. P.** 1977. A new bacterial gene *groPC* which affects phage lambda DNA replication. *Mol. Gen. Genet.* **151**:35–40.
258. **Georgopoulos, C. P., R. W. Hendrix, and A. D. Kaiser.** 1972. Role of the host cell in bacteriophage morphogenesis: effects of a bacterial mutation on T4 head assembly. *Nature (London) New Biol.* **239**:38–41.
259. **Georgopoulos, C. P., and I. Herskowitz.** 1971. *Escherichia coli* mutants blocked in lambda DNA synthesis, p. 553–564. In A. D. Hershey (ed.), *The Bacteriophage Lambda*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
260. **Georgopoulos, C. P., J. Swindle, F. Keppel, M. Ballivet, R. Bisig, and H. Eisen.** 1980. Studies on the *E. coli* *groNB* (*nusB*) gene which affects bacteriophage λ N gene function. *Mol. Gen. Genet.* **179**:55–61.
261. **Ghysen, A., and M. Pirionio.** 1972. Relationship between the N function of bacteriophage λ and host RNA polymerase. *J. Mol. Biol.* **65**:259–272.
262. **Gibson, M. M., D. A. Bagga, C. G. Miller, and M. E. Maguire.** 1991. Magnesium transport in *Salmonella typhimurium*: the influence of new mutations conferring Co²⁺ resistance on the CorA Mg²⁺ transport system. *Mol. Microbiol.* **5**:2753–2762.
263. **Gibson, M. M., M. Price, and C. F. Higgins.** 1984. Genetic characterization and molecular cloning of the tripeptide permease (*tpp*) genes of *Salmonella typhimurium*. *J. Bacteriol.* **160**:122–130.
264. **Ginther, C. L., and J. L. Ingraham.** 1974. Cold-sensitive mutant of *Salmonella typhimurium* defective in nucleoside diphosphokinase. *J. Bacteriol.* **118**:1020–1026.
265. **Giordano, G., L. Grillet, R. Rosset, J. H. Dou, and E. Azoulay.** 1978. Characterization of an *E. coli* mutant that is sensitive to chlorate when grown aerobically. *Biochem. J.* **176**:553–561.
266. **Glaser, J. H., and J. A. DeMoss.** 1972. Comparison of nitrate reductase mutants of *Escherichia coli* selected by alternative procedures. *Mol. Gen. Genet.* **116**:1–10.
267. **Glickman, B. W., and M. Radman.** 1980. *Escherichia coli* mutator mutants deficient in methylation instructed DNA mismatch correction. *Proc. Natl. Acad. Sci. USA* **77**:1063–1067.
268. **Glover, S. W.** 1962. Valine-resistant mutants of *Escherichia coli* K-12. *Genet. Res.* **3**:448–460.
269. **Gollop, N., H. Tavori, and Z. Barak.** 1982. Acetohydroxy acid synthase is a target for leucine-containing peptide toxicity in *Escherichia coli*. *J. Bacteriol.* **149**:387–390.
270. **Gollub, E., and D. B. Sprinson.** 1969. A regulatory mutation in tyrosine biosynthesis. *Biochem. Biophys. Res. Commun.* **35**:389–395.
271. **Gollub, E. G., K. P. Liu, and D. B. Sprinson.** 1973. A regulatory gene of phenylalanine biosynthesis (*pheR*) in *Salmonella typhimurium*. *J. Bacteriol.* **115**:121–128.
272. **Gots, J. S., C. E. Benson, and S. R. Shumas.** 1972. Genetic separation of hypoxanthine and guanine-xanthine phosphoribosyltransferase activities by deletion mutations in *Salmonella typhimurium*. *J. Bacteriol.* **112**:910–916.
273. **Green, L., and C. G. Miller.** 1980. Genetic mapping of the *Salmonella typhimurium* *pepB* locus. *J. Bacteriol.* **143**:1524–1526.

274. **Greenberg, J. T., J. H. Chou, P. A. Monach, and B. Demple.** 1991. Activation of oxidative stress genes by mutations at the *soxQ/cfxB/marA* locus of *Escherichia coli*. *J. Bacteriol.* **173**:4433–4439.
275. **Greene, R. C., J. V. Hunter, and E. H. Coch.** 1973. Properties of *metK* mutants of *Escherichia coli* K-12. *J. Bacteriol.* **115**:57–67.
276. **Gruell, J. M., H. Hennecke, J. Froehler, J. Thomale, G. Nass, and A. Böck.** 1979. *Escherichia coli* mutants overproducing phenylalanyl transfer RNA synthetase and threonyl transfer RNA synthetase. *J. Bacteriol.* **137**:480–489.
277. **Guardiola, J., M. DeFelice, T. Klopotowski, and M. Iaccarino.** 1974. Mutations affecting the different transport systems for isoleucine, leucine, and valine in *Escherichia coli* K-12. *J. Bacteriol.* **117**:393–405.
278. **Guardiola, J., and M. Iaccarino.** 1971. *Escherichia coli* K-12 mutants altered in the transport of branched-chain amino acids. *J. Bacteriol.* **108**:1034–1044.
279. **Guarneros, G., G. Machado, P. Guzman and E. Garay.** 1987. Genetic and physical location of the *Escherichia coli* *rap* locus, which is essential for growth of bacteriophage lambda. *J. Bacteriol.* **169**:5188–5192.
280. **Guest, J. R.** 1969. Biochemical and genetic studies with nitrate reductase C-gene mutants of *Escherichia coli*. *Mol. Gen. Genet.* **105**:285–297.
281. **Guest, J. R.** 1979. Anaerobic growth of *Escherichia coli* K12 with fumarate as terminal electron acceptor. Genetic studies with menaquinone and fluoroacetate-resistant mutants. *J. Gen. Microbiol.* **115**:259–271.
282. **Gupta, A., and S. Kumar.** 1985. Roles of internally and externally supplied cyclic AMP in the growth response of *Escherichia coli* to sodium chloride. *Indian J. Exp. Biol.* **23**:647–652.
283. **Guterman, S. K., and L. Dann.** 1973. Excretion of enterochelin by *exbA* and *exbB* mutants of *Escherichia coli*. *J. Bacteriol.* **114**:1225–1230.
284. **Guterman, S. K., A. Wright, and D. H. Boyd.** 1975. Genes affecting coliphage BF23 and E colicin sensitivity in *Salmonella typhimurium*. *J. Bacteriol.* **124**:1351–1358.
285. **Guth, A., R. Engel, and B. E. Tropp.** 1980. Uptake of glycerol 3-phosphate and some of its analogs by the hexose phosphate transport system of *Escherichia coli*. *J. Bacteriol.* **143**:538–539.
286. **Hachler, H., S. P. Cohen, and S. B. Levy.** 1991. *marA*, a regulated locus which controls expression of chromosomal multiple antibiotic resistance in *Escherichia coli*. *J. Bacteriol.* **173**: 5532–5538.
287. **Hacking, A. J., and E. C. C. Lin.** 1976. Disruption of the fucose pathway as a consequence of genetic adaptation to propanediol as a carbon source in *Escherichia coli*. *J. Bacteriol.* **126**:1166–1172.
288. **Hadar, R., and J. Kuhn.** 1977. A mutant constitutive for aromatic permease. *FEBS Lett.* **76**:77–80.
289. **Hafner, E. W., C. W. Tabor, and H. Tabor.** 1977. Isolation of a *metK* mutant with a temperature-sensitive S-adenosylmethionine synthetase. *J. Bacteriol.* **132**:832–840.
290. **Hall, B. G.** 1982. Chromosomal mutation for citrate utilization by *Escherichia coli* K-12. *J. Bacteriol.* **151**:269–273.
291. **Hall, M. N., and T. J. Silhavy.** 1981. The *ompB* locus and the regulation of the major outer membrane porin proteins of *Escherichia coli* K12. *J. Mol. Biol.* **146**:23–44.
292. **Halpern, Y. S., and H. E. Umbarger.** 1961. Utilization of L-glutamic acid and 2-oxoglutaric acid as sole sources of carbon by *Escherichia coli*. *J. Gen. Microbiol.* **26**:175–183.
293. **Halsall, D. M.** 1975. Strains of *E. coli* with defective lysine transport systems. *Biochem. Genet.* **13**:109–124.
294. **Hama, H., Y. Sumita, Y. Kakutani, M. Tsuda, and T. Tsuchiya.** 1990. Target of serine inhibition in *Escherichia coli*. *Biochem. Biophys. Res. Commun.* **168**:1211–1216.
295. **Hammelburger, J. W., and G. A. Orr.** 1983. Interaction of *sn*-glycerol 3-phosphothioate with *Escherichia coli*: effect on cell growth and metabolism. *J. Bacteriol.* **156**:789–799.
296. **Hammer, K., K. F. Jensen, P. Poulsen, A. B. Oppenheim, and M. Gottesman.** 1987. Isolation of *Escherichia coli* *rpoB* mutants resistant to killing by lambda cII protein and altered in *pyrE* gene

- attenuation. *J. Bacteriol.* **169**:5289–5297.
297. **Hancock, R. E. W., S. W. Farmer, Z. Li, and K. Poole.** 1991. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and *ompF* porin of *Escherichia coli*. *Antimicrob. Agents Chemother.* **35**:1309–1314.
298. **Hane, M. W., and T. H. Wood.** 1969. *Escherichia coli* K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. *J. Bacteriol.* **99**:238–241.
299. **Hantke, K.** 1976. Phage T6-colicin K receptor and nucleoside transport in *Escherichia coli*. *FEBS Lett.* **70**:109–112.
300. **Hantke, K.** 1987. Selection procedure for deregulated iron transport mutants (*fur*) in *Escherichia coli* K12: *fur* not only affects iron metabolism. *Mol. Gen. Genet.* **210**:135–139.
301. **Hardaway, K. L., and C. S. Buller.** 1979. Effects of ethylenediaminetetraacetate on phospholipids and outer membrane function in *Escherichia coli*. *J. Bacteriol.* **137**:62–68.
302. **Harkness, R. E., and V. Braun.** 1990. In vitro peptidoglycan synthesis by envelopes from *Escherichia coli tolM* mutants is inhibited by colicin M. *J. Bacteriol.* **172**:498–500.
303. **Harrison, L. I., H. N. Christiansen, M. E. Handlogten, D. L. Oxender, and S. C. Quay.** 1975. Transport of L-4-azaleucine in *Escherichia coli*. *J. Bacteriol.* **122**:957–965.
304. **Hasenbank, R., C. Guthrie, G. Stoffler, H. G. Wittmann, L. Rosen, and D. Apirion.** 1973. Electrophoretic and immunological studies on ribosomal proteins of 100 *Escherichia coli* revertants from streptomycin dependence. *Mol. Gen. Genet.* **127**:1–18.
305. **Heatwole, V. M., and R. L. Somerville.** 1991. Cloning, nucleotide sequence, and characterization of *mtr*, the structural gene for a tryptophan-specific permease of *Escherichia coli* K-12. *J. Bacteriol.* **173**:108–115.
306. **Hedges, R. W., and K. P. Shannon.** 1984. Resistance to apramycin in *Escherichia coli* isolated from animals: detection of a novel aminoglycoside-modifying enzyme. *J. Gen. Microbiol.* **130**:473–482.
307. **Held, W. A., and O. H. Smith.** 1970. Regulation of the *Escherichia coli* tryptophan operon by early reactions in the aromatic pathway. *J. Bacteriol.* **101**:202–208.
308. **Held, W. A., and O. H. Smith.** 1970. Mechanism of 3-methylanthranilic acid derepression of the tryptophan operon in *Escherichia coli*. *J. Bacteriol.* **101**:209–217.
309. **Helling, R. B.** 1968. Selection of a mutant of *Escherichia coli* which has high mutation rates. *J. Bacteriol.* **96**:975–980.
310. **Helling, R. B., and B. S. Adams.** 1970. Nalidixic acid-resistant auxotrophs of *Escherichia coli*. *J. Bacteriol.* **104**:1027–1029.
311. **Helling, R. B., and J. Kukora.** 1971. Nalidixic acid-resistant mutants of *Escherichia coli* deficient in isocitrate dehydrogenase. *J. Bacteriol.* **105**:1224–1226.
312. **Helser, T. L., J. E. Davies, and J. E. Dahlberg.** 1972. Mechanism of kasugamycin resistance in *Escherichia coli*. *Nature (London) New Biol.* **235**:6–9.
313. **Hengge, R., T. J. Larson, and W. Boos.** 1983. *sn*-Glycerol-3-phosphate transport in *Salmonella typhimurium*. *J. Bacteriol.* **155**:186–195.
314. **Henning, U., I. Hindennach, and I. Haller.** 1976. The major proteins of the *Escherichia coli* outer cell envelope membrane: evidence for the structural gene of protein II. *FEBS Lett.* **61**:46–48.
315. **Heyde, M., and R. Portalier.** 1982. New pleiotropic alkaline phosphatase-negative mutants of *Escherichia coli* K-12. *J. Bacteriol.* **151**:529–533.
316. **Heyde, M., and R. Portalier.** 1983. Isolation and characterization of a new type of *Escherichia coli* K12 *phoB* mutants. *Mol. Gen. Genet.* **190**:122–127.
317. **Higgins, C. F., M. M. Hardie, D. Jamieson, and L. M. Powell.** 1983. Genetic map of the *opp* (oligopeptide permease) locus of *Salmonella typhimurium*. *J. Bacteriol.* **153**:830–836.
318. **Hiraga, S.** 1969. Operator mutants of the tryptophan operon in *Escherichia coli*. *J. Mol. Biol.* **39**:159–179.
319. **Hiraga, S., K. Igarashi, and T. Yura.** 1967. A deoxythymidine kinase deficient mutant of *Escherichia coli*. I. Isolation and some properties. *Biochem. Biophys. Acta* **145**:41–51.
320. **Hiraga, S., K. Ito, T. Matsuyama, H. Ozaki, and T. Yura.** 1968. 5-Methyltryptophan-resistant

- mutations linked with the arginine G marker in *Escherichia coli*. *J. Bacteriol.* **96**:1880–1881.
321. **Hirota, Y., M. Inuzuka, and M. Tomoeda.** 1966. Elective selection of proline-requiring mutants. *J. Bacteriol.* **91**:2392.
322. **Hirshfield, I. N., R. Dedeken, P. C. Horn, D. A. Hopwood, and W. K. Maas.** 1968. Studies on the mechanism of repression of arginine biosynthesis in *Escherichia coli*. III. Repression of enzymes of arginine biosyntheses in arginyl-tRNA synthetase mutants. *J. Mol. Biol.* **35**:83–93.
323. **Hirshfield, I. N., and P. C. Zamecnik.** 1972. Thiosine-resistant mutants of *Escherichia coli* K-12 with growth medium-dependent lysyl-tRNA synthetase activity. I. Isolation and physiological characterization. *Biochim. Biophys. Acta* **259**:330–343.
324. **Hobson, A. C.** 1974. A norleucine-resistant mutant of *Salmonella typhimurium* with a possible defect in valine uptake or regulation. *J. Gen. Microbiol.* **82**:425–429.
325. **Hoffee, P. A.** 1968. 2-Deoxyribose gene-enzyme complex in *Salmonella typhimurium*. *J. Bacteriol.* **95**:449–457.
326. **Hoffmeyer, J., and J. Neuhardt.** 1971. Metabolism of exogenous purine bases and nucleosides by *Salmonella typhimurium*. *J. Bacteriol.* **106**:14–24.
327. **Hofnung, M., and M. Schwartz.** 1971. Mutations allowing growth on maltose of *Escherichia coli* K-12 strains with a deleted *malT* gene. *Mol. Gen. Genet.* **112**:117–132.
328. **Holland, J., I. B. Holland, and S. I. Ahmad.** 1991. DNA damage by 8-methoxypsoralen plus near UV light, *puvA* and its repair in *Escherichia coli*: genetic analysis. *Mutat. Res.* **254**:289–298.
329. **Hooper, D. C., J. S. Wolfson, M. A. Bozza, and E. Y. Ng.** 1992. Genetics and regulation of outer membrane protein expression by quinolone resistance loci *nfxB*, *nfxC*, and *cfxB*. *Antimicrob. Agents Chemother.* **36**:1151–1154.
330. **Horiuchi, T., S. Horiuchi, and A. Novick** 1963. The genetic basis of hyper-synthesis of β-galactoside. *Genetics* **48**:157–169.
331. **Housley, P. R., A. D. Leavitt, and H. J. Whitfield.** 1981. Genetic analysis of a temperature-sensitive *Salmonella typhimurium rho* mutant with an altered Rho-associated polycytidylate-dependent adenosine triphosphatase activity. *J. Bacteriol.* **147**:13–24.
332. **Howard-Flanders, P., and L. Theriot.** 1962. A method for selecting radiation-sensitive mutants of *Escherichia coli*. *Genetics* **47**:1219–1224.
333. **Hrebenda, J., H. Heleszko, K. Brzostek, and J. Bielecki.** 1985. Mutation affecting resistance of *Escherichia coli* K12 to nalidixic acid. *J. Gen. Microbiol.* **131**:2285–2292.
334. **Hudson, H. P., A. A. Lindberg, and B. A. D. Stocker.** 1978. Lipopolysaccharide core defects in *Salmonella typhimurium* mutants which are resistant to Felix O phage but retain smooth character. *J. Gen. Microbiol.* **109**:97–112.
335. **Hughes, D.** 1986. The isolation and mapping of EF-Tu mutations in *Salmonella typhimurium*. *Mol. Gen. Genet.* **202**:108–111.
336. **Hughes, K. T., B. T. Cookson, D. Ladika, B. M. Olivera, and J. R. Roth.** 1983. 6-Aminonicotinamide-resistant mutants of *Salmonella typhimurium*. *J. Bacteriol.* **154**:1126–1136.
337. **Hughes, K. T., D. Ladika, J. R. Roth, and B. M. Olivera.** 1983. An indispensable gene for NAD biosynthesis in *Salmonella typhimurium*. *J. Bacteriol.* **155**:213–221.
338. **Hulanicka, D.** 1972. Resistance to sulfate analogs in *Salmonella typhimurium*. *Acta Biochim. Pol.* **19**:367–376.
339. **Hulanicka, D., and T. Klopotowski.** 1972. Mutants of *Salmonella typhimurium* resistant to triazole. *Acta Biochim. Pol.* **19**:251–260.
340. **Hulanicka, M. D., S. G. Hallquist, N. M. Kredich, and T. Mojica-A.** 1979. Regulation of O-acetylserine sulfhydrylase B by L-cysteine in *Salmonella typhimurium*. *J. Bacteriol.* **140**:141–146.
341. **Hulanicka, M. D., and N. M. Kredich.** 1976. A mutation affecting expression of the gene coding for serine transacetylase in *Salmonella typhimurium*. *Mol. Gen. Genet.* **148**:143–148.
342. **Hull, R., J. D. Klinger, and E. E. M. Moody.** 1976. Isolation and characterization of mutants of *Escherichia coli* K12 resistant to the new aminoglycoside antibiotic, amikacin. *J. Gen. Microbiol.* **94**:389–394.
343. **Hummel, H., W. Piepersberg, and A. Böck.** 1979. Analysis of lincomycin resistance mutations

- in *Escherichia coli*. *Mol. Gen. Genet.* **169**:345–347.
344. **Hussain, M., S. Ichihara, and S. Mizushima.** 1980. Accumulation of glyceride containing precursor of the outer membrane lipoprotein in the cytoplasmic membrane of *Escherichia coli* treated with globomycin. *J. Biol. Chem.* **255**:3707–3712.
345. **Hwang, Y.-W., R. Engel, and B. E. Tropp.** 1984. Correlation of 3,4-dihydroxybutyl 1-phosphonate resistance with a defect in cardiolipin synthesis in *Escherichia coli*. *J. Bacteriol.* **157**:846–856.
346. **Ibe, S. N., A. J. Sinskey, and D. Botstein.** 1982. Genetic mapping of mutations in a highly radiation-resistant mutant of *Salmonella typhimurium* LT2. *J. Bacteriol.* **152**:260–268.
347. **Icho, T., and T. Iino.** 1978. Isolation and characterization of motile *Escherichia coli* mutants resistant to bacteriophage χ . *J. Bacteriol.* **134**:854–860.
348. **Igarishi, K., S. Hiraga, and T. Yura.** 1967. A deoxythymidine kinase deficient mutant of *Escherichia coli*. II. Mapping and transduction studies with phage ϕ 80. *Genetics* **57**:643–654.
349. **Iino, T.** 1977. Genetics of structure and function of bacterial flagella. *Annu. Rev. Genet.* **11**:161–182.
350. **Ilag, L. L., D. Jahn, G. Eggertsson, and D. Söll.** 1991. The *Escherichia coli* *hemL* gene encodes glutamate 1-semialdehyde aminotransferase. *J. Bacteriol.* **173**:3408–3413.
351. **Im, S. W. K., and J. Pittard.** 1971. Phenylalanine biosynthesis in *Escherichia coli* K-12: mutants derepressed for chorismate mutase P-prephenate dehydratase. *J. Bacteriol.* **106**:784–790.
352. **Inoko, H., and M. Imai.** 1976. Isolation and genetic characterization of the *nitA* mutants of *Escherichia coli* affecting the termination factor rho. *Mol. Gen. Genet.* **143**:211–221.
353. **Inoko, H., K. Shigesada, and M. Imai.** 1977. Isolation and characterization of conditional-lethal *rho* mutants of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **74**:1162–1166.
354. **Ishidsu, J.-I.** 1973. Device of a method for isolation of arginine sensitive mutants in *Salmonella typhimurium*. *Jpn. J. Genet.* **48**:377–379.
355. **Ito, M., and Y. Ohnishi.** 1981. Isolation of *Escherichia coli* mutants which are resistant to an inhibitor of proton-ATPase, tributyltin and also to uncouplers of oxidative phosphorylation. *FEBS Lett.* **136**:225–230.
356. **Ivell, R., O. Fasano, J.-B. Crechet, and A. Parmeggiani.** 1981. Characterization of a kirromycin resistant elongation factor Tu from *Escherichia coli*. *Biochemistry* **20**:1355–1361.
357. **Iwakura, Y., A. Ishihama, and T. Yura.** 1973. RNA polymerase mutants of *Escherichia coli*. II. Streptolydigin resistance and its relation to rifampicin resistance. *Mol. Gen. Genet.* **121**:181–196.
358. **Iwaya, M., R. Goldman, D. J. Tipper, B. Feingold, and J. L. Strominger.** 1978. Morphology of an *Escherichia coli* mutant with a temperature-dependent round cell shape. *J. Bacteriol.* **136**:1143–1158.
359. **Iwaya, M., C. W. Jones, J. Khorana, and J. L. Strominger.** 1978. Mapping of the mecillinam-resistant, round morphological mutants of *Escherichia coli*. *J. Bacteriol.* **133**:196–202.
360. **Jackson, B. J., J.-P. Bohin, and E. P. Kennedy.** 1984. Biosynthesis of membrane-derived oligosaccharides: characterization of *mdoB* mutants defective in phosphoglycerol transferase I activity. *J. Bacteriol.* **160**:976–981.
361. **Jackson, J. H., E. J. Davis, A. C. Madu, and S. E. Braxter.** 1981. Three-factor reciprocal cross mapping of a gene that causes expression of feedback resistant acetohydroxy acid synthase in *Escherichia coli* K-12. *Mol. Gen. Genet.* **181**:417–419.
362. **Jaffe, A., Y. A. Chabbert, and E. Derlot.** 1983. Selection and characterization of beta-lactam-resistant *Escherichia coli* K-12 mutants. *Antimicrob. Agents Chemother.* **23**:622–625.
363. **Jaffe, A., Y. A. Chabbert, and O. Semonin.** 1982. Role of porin proteins *ompF* and *ompC* in the permeation of beta lactams. *Antimicrob. Agents Chemother.* **22**:942–948.
364. **Janzer, J. J., H. Stan-Lotter, and K. E. Sanderson.** 1981. Isolation and characterization of hemin-permeable envelope-defective mutants of *Salmonella typhimurium*. *Can. J. Microbiol.* **27**:226–237.
365. **Jegede, V. A., F. Spencer, and J. E. Brenchley.** 1976. Thialysine-resistant mutant of *Salmonella typhimurium* with a lesion in the *thrA* gene. *Genetics* **83**:619–632.

366. **Jenness, D. D., and H. K. Schachman.** 1980. *pyrB* mutations as suppressors of arginine auxotrophy in *Salmonella typhimurium*. *J. Bacteriol.* **141**:33–40.
367. **Jensen, K. F.** 1979. Apparent involvement of purines in the control of expression of *Salmonella typhimurium* *pyr* genes: analysis of a leaky *guaB* mutant resistant to pyrimidine analogs. *J. Bacteriol.* **138**:731–738.
368. **Jensen, K. F., J. Neuhard, and L. Shack.** 1982. RNA polymerase involvement in the control of *Salmonella typhimurium* *pyr* gene expression. Isolation and characteristics of a fluorouracil resistant mutant with high, constitutive expression of *pyrB* and *pyrE* due to a mutation in *rpoBC*. *EMBO J.* **1**:69–74.
369. **Jin, D. J., and C. A. Gross.** 1988. Mapping and sequencing of mutations in the *Escherichia coli* *rpoB* gene that lead to rifampicin resistance. *J. Mol. Biol.* **202**:45–58.
370. **Jochimsen, B., P. Nygaard, and T. Vestergaard.** 1975. Location on the chromosome of *Escherichia coli* of genes governing purine metabolism: adenosine deaminase (*add*), guanosine kinase (*gsk*) and hypoxanthine phosphoribosyltransferase (*hpt*). *Mol. Gen. Genet.* **143**:85–91.
371. **Jochimsen, B. U., B. Hove-Jensen, B. B. Carber, and J. S. Gots.** 1985. Characteristics of a *Salmonella typhimurium* mutant defective in phosphoribosylpyrophosphate synthetase. *J. Gen. Microbiol.* **131**:245–252.
372. **Johansson, V., A. Aarti, M. Nurminen, and P. H. Makela.** 1978. Outer membrane protein-specific bacteriophages of *Salmonella typhimurium*. *J. Gen. Microbiol.* **107**:183–187.
373. **Johnson, B. F.** 1977. Fine structure mapping and properties of mutations suppressing the *lon* mutation in *Escherichia coli* K-12 and B strains. *Genet. Res.* **30**:273–286.
374. **Johnston, H. M., and J. R. Roth.** 1979. Histidine mutants requiring adenine: selection of mutants with reduced *hisG* expression in *Salmonella typhimurium*. *Genetics* **92**:1–15.
375. **Johnston, H. M., and J. R. Roth.** 1981. Genetic analysis of the histidine operon control region of *Salmonella typhimurium*. *J. Mol. Biol.* **145**:713–734.
376. **Johnston, M. A., and H. Pivnick.** 1970. Use of autolytic β-D-galactosides for selective growth of *Salmonella typhimurium* in the presence of coliforms. *Can. J. Microbiol.* **16**:83–89.
377. **Jones-Mortimer, M., and H. L. Kornberg.** 1974. Genetical analysis of fructose utilization by *Escherichia coli*. *Proc. R. Soc. London Ser. B* **187**:121–131.
378. **Jones-Mortimer, M. C., and H. L. Kornberg.** 1976. Uptake of fructose by the sorbitol phosphotransferase of *Escherichia coli* K12. *J. Gen. Microbiol.* **96**:383–391.
379. **Jones-Mortimer, M. C., and H. L. Kornberg.** 1980. Amino-sugar transport systems of *Escherichia coli* K12. *J. Gen. Microbiol.* **117**:369–376.
380. **Josephsen, J., K. Hammer-Jespersen, and T. D. Hansen.** 1983. Mapping of the gene for cytidine deaminase (*cdd*) in *Escherichia coli* K-12. *J. Bacteriol.* **154**:72–75.
381. **Joshi, A., J. Z. Siddiqui, M. Verma, and M. Chakravorty.** 1982. Participation of host proteins in the morphogenesis of bacteriophage P22. *Mol. Gen. Genet.* **186**:44–49.
382. **Joshi, A., M. Verma, and M. Chakravorty.** 1982. Thiolutin-resistant mutants of *Salmonella typhimurium*. *Antimicrob. Agents Chemother.* **22**:541–547.
383. **Juhl, M. J., and D. P. Clark.** 1990. Thiophene-degrading *Escherichia coli* mutants possess sulfone oxidase activity and show altered resistance to sulfur-containing antibiotics. *Appl. Environ. Microbiol.* **56**:3179–3185.
384. **Jung, J. U., C. Gutierrez, and M. R. Villarejo.** 1989. Sequence of an osmotically inducible lipoprotein gene. *J. Bacteriol.* **171**:511–520.
385. **Justesen, J., and J. Neuhard.** 1975. *pyrR* identical to *pyrH* in *Salmonella typhimurium*: control of expression of the *pyr* genes. *J. Bacteriol.* **123**:851–854.
386. **Kadner, R. J.** 1977. Transport and utilization of D-methionine and other methionine sources in *Escherichia coli*. *J. Bacteriol.* **129**:207–216.
387. **Kadner, R. J., K. Heller, J. W. Coulton, and V. Braun.** 1980. Genetic control of hydroxamate-mediated iron uptake in *Escherichia coli*. *J. Bacteriol.* **143**:256–264.
388. **Kadner, R. J., and C. L. Liggins.** 1973. Transport of vitamin B₁₂ in *Escherichia coli*: genetic studies. *J. Bacteriol.* **115**:514–521.

389. **Kadner, R. J., and D. M. Shattuck-Eidens.** 1983. Genetic control of the hexose phosphate transport system of *Escherichia coli*: mapping of deletion and insertion mutations in the *uhp* region. *J. Bacteriol.* **155**:1052–1061.
390. **Kalle, C. P., and J. S. Gots.** 1961. Alterations in purine nucleotide pyrophosphorylases and resistance to purine analogues. *Biochim. Biophys. Acta* **53**:66–173.
391. **Kalman, M., D. R. Gentry, and M. Cashel.** 1991. Characterization of the *Escherichia coli* K12 *gltS* glutamate permease gene. *Mol. Gen. Genet.* **225**:379–386.
392. **Kanner, B. I., and D. L. Gutnick.** 1972. Use of neomycin in the isolation of mutants blocked in energy conservation in *Escherichia coli*. *J. Bacteriol.* **111**:287–289.
393. **Kaplan, L., H. C. Reilly, and C. C. Stock.** 1959. Action of azaserine on *Escherichia coli*. *J. Bacteriol.* **78**:511–519.
394. **Kaplan, S., and D. Anderson.** 1968. Selection of temperature-sensitive activating enzyme mutants in *Escherichia coli*. *J. Bacteriol.* **95**:991–997.
395. **Kast, P., and H. Hennecke.** 1991. Amino acid substrate specificity of *Escherichia coli* phenylalanyl-tRNA synthetase altered by distinct mutations. *J. Mol. Biol.* **222**:99–124.
396. **Katz, L.** 1970. Selection of *AraB* and *AraC* mutants of *Escherichia coli* B/r by resistance to ribitol. *J. Bacteriol.* **102**:593–595.
397. **Kawakami, T., Y. Akizawa, T. Ishikawa, T. Shimamoto, M. Tsuda, and T. Tsuchiya.** 1988. Amino acid substitutions and alteration in cation specificity in the melibiose carrier of *Escherichia coli*. *J. Biol. Chem.* **263**:14276–14280.
398. **Kawamoto, S., S. Tokuyama, S. Yashima, and Y. Eguchi.** 1984. Genetic mapping of cold resistance gene of *Escherichia coli*. *Agric. Biol. Chem.* **48**:2067–2071.
399. **Kawasaki, T., and Y. Nose.** 1969. Thiamine regulatory mutants in *Escherichia coli*. *J. Biochem. (Tokyo)* **65**:417–425.
400. **Kay, W. W.** 1972. Genetic control of the metabolism of propionate by *Escherichia coli* K12. *Biochim. Biophys. Acta* **264**:508–521.
401. **Kay, W. W., and H. L. Kornberg.** 1969. Genetic control of the uptake of Ci-dicarboxylic acids by *Escherichia coli*. *FEBS Lett.* **3**:93–96.
402. **Kelker, N. E., and W. K. Maas.** 1974. Selection for genetically repressible (Arg R+) strains of *Escherichia coli* K12 from genetically derepressed (Arg R-) mutants using acetyl norvaline. *Mol. Gen. Genet.* **131**:131–136.
403. **Kelln, R. A., and G. A. O'Donovan.** 1976. Isolation and partial characteristics of an *argR* mutant of *Salmonella typhimurium*. *J. Bacteriol.* **128**:528–535.
404. **Kelln, R. A., and V. L. Zak.** 1980. A mutation in *Salmonella typhimurium* imparting conditional resistance to 5-fluorouracil and a bioenergetic defect mapping of *cad*. *Mol. Gen. Genet.* **179**:678–682.
405. **Kemper, J.** 1974. Gene order and co-transduction in the *leu-ara-fol-pyrA* region of the *Salmonella typhimurium* linkage map. *J. Bacteriol.* **117**:94–99.
406. **Kessler, D. P., and H. V. Rickenberg.** 1964. A new method for the selection of mutants of *Escherichia coli* forming β-galactosidase constitutively. *Biochim. Biophys. Acta* **90**:609–610.
407. **Kier, L. D., R. M. Weppelman, and B. N. Ames.** 1977. Regulation of two phosphatases and a cyclic phosphodiesterase of *Salmonella typhimurium*. *J. Bacteriol.* **130**:420–428.
408. **Kier, L. D., R. M. Weppelman, and B. N. Ames.** 1979. Regulation of nonspecific acid phosphatase in *Salmonella*: *phoN* and *phoP* genes. *J. Bacteriol.* **138**:155–161.
409. **Killmann, H., and V. Braun.** 1992. An aspartate deletion mutation defines a binding site of the multifunctional *fhuA* outer membrane receptor of *Escherichia coli* K-12. *J. Bacteriol.* **174**:3479–3486.
410. **Kim, K. T., and O. J. Yoo.** 1987. Inhibition of coliphage N4 infection of *Escherichia coli* mutant defective in mannose permease. *Korean J. Microbiol.* **25**:184–188.
411. **Kleckner, N., J. Roth, and D. Botstein.** 1977. Genetic engineering *in vivo* using translocatable drug-resistance elements. New methods in bacterial genetics. *J. Mol. Biol.* **116**:125–159.
412. **Kline, E. L.** 1972. New amino acid regulatory locus having unusual properties in heterozygous merodiploids. *J. Bacteriol.* **110**:1127–1134.
413. **Kocharyan, S. M.** 1979. Positive method for selection of adenylate cyclase and cyclic adenosine

- 3', 5'-monophosphate receptor protein deficient mutants of *Escherichia coli* K12. *Biol. Zh. Arm.* **32**:346–351.
414. **Kohara, Y., K. Akiyama, and K. Isono.** 1987. The physical map of the whole *E. coli* chromosome: application of a new strategy for the rapid analysis and sorting of a large genomic library. *Cell* **50**:495–508.
415. **Komatsu, Y., and K. Tanaka.** 1972. A showdomycin-resistant mutant of *Escherichia coli* K-12 with altered nucleoside transport character. *Biochim. Biophys. Acta* **288**:390–403.
416. **Komeda, Y.** 1982. Fusions of flagellar operons to lactose genes on a Mu lac bacteriophage. *J. Bacteriol.* **150**:16–26.
417. **Komeda, Y., M. Silverman, and M. Simon.** 1977. Genetic analysis of *Escherichia coli* K-12 region I flagellar mutants. *J. Bacteriol.* **131**:801–808.
418. **Kornberg, H. L., and J. Smith.** 1972. Genetic control of glucose uptake by *Escherichia coli*. *FEBS Lett.* **20**:270–272.
419. **Kornberg, H. L., and P. D. Watts.** 1978. Roles of *crr*-gene products in regulating carbohydrate uptake by *Escherichia coli*. *FEBS Lett.* **89**:329–332.
420. **Korteland, J., N. Overbeeke, P. De Graaff, P. Overduin, and B. Lugtenberg.** 1985. Role of the Arg158 residue of the outer membrane *phoE* pore protein of *Escherichia coli* K12 in bacteriophage TC45 recognition and in channel characteristics. *Eur. J. Biochem.* **152**:691–697.
421. **Kowit, J. D., W.-N. Choy, S. P. Champe, and A. L. Goldberg.** 1976. Role and location of “protease 1” from *Escherichia coli*. *J. Bacteriol.* **128**:776–784.
422. **Krajewska-Grynkiewicz, K., W. Walczak, and T. Kłopotowski.** 1971. Mutants of *Salmonella typhimurium* able to utilize D-histidine as a source of L-histidine. *J. Bacteriol.* **105**:28–37.
423. **Kramer, G. F., and B. N. Ames.** 1988. Mechanisms of mutagenicity and toxicity of sodium selenite in *Salmonella typhimurium*. *Mutat. Res.* **201**:169–180.
424. **Kramer, G. F., J. C. Baker, and B. N. Ames.** 1988. Near-UV stress in *Salmonella typhimurium*: 4-thiouridine in tRNA, ppGpp, and AppGpp as components of an adaptive response. *J. Bacteriol.* **170**: 2344–2351.
425. **Kraus, J., D. Söll, and K. B. Low.** 1979. Glutamyl- γ -methyl ester acts as a methionine analogue in *Escherichia coli*: analogue resistant mutants map at the *metJ* and *metK* loci. *Genet. Res.* **33**:49–55.
426. **Kricker, M., and B. G. Hall.** 1984. Directed evolution of cellobiose utilization in *Escherichia coli* K12. *Mol. Biol. Evol.* **1**:171–182.
427. **Kuhn, A. H. U., M. L. J. Moncany, E. Kellenberger, and R. Hausmann.** 1982. Involvement of the bacterial *groM* gene product in bacteriophage T7 reproduction. *J. Virol.* **41**:657–673.
428. **Kuhn, J., and R. L. Somerville.** 1971. Mutant strains of *Escherichia coli* K12 that can use D-amino acids. *Proc. Natl. Acad. Sci. USA* **68**:2484–2487.
429. **Kumar, S.** 1976. Properties of adenyl cyclase and cyclic adenosine 3',5'-monophosphate receptor protein-deficient mutants of *Escherichia coli*. *J. Bacteriol.* **125**:545–555.
430. **Kunert, K. J., C. F. Cresswell, A. Schmidt, P. M. Mullineaux, and C. H. Foyer.** 1990. Variations in the activity of glutathione reductase and the cellular glutathione content in relation to sensitivity to methyl viologen in *Escherichia coli*. *Arch. Biochem. Biophys.* **282**:233–238.
431. **Kuroda, M., S. De Waard, K. Mizushima, M. Tsuda, P. Postma, and T. Tsuchiya.** 1992. Resistance of the melibiose carrier to inhibition by the phosphotransferase system due to substitutions of amino acid residues in the carrier of *Salmonella typhimurium*. *J. Biol. Chem.* **267**:18336–18341.
432. **Kustu, S. G., and G. F.-L. Ames.** 1973. The *hisP* protein, a known histidine transport component in *Salmonella typhimurium*, is also an arginine transport component. *J. Bacteriol.* **116**:107–113.
433. **Kustu, S. G., N. C. McFarland, S. P. Hui, B. Esmon, and G. F.-L. Ames.** 1979. Nitrogen control in *Salmonella typhimurium*: coregulation of synthesis of glutamine synthetase and amino acid transport systems. *J. Bacteriol.* **138**:218–234.
434. **Kuwano, M., D. Schlessinger, G. Rinaldi, L. Felicetti, and G. P. Tocchini-Valentini.** 1971. G factor mutants of *Escherichia coli*: map location and properties. *Biochem. Biophys. Res. Commun.* **42**:441–444.
435. **Lakshmi, T. M., and R. B. Helling.** 1976. Selection for citrate synthase deficiency in *icd*

- mutants of *Escherichia coli*. *J. Bacteriol.* **127**:76–83.
436. **Lambden, P. R., and J. R. Guest.** 1976. A novel method for isolating chlorate-resistant mutants of *Escherichia coli* K12 by anaerobic selection on a lactate plus fumarate medium. *J. Gen. Microbiol.* **93**:173–176.
437. **Langley, D., and J. R. Guest.** 1974. Biochemical and genetic characteristics of deletion and other mutant strains of *Salmonella typhimurium* LT2 lacking α -ketoacid dehydrogenase complex activities. *J. Gen. Microbiol.* **82**:319–335.
438. **Langley, D., and J. R. Guest.** 1977. Biochemical studies of the α -ketoacid dehydrogenase complexes of *Escherichia coli* K12: isolation and biochemical properties of deletion mutants. *J. Gen. Microbiol.* **99**:263–276.
439. **Langley, D., and J. R. Guest.** 1978. Biochemical genetics of the α -keto acid dehydrogenase complexes of *Escherichia coli* K12: genetic characterization and regulatory properties of deletion mutants. *J. Gen. Microbiol.* **106**:103–117.
440. **Langridge, J.** 1969. Mutations conferring quantitative and qualitative increases in β -galactosidase activity in *Escherichia coli*. *Mol. Gen. Genet.* **105**:74–83.
441. **LaRossa, R. A., and J. V. Schloss.** 1984. The sulfonylurea herbicide sulfometuron methyl is an extremely potent and selective inhibitor of acetolactate synthase in *Salmonella typhimurium*. *J. Biol. Chem.* **259**:8753–8757.
442. **LaRossa, R. A., and D. R. Smulski.** 1984. *ilvB*-enclosed acetolactate synthase is resistant to the herbicide sulfometuron methyl. *J. Bacteriol.* **160**:391–394.
443. **LaRossa, R. A., T. K. Van Dyk, and D. R. Smulski.** 1987. Toxic accumulation of α -ketobutyrate caused by inhibition of the branched-chain amino acid biosynthetic enzyme acetolactate synthase in *Salmonella typhimurium*. *J. Bacteriol.* **169**:1372–1378.
444. **LaRossa, R. A., T. K. Van Dyk, and D. R. Smulski.** 1990. A need for metabolic insulation: lessons from sulfonylurea genetics, p. 109–121. In Z. Barak, M. Chipman, and J. V. Schloss (ed.), *Biosynthesis of Branched Chain Amino Acids*. VCH Publishers, New York.
445. **Latil, M., M. Murgier, A. Lazdunski, and C. Lazdunski.** 1976. Isolation and genetic mapping of *Escherichia coli* aminopeptidase mutants. *Mol. Gen. Genet.* **148**:43–47.
446. **Lavina, M., A. P. Pugsley, and F. Moreno.** 1986. Identification, mapping, cloning, and characterization of a gene (*sbmA*) required for microcin B17 action on *Escherichia coli* K-12. *J. Gen. Microbiol.* **132**:1685–1693.
447. **Lawrence, D. A., D. A. Smith, and R. J. Rowbury.** 1968. Regulation of methionine synthesis in *Salmonella typhimurium*: mutants resistant to inhibition by analogues of methionine. *Genetics* **58**:473–492.
448. **Lawther, R. P., D. H. Calhoun, C. W. Adams, C. A. Hauser, J. Gray, and G. W. Hatfield.** 1981. Molecular basis of valine resistance in *Escherichia coli* K-12. *Proc. Natl. Acad. Sci. USA* **78**:922–925.
449. **Lazzaroni, J. C., and R. C. Portalier.** 1981. Genetic and biochemical characterization of periplasmic-leaky mutants of *Escherichia coli* K-12. *J. Bacteriol.* **145**:1351–1358.
450. **LeBlanc, D. J., and R. P. Mortlock.** 1971. Metabolism of D-arabinose: a new pathway in *Escherichia coli*. *J. Bacteriol.* **106**:90–96.
451. **Lee, R. S.-F., J. Pagan, S. Wilke-Mounts, and A. E. Senior.** 1991. Characterization of *Escherichia coli* ATP synthase beta-subunit mutations using a chromosomal deletion strain. *Biochemistry* **30**:6842–6847.
452. **Lehmann, V., E. Rupprecht, and M. J. Osborn.** 1977. Isolation of mutants conditionally blocked in the biosynthesis of the 3-deoxy-D-manno-octulosonic acid-lipid A part of lipopolysaccharides derived from *Salmonella typhimurium*. *Eur. J. Biochem.* **76**:41–49.
453. **Leifer, Z., R. Engel, and B. E. Tropp.** 1977. Transport of 3,4-dihydroxybutyl-l-phosphonate, an analogue of *sn*-glycerol 3-phosphate. *J. Bacteriol.* **130**:968–971.
454. **Leisinger, T., D. Haas, and M. P. Hegarty.** 1972. Indospicine as an arginine antagonist in *Escherichia coli* and *Pseudomonas aeruginosa*. *Biochim. Biophys. Acta* **262**:214–219.
455. **Lemmon, R. D., J. J. Rowe, and G. J. Tritz.** 1980. Isolation and characterization of mutants of

- Escherichia coli* defective in pyridine nucleotide cycle enzymes. *Curr. Microbiol.* **4**:31–35.
456. **Lengeler, J.** 1980. Characterization of mutants of *Escherichia coli* K12, selected by resistance to streptozotocin. *Mol. Gen. Genet.* **179**:49–54.
457. **Lengeler, J., and H. Steinberger.** 1978. Analysis of the regulatory mechanisms controlling the synthesis of the hexitol transport systems in *Escherichia coli* K12. *Mol. Gen. Genet.* **164**:163–169.
458. **Lerman, R. D., and B. A. D. Stocker.** 1981. Mutations in *Salmonella typhimurium* affecting synthesis of lipopolysaccharide core at high temperature. *Wasmann J. Biol.* **39**:42–49.
459. **Lester, B., and D. M. Bonner.** 1957. Genetic control of raffinose utilization in *Escherichia coli*. *J. Bacteriol.* **73**:544–552.
460. **Levin, D. E., L. J. Marnett, and B. N. Ames.** 1984. Spontaneous and mutagen-induced deletions: mechanistic studies in *Salmonella* tester strain TA102. *Proc. Natl. Acad. Sci. USA* **81**:4457–4461.
461. **Levine, R. A., and M. W. Taylor.** 1981. Selection for purine regulatory mutants in an *E. coli* hypoxanthine phosphoribosyl transferase-guanine phosphoribosyl transferase double mutant. *Mol. Gen. Genet.* **181**:313–318.
462. **Levine, R. A., and M. W. Taylor.** 1982. Mechanism of adenine toxicity in *Escherichia coli*. *J. Bacteriol.* **149**:923–930.
463. **LeVine, S. M., F. Ardesir, and G. F.-L. Ames.** 1980. Isolation and characterization of acetate kinase and phosphotransacetylase mutants of *Escherichia coli* and *Salmonella typhimurium*. *J. Bacteriol.* **143**:1081–1085.
464. **Lieberman, M. A., and J.-S. Hong.** 1974. A mutant of *Escherichia coli* defective in the coupling of metabolic energy to active transport. *Proc. Natl. Acad. Sci. USA* **71**:4395–4399.
465. **Lieberman, M. A., M. Simon, and J.-S. Hong.** 1977. Characterization of *Escherichia coli* mutant incapable of maintaining a transmembrane potential. *J. Biol. Chem.* **252**:4056–4067.
466. **Link, C. D., and A. M. Reiner.** 1983. Genotypic exclusion: a novel relationship between the ribitol-arabitol and galactitol genes of *E. coli*. *Mol. Gen. Genet.* **189**:337–339.
467. **Liou, T.-F., M. Yoshikawa, and N. Tanaka.** 1975. Alteration of ribosomal protein L5 in a thiopeptin resistant mutant of *Escherichia coli*. *Biochem. Biophys. Res. Commun.* **65**:1096–1101.
468. **Lipsett, M. N.** 1978. Enzymes producing 4-thiouridine in *Escherichia coli* tRNA: approximate chromosomal locations of the genes and enzyme activities in a 4-thiouridine-deficient mutant. *J. Bacteriol.* **135**:993–997.
469. **Lisitsyn, N. A., E. D. Sverdlov, E. P. Moiseeva, and V. G. Nikiforov.** 1985. Localization of a mutation leading to antibiotic streptolydigin resistance of *E. coli* RNA polymerase in the *rpoB* gene coding for beta-subunit of the enzyme. *Bioorg. Khim.* **11**:132–134.
470. **Livshits, V. A.** 1976. Effect of 2,6-diaminopurine resistant mutations on the uptake of adenine and adenosine by adenine-requiring strains of *Escherichia coli* K12. *Genetika* **12**:180–182.
471. **Lomax, M. S., and G. R. Greenberg.** 1968. Characteristics of the *deo* operon: role in thymine utilization and sensitivity to deoxyribonucleosides. *J. Bacteriol.* **96**:501–514.
472. **Lomovskaya, O., and K. Lewis.** 1992. *emr*, an *Escherichia coli* locus for multidrug resistance. *Proc. Natl. Acad. Sci. USA* **89**:8938–8942.
473. **Long, W. S., C. L. Slayman, and K. B. Low.** 1978. Production of giant cells of *Escherichia coli*. *J. Bacteriol.* **133**:995–1007.
474. **Loomis, W. F., Jr., and B. Magasanik.** 1965. Genetic control of catabolite repression of the *lac* operon in *Escherichia coli*. *Biochem. Biophys. Res. Commun.* **20**:230–234.
475. **Loomis, W. F., Jr., and B. Magasanik.** 1967. The catabolite repression gene of the *lac* operon in *Escherichia coli*. *J. Mol. Biol.* **23**:487–494.
476. **Lorowitz, W., and D. Clark.** 1982. *Escherichia coli* mutants with a temperature-sensitive alcohol dehydrogenase. *J. Bacteriol.* **152**:935–938.
477. **Low, K. B., F. Gates, T. Goldstein, and D. Söll.** 1971. Isolation and partial characterization of temperature-sensitive *Escherichia coli* mutants with altered leucyl- and seryl-transfer ribonucleic acid synthetases. *J. Bacteriol.* **108**:742–750.
478. **Luckey, M., and J. B. Neilands.** 1976. Iron transport in *Salmonella typhimurium* LT-2: prevention, by ferrichrome, of adsorption of bacteriophages ES18 and ES18.hl to a common cell

- envelope receptor. *J. Bacteriol.* **127**:1036–1037.
479. **Luckey, M., J. R. Pollack, R. Wayne, B. N. Ames, and J. B. Neilands.** 1972. Iron uptake in *Salmonella typhimurium*: utilization of exogenous siderochromes as iron carriers. *J. Bacteriol.* **111**:731–738.
480. **Lutkenhaus, J. F.** 1977. Role of a major outer membrane protein in *Escherichia coli*. *J. Bacteriol.* **131**:631–637.
481. **Maas, W. K.** 1952. Pantothenate studies. II. Evidence from mutants for interference by salicylate with pantoate synthesis. *J. Bacteriol.* **63**:227–232.
482. **Maas, W. K.** 1961. Repression of arginine formation. *Cold Spring Harbor Symp. Quant. Biol.* **26**:183–190.
483. **Maas, W. K.** 1965. Genetic defect affecting an arginine permease and repression of arginine synthesis in *E. coli*. *Fed. Proc.* **24**:1239.
484. **MacPhee, D. G., V. Krishnapillai, R. J. Roantree, and B. A. D. Stocker.** 1975. Mutations in *Salmonella typhimurium* conferring resistance to Felix O phage without loss of smooth character. *J. Gen. Microbiol.* **87**:1–10.
485. **Makela, P. H., M. Sarvas, S. Calcagno, and K. Lounatmaa.** 1978. Isolation and genetic characterization of polymyxin resistant mutants of *Salmonella*. *FEMS Microbiol. Lett.* **3**:323–326.
486. **Makela, P. H., and B. A. D. Stocker.** 1969. Genetics of polysaccharide biosynthesis. *Annu. Rev. Genet.* **3**:291–322.
487. **Maloy, S. R., and W. D. Nunn.** 1981. Selection for loss of tetracycline resistance by *Escherichia coli*. *J. Bacteriol.* **145**:1110–1112.
488. **Maloy, S. R., and W. D. Nunn.** 1982. Genetic regulation of the glyoxylate shunt in *Escherichia coli* K-12. *J. Bacteriol.* **149**:173–180.
489. **Manning, P. A., A. Puspurs, and P. Reeves.** 1976. Outer membrane of *Escherichia coli* K12: isolation of mutants with altered protein 3A by using host range mutants of bacteriophage K3. *J. Bacteriol.* **127**:1080–1084.
490. **Manning, P. A., and P. Reeves.** 1976. Outer membrane of *Escherichia coli* K12: *tsx* mutants (resistant to bacteriophage T6 and colicin K) lack an outer membrane protein. *Biochem. Biophys. Res. Commun.* **71**:466–471.
491. **Manning, P. A., and P. Reeves.** 1976. Outer membrane of *Escherichia coli* K12: differentiation of proteins 3A and 3B on acrylamide gels and further characterization of *con tolG* mutants. *J. Bacteriol.* **127**:1070–1079.
492. **Manning, P. A., and P. Reeves.** 1978. Outer membrane proteins of *Escherichia coli* K12. Isolation of a common receptor protein for bacteriophage T-6 and colicin K. *Mol. Gen. Genet.* **158**:279–286.
493. **Manoil, C., and J. P. Rosenbusch.** 1982. Conjugation deficient mutants of *Escherichia coli* distinguish classes of functions of the outer membrane *ompA* protein. *Mol. Gen. Genet.* **187**:148–156.
494. **Mao, Y., and Z. Sheng.** 1986. A phenylethyl alcohol resistant temperature sensitive *dnaB* mutant in *Escherichia coli*. *Acta Genet. Sin.* **13**:81–88.
495. **Marakusha, B. I., V. G. Petrovskaya, and K. I. Volkovoi.** 1986. Obtaining *Salmonella typhimurium* and *Salmonella dublin* neamine resistant mutants suitable for the development of vaccines and the characterization of their biological and genetic properties. *Zh. Mikrobiol. Epidemiol. Immunobiol.* **1986**:3–8.
496. **Marcus, M., and Y. S. Halpern.** 1967. Genetic analysis of glutamate transport in *Escherichia coli*. *J. Bacteriol.* **93**:1409–1415.
497. **Marcus, M., and Y. S. Halpern.** 1969. Genetic analysis of the glutamate permease in *Escherichia coli* K-12. *J. Bacteriol.* **97**:1118–1128.
498. **Mark, D. F., J. W. Chang, and C. F. Richardson.** 1977. Genetic mapping of *trxA*, a gene affecting thioredoxin in *Escherichia coli* K12. *Mol. Gen. Genet.* **155**:145–152.
499. **Marquardt, J. L., D. A. Siegle, R. Kolter, and C. T. Walsh.** 1992. Cloning and sequencing of *Escherichia coli murZ* and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. *J. Bacteriol.* **174**:5748–5752.

500. **Martinez, D., and F. Whitehouse, Jr.** 1973. Selective autotoxicity in a model system of *Escherichia coli* recombinants. *J. Bacteriol.* **114**:882–884.
501. **Masters, P. S., and J.-S. Hong.** 1981. Genetics of the glutamine transport system in *Escherichia coli*. *J. Bacteriol.* **147**:805–819.
502. **Matsuzawa, H., S. Asoh, T. Ohta, S. Tamaki, and M. Matsuhashi.** 1980. Further studies on *rodA* mutant: a round morphological mutant of *Escherichia coli* K12 with wild-type penicillin-binding protein 2. *Agric. Biol. Chem.* **44**:2937–2941.
503. **Matsuzawa, H., S. Ushiyama, Y. Koyama, and T. Ohta.** 1984. *Escherichia coli* K-12 *tolZ* mutants tolerant to colicins E2, E3, D, Ia and Ib: defect in generation of the electrochemical proton gradient. *J. Bacteriol.* **160**:733–739.
504. **Mattern, I. E., and J. Pittard.** 1971. Regulation of tyrosine biosynthesis in *Escherichia coli* K-12: isolation and characterization of operator mutants. *J. Bacteriol.* **107**:8–15.
505. **McCalla, D. R., C. Kaiser, and M. H. L. Green.** 1978. Genetics of nitrofurazone resistance in *Escherichia coli*. *J. Bacteriol.* **133**:10–16.
506. **McConville, M. L., and H. P. Charles.** 1979. Mutants of *Escherichia coli* K12 accumulating porphobilinogen: a new locus, *hemC*. *J. Gen. Microbiol.* **111**:193–200.
507. **McConville, M. L., and H. P. Charles.** 1979. Isolation of haemin-requiring mutants of *Escherichia coli* K12. *J. Gen. Microbiol.* **113**:155–164.
508. **McEwen, J., and P. Silverman.** 1980. Chromosomal mutations of *Escherichia coli* that alter expression of conjugative plasmid functions. *Proc. Natl. Acad. Sci. USA* **77**:513–517.
509. **Meiss, H. K., W. J. Brill, and B. Magasanik.** 1969. Genetic control of histidine degradation in *Salmonella typhimurium* LT-2. *J. Biol. Chem.* **244**:5382–5391.
510. **Melton, T., W. Kundig, P. E. Hartman, and N. Meadow.** 1976. 3-Deoxy-3-fluoro-D-glucose-resistant *Salmonella typhimurium* mutants defective in the phosphoenolpyruvate:glycose phosphotransferase system. *J. Bacteriol.* **128**:794–800.
511. **Menzel, R., and J. Roth.** 1981. Regulation of the genes for proline utilization in *Salmonella typhimurium*: autogenous repression by the *putA* gene product. *J. Mol. Biol.* **148**:21–44.
512. **Mett, V. L., F. I. Urmeeva, N. S. Kobets, T. V. Kolganova, K. A. Aliev, and E. S. Piruzyan.** 1991. Cloning and expression of a mutant EPSP-synthase gene of *E. coli* in transgenic plants. *Biotekhnologiya* **3**:19–22.
513. **Meynell, E. W.** 1961. A phage χ , which attacks motile bacteria. *J. Gen. Microbiol.* **25**:253–290.
514. **Mikulka, T. W., B. I. Stieglitz, and J. M. Calvo.** 1972. Leucyltransfer-ribonucleic acid synthetase from a wild-type and temperature-sensitive mutant of *Salmonella typhimurium*. *J. Bacteriol.* **19**:584–593.
515. **Mildener, B., T. P. Fondy, R. Engel, and B. E. Tropp.** 1981. Effects of halo analogs of glycerol 3-phosphate and dihydroxyacetone phosphate upon *Escherichia coli*. *Antimicrob. Agents Chemother.* **19**:678–681.
516. **Miller, C. G., C. Heiman, and C. Yen.** 1976. Mutants of *Salmonella typhimurium* deficient in an endopeptidase. *J. Bacteriol.* **127**:490–497.
517. **Miller, C. G., and G. Schwartz.** 1978. Peptidase-deficient mutants of *Escherichia coli*. *J. Bacteriol.* **135**:603–611.
518. **Miller, E. S., and J. E. Brenchley.** 1981. L-methionine SR-sulfoximine resistant glutamine synthetase from mutants of *Salmonella typhimurium*. *J. Biol. Chem.* **256**:11307–11312.
519. **Miller, H. I., and D. I. Friedman.** 1977. Isolation of *Escherichia coli* mutants unable to support lambda integrative recombination, p. 349–356. In A. I. Bukhari, J. A. Shapiro, and S. L. Adhya (ed.), *DNA Insertion Elements, Plasmids, and Episomes*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
520. **Miller, H. I., and D. I. Friedman.** 1980. An *E. coli* gene product required for λ site specific recombination. *Cell* **20**:711–719.
521. **Miller, H. I., A. Kikuchi, H. A. Nash, R. A. Weisberg, and D. I. Friedman.** 1978. Site-specific recombination of bacteriophage λ : the role of host gene products. *Cold Spring Harbor Symp. Quant. Biol.* **43**:1121–1126.

522. **Miller, H. I., M. Kirk, and H. Echols.** 1981. SOS induction and autoregulation of the *himA* gene for site-specific recombination in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **78**:6754–6758.
523. **Miller, J. H.** 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
524. **Miller, J. H.** 1992. *A Short Course in Bacterial Genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
525. **Miner, K. M., and L. Frank.** 1974. Sodium-stimulated glutamate transport in osmotically shocked cells and membrane vesicles of *Escherichia coli*. *J. Bacteriol.* **117**:1093–1098.
526. **Miyoshi, Y., and H. Yamagata.** 1976. Sucrose-dependent spectinomycin-resistant mutants of *Escherichia coli*. *J. Bacteriol.* **125**:142–148.
527. **Mojica, A. T.** 1975. Transduction by phage PICM *clr-100* in *Salmonella typhimurium*. *Mol. Gen. Genet.* **138**:113–126.
528. **Mojica, A. T., and E. Garcia.** 1976. Growth of coliphage BF-23 on rough strains of *Salmonella typhimurium*. the *bfe* locus. *Mol. Gen. Genet.* **147**:195–202.
529. **Molnar, J., I. B. Holland, and Y. Mandi.** 1977. Selection of *lon* mutants in *Escherichia coli* by treatment with phenothiazines. *Genet. Res.* **30**:13–20.
530. **Monard, D., J. Janecek, and H. V. Rickenberg.** 1969. The enzymatic degradation of 3',5' cyclic AMP in strains of *E. coli* sensitive and resistant to catabolite repression. *Biochem. Biophys. Res. Commun.* **35**:584–591.
531. **Morimoto, R. I., A. Tissières, and C. Georgopoulos (ed.).** 1994. *The Biology of Heat Shock Proteins and Molecular Chaperones*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
532. **Morimyo, M., E. Hongo, H. Hama-Inaba, and I. Machida.** 1992. Cloning and characterization of the *mvrC* gene of *Escherichia coli* K12 which confers resistance against methyl viologen toxicity. *Nucleic Acids Res.* **20**:3159–3165.
533. **Morona, R., and U. Henning.** 1984. Host range mutants of bacteriophage OX-2 can use two different outer membrane proteins of *Escherichia coli* K-12 as receptors. *J. Bacteriol.* **159**:579–582.
534. **Morona, R., and U. Henning.** 1986. New locus (*ttr*) in *Escherichia coli* K-12 affecting sensitivity to bacteriophage T2 and growth on oleate as the sole carbon source. *J. Bacteriol.* **168**:534–540.
535. **Morona, R., M. Klose, and U. Henning.** 1984. *Escherichia coli* K-12 outer membrane protein OmpA as a bacteriophage receptor: analysis of mutant genes expressing altered proteins. *J. Bacteriol.* **159**:570–578.
536. **Morona, R., and P. Reeves.** 1982. The *tolC* locus of *Escherichia coli* affects the expression of three major outer membrane proteins. *J. Bacteriol.* **150**:1016–1023.
537. **Mosher, M. E., L. K. White, J. Hermolin, and R. H. Fillingame.** 1985. Proton-translocating ATPase of *Escherichia coli*: an *uncE* mutation impairing coupling between F-1 and F-0 but not F-0 mediated proton translocation. *J. Biol. Chem.* **260**:4807–4814.
538. **Mount, D. W.** 1977. A mutant of *Escherichia coli* showing constitutive expression of the lysogenic induction and error-prone DNA repair pathways. *Proc. Natl. Acad. Sci. USA* **74**:300–304.
539. **Moyed, H. S.** 1960. False feedback inhibition: inhibition of tryptophan biosynthesis by 5-methyltryptophan. *J. Biol. Chem.* **235**:1098–1102.
540. **Moyed, H. S.** 1961. Interference with the feed-back control of histidine biosynthesis. *J. Biol. Chem.* **236**:2261–2267.
541. **Moyed, H. S., and K. P. Bertrand.** 1983. *hipA*, a newly recognized gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J. Bacteriol.* **155**:768–775.
542. **Muir, M. E., D. R. Hanwell, and B. J. Wallace.** 1981. Characterization of a respiratory mutant of *Escherichia coli* with reduced uptake of aminoglycoside antibiotics. *Biochim. Biophys. Acta* **638**:234–241.
543. **Muller-Hill, B., L. Crapo, and W. Gilbert.** 1968. Mutants that make more lac repressor. *Proc. Natl. Acad. Sci. USA* **59**:1259–1264.
544. **Munch-Petersen, A., and B. Mygind.** 1976. Nucleoside transport systems in *Escherichia coli* K12: specificity and regulation. *J. Cell. Physiol.* **89**:551–560.
545. **Munch-Petersen, A., B. Mygind, A. Nicolaisen, and N. J. Pihl.** 1979. Nucleoside transport in

- cells and membrane vesicles from *Escherichia coli* K12. *J. Biol. Chem.* **254**:3730–3737.
546. **Munch-Petersen, A., P. Nygaard, K. Hammer-Jespersen, and N. Fiil.** 1972. Mutants constitutive for nucleoside-catabolizing enzymes in *Escherichia coli* K12. *Eur. J. Biochem.* **27**:208–215.
547. **Munekiyo, R., T. Tsuzuki, and M. Sekiguchi.** 1979. A new locus of *Escherichia coli* that determines sensitivity to bacteriophage φX174. *J. Bacteriol.* **138**:1038–1040.
548. **Murata, K., K. Tani, J. Kato, and I. Chibata.** 1980. Excretion of glutathione by methylglyoxal-resistant *Escherichia coli*. *J. Gen. Microbiol.* **120**:545–547.
549. **Murooka, Y., and T. Harada.** 1981. Regulation of derepressed synthesis of arylsulfatase by tyramine oxidase in *Salmonella typhimurium*. *J. Bacteriol.* **145**:796–802.
550. **Myers, D. E., B. A. D. Stocker, and R. J. Roantree.** 1980. Mapping of genes determining penicillin-resistance and serum-sensitivity in *Salmonella enteritidis*. *J. Gen. Microbiol.* **118**:367–376.
551. **Myers, R. S., and S. R. Maloy.** 1988. Mutations of *putP* that alter the lithium sensitivity of *Salmonella typhimurium*. *Mol. Microbiol.* **2**:749–755.
552. **Nagelkerke, F., and P. W. Postma.** 1978. 2-Deoxygalactose, a specific substrate of the *Salmonella typhimurium* galactose permease: its use for the isolation of *galP* mutants. *J. Bacteriol.* **133**:607–613.
553. **Nakamura, H.** 1979. Novel acriflavine resistance genes, *acrC* and *acrD*, in *Escherichia coli* K-12. *J. Bacteriol.* **139**:8–12.
554. **Nakamura, H.** 1980. Complementation analysis between genes determining cell division, *arcC*, and DNA polymerase III, *dnaE*, in *Escherichia coli* K12. *Mem. Konan Univ. Sci. Ser.* **25**:31–33.
555. **Nakamura, H., A. Hase, and K. Hirayoshi.** 1987. Temperature-sensitive phase in the cell cycle of ACR-C mutants of *Escherichia coli* K12. *Mem. Konan Univ. Sci. Ser.* **34**:87–98.
556. **Nakamura, Y., T. Kurihara, H. Saito, and H. Uchida.** 1979. σ-subunit of *Escherichia coli* RNA polymerase affects the function of λ N gene. *Proc. Natl. Acad. Sci. USA* **76**:4593–4597.
557. **Nakayama, H., K. Nakayama, R. Nakayama, N. Irino, Y. Nakayama, and P. C. Hanawalt.** 1984. Isolation and genetic characterization of a thymineless death-resistant mutant of *Escherichia coli* K12: identification of a new mutation (*recQ1*) that blocks the RecF recombination pathway. *Mol. Gen. Genet.* **195**:474–480.
558. **Nakayama, K., S. Shiota, and H. Nakayama.** 1988. Thymineless death in *Escherichia coli* mutants deficient in the *recF* recombination pathway. *Can. J. Microbiol.* **34**:905–907.
559. **Nashimoto, H., and H. Uchida.** 1975. Late steps in the assembly of 30s ribosomal proteins *in vivo* in a spectinomycin-resistant mutant of *Escherichia coli*. *J. Mol. Biol.* **96**:443–453.
560. **Nass, G., and J. Thomale.** 1974. Alteration of structure or level of threonyl-tRNA synthetase in borrelidin-resistant mutants of *Escherichia coli*. *FEBS Lett.* **39**:182–186.
561. **Nazos, P. M., M. M. Mayo, T. Z. Su, J. J. Anderson, and D. L. Oxender.** 1985. Identification of *livG*, a membrane-associated component of the branched-chain amino acid transport in *Escherichia coli*. *J. Bacteriol.* **163**:1196–1202.
562. **Nelson, B. W., and R. J. Roantree.** 1967. Analysis of lipopolysaccharides extracted from penicillin-resistant, serum-sensitive *Salmonella* mutants. *J. Gen. Microbiol.* **48**:179–188.
563. **Nelson, S. O., B. J. Scholte, and P. W. Postma.** 1982. Phosphoenolpyruvate:sugar phosphotransferase system-mediated regulation of carbohydrate metabolism in *Salmonella typhimurium*. *J. Bacteriol.* **150**:604–615.
564. **Nelms, J., R. M. Edwards, J. Warwick, and I. Fotheringham.** 1992. Novel mutations in the *pheA* gene of *Escherichia coli* K-12 which result in highly feedback inhibition resistant variants of chorismate mutase/prephenate dehydratase. *Appl. Environ. Microbiol.* **58**:2592–2598.
565. **Neuhard, J., and K. Thomassen.** 1976. Altered deoxyribonucleotide pools in P2 eductants of *Escherichia coli* K-12 due to deletion of the *dcd* gene. *J. Bacteriol.* **126**:999–1001.
566. **Newell, S. L., and W. J. Brill.** 1972. Mutants of *Salmonella typhimurium* that are insensitive to catabolite repression of proline degradation. *J. Bacteriol.* **111**:375–382.
567. **Newman, E. B., N. Malik, and C. Walter.** 1982. L-Serine degradation in *Escherichia coli* K-12: directly isolated *ssd* mutants and their intragenic revertants. *J. Bacteriol.* **150**:710–715.

568. **Ng, H., and T. K. Gartner.** 1963. Selection of mutants of *Escherichia coli* constitutive for tryptophanase. *J. Bacteriol.* **85**:245–246.
569. **Nikaido, H.** 1961. Galactose sensitive mutants of *Salmonella*. I. Metabolism of galactoside. *Biochim. Biophys. Acta* **48**:460 469.
570. **Normark, S., T. Edlund, T. Grundstrom, S. Bergstrom, and H. Wolf-Watz.** 1977. *Escherichia coli* K-12 mutants hyperproducing chromosomal beta-lactamase by gene repetitions. *J. Bacteriol.* **132**:912–922.
571. **Norwood, W. I., and J. R. Sadler.** 1977. Pseudoreversion of lactose operator-constitutive mutants. *J. Bacteriol.* **130**:100–106.
572. **Novel, G., and M. Novel.** 1973. Mutants d'*Escherichia coli* K12 affectés pour leur croissance sur méthyl-β-D-glucuronide: localisation du gène de structure de la β-D-glucuronidase (*uidA*). *Mol. Gen. Genet.* **120**:319–335.
573. **Novel, M., and G. Novel.** 1976. Regulation of β-glucuronidase synthesis in *Escherichia coli* K-12: constitutive mutants specifically derepressed for *uidA* expression. *J. Bacteriol.* **127**:406–417.
574. **Novel, M., and G. Novel.** 1976. Regulation of β-glucuronidase synthesis in *Escherichia coli* K-12: pleiotropic constitutive mutations affecting *uxu* and *uidA* expression. *J. Bacteriol.* **127**:418–432.
575. **Nummer, B. A., S. F. Barefoot, and E. L. Kline.** 1992. Effects of the *ftrA* regulatory locus on biosynthesis and excretion of amino acids in *Escherichia coli* B/r. *Biochem. Biophys. Res. Commun.* **183**:343–349.
576. **Nurminen, M., K. Lounatmaa, M. Sarvas, P. H. Makela, and T. Nakae.** 1976. Bacteriophage-resistant mutants of *Salmonella typhimurium* deficient in two major outer membrane proteins. *J. Bacteriol.* **127**:941–955.
577. **Obukowicz, M. G., N. R. Staten, and G. G. Krivi.** 1992. Enhanced heterologous gene expression in novel *rpoH* mutants of *Escherichia coli*. *Appl. Environ. Microbiol.* **58**:1511–1523.
578. **Odoevskaya, E. R., and S. P. Sineolsii.** 1987. Isolation and genetic study of bacterial mutations *gpr* blocking the replication of certain lambdoid phages. *Sov. Genet.* **23**:432–440.
579. **O'Donovan, G. A., G. Edlin, J. A. Fuchs, J. Neuhard, and E. Thomassen.** 1971. Deoxycytidine triphosphate deaminase: characterization of an *Escherichia coli* mutant deficient in the enzyme. *J. Bacteriol.* **105**:666–672.
580. **Ohnishi, K., and K. Kiritani.** 1978. Glycyl-L-leucine-resistance mutation affecting transport of branched-chain amino acids in *Salmonella typhimurium*. *Jpn. J. Genet.* **53**:275–283.
581. **Ohta, N., P. R. Galsworthy, and A. B. Pardee.** 1971. Genetics of sulfate transport by *Salmonella typhimurium*. *J. Bacteriol.* **105**:1053–1062.
582. **Okada, Y., M. Wachi, K. Nagai, and M. Matsuhashi.** 1992. Change of the quantity of penicillin-binding proteins and other cytoplasmic and membrane proteins by mutations of the cell shape-determination genes *mreB* *mrec* and *mreD* of *Escherichia coli*. *J. Gen. Appl. Microbiol.* **38**:157–163.
583. **Okuyama, A., M. Yoshikawa, and N. Tanaka.** Alteration of ribosomal protein S2 in kasugamycin resistant mutant derived from *Escherichia coli* AB312. *Biochem. Biophys. Res. Commun.* **60**:1163–1169.
584. **Oliver, D. B., R. J. Cabelli, K. M. Dolan, and G. P. Jarosik.** 1990. Azide resistant mutants of *Escherichia coli* alter the SecA protein, an azide-sensitive component of the protein export machinery. *Proc. Natl. Acad. Sci. USA* **87**:8227–8231.
585. **O'Neill, G. P., S. Thorbjarnardottir, U. Michelsen, S. Palsson, D. Söll, and G. Eggertsson.** 1991. Δ-Aminolevulinic acid dehydratase deficiency can cause Δ-aminolevulinate auxotrophy in *Escherichia coli*. *J. Bacteriol.* **173**:94–100.
586. **O'Neill, J. B., and M. Freundlich.** 1972. Effects of cyclopentane glycine on metabolism in *Salmonella typhimurium*. *J. Bacteriol.* **111**:510–515.
587. **Oppezzo, O. J., B. Avanzati, and D. N. Anton.** 1991. Increased susceptibility to beta lactam antibiotics and decreased porin content caused by *envB* mutations of *Salmonella typhimurium*. *Antimicrob. Agents Chemother.* **35**:1203–1207.
588. **Ornellas, E. P., and B. A. D. Stocker.** 1974. Relation of lipopolysaccharide character to Pl

- sensitivity in *Salmonella typhimurium*. *Virology* **60**:491–502.
589. **Orr, E., N. F. Fairweather, I. B. Holland, and R. H. Pritchard.** 1979. Isolation and characterization of a strain carrying a conditional lethal mutation in the *cou* gene of *Escherichia coli* K12. *Mol. Gen. Genet.* **177**:103–112.
590. **Orr, J. C., D. W. Bryant, D. R. McCalla, and M. A. Quilliam.** 1985. Dinitropyrene resistant *Salmonella typhimurium* are deficient in an acetyl-CoA acetyltransferase. *Chem. Biol. Interact.* **54**:281–288.
591. **Osborn, M. J., S. M. Rosen, L. Rothfield, and B. L. Horecker.** 1962. Biosynthesis of bacterial lipopolysaccharide. I. Enzymatic incorporation of galactose in a mutant strain of *Salmonella*. *Proc. Natl. Acad. Sci. USA* **48**:1831–1838.
592. **Osorio, A. V., L. Servin-Gonzalez, M. Rocha, A. A. Covarrubias, and F. Bastarrachea.** 1984. *cis*-dominant, glutamine synthetase constitutive mutations of *Escherichia coli* independent of activation by the *glnG* and *glnF* products. *Mol. Gen. Genet.* **194**:114–123.
593. **Ostrowski, J., and D. Hulanicka.** 1981. Effect of DNA gyrase inhibitors on gene expression of the cysteine region. *Mol. Gen. Genet.* **181**:363–366.
594. **Oxender, D. L.** 1972. Membrane transport. *Annu. Rev. Biochem.* **41**:777–814.
595. **Oxender, D. L., J. J. Anderson, M. M. Mayo, and S. C. Quay.** 1977. Leucine binding protein and regulation of transport in *Escherichia coli*. *J. Supramol. Struct.* **6**:419–432.
596. **Paetz, W., and G. Nass.** 1973. Biochemical and immunological characterization of threonyl-tRNA synthetase of two borrelidin resistant mutants of *Escherichia coli* K12. *Eur. J. Biochem.* **35**:331–337.
597. **Pai, C. H.** 1974. Biochemical and genetic characterization of dehydrobiotin resistant mutants of *Escherichia coli*. *Mol. Gen. Genet.* **134**:345–357.
598. **Pardee, A. B., E. J. Benz, Jr., D. A. St. Peter, J. N. Krieger, M. Meuth, and H. W. Triesmann, Jr.** 1971. Hyperproduction and purification of nicotinamide deamidase, a microconstitutive enzyme of *Escherichia coli*. *J. Biol. Chem.* **246**:6792–6796.
599. **Pardo, D., and R. Rosset.** 1977. Properties of ribosomes from erythromycin resistant mutants of *Escherichia coli*. *Mol. Gen. Genet.* **156**:267–271.
600. **Park, M. H., B. B. Wong, and J. E. Lusk.** 1976. Mutants in three genes affecting transport of magnesium in *Escherichia coli*: genetics and physiology. *J. Bacteriol.* **126**:1096–1103.
601. **Parker, C. T., A. W. Kloser, C. A. Schnaitman, M. A. Stein, S. Gottesman, and B. W. Gibson.** 1992. Role of the *rfaG* and *rfaP* genes in determining the lipopolysaccharide core structure and cell surface properties of *Escherichia coli* K-12. *J. Bacteriol.* **174**:2525–2538.
602. **Pauli, G., and P. Overath.** 1972. *ato* operon: a highly inducible system for acetoacetate and butyrate degradation in *Escherichia coli*. *Eur. J. Biochem.* **29**:553–562.
603. **Payne, J. W., J. S. Morley, P. Armitage, and G. M. Payne.** 1984. Transport and hydrolysis of antibacterial peptide analogues in *Escherichia coli*: backbone-modified aminoxy peptides. *J. Gen. Microbiol.* **130**:2253–2265.
604. **Penninckx, M., and D. Gigot.** 1979. Synthesis of a peptide form of N- δ -(phosphonoacetyl)-L-ornithine. Its antibacterial effect through the specific inhibition of *Escherichia coli* L-ornithine carbamoyltransferase. *J. Biol. Chem.* **254**:6392–6395.
605. **Pierard, A., and N. Glansdorf.** 1972. Mutations affecting uridine monophosphate pyrophosphorylase or the *argR* gene in *Escherichia coli*. *Mol. Gen. Genet.* **118**:235–245.
606. **Pierard, A., N. Glansdorf, D. Gigot, M. Crabeel, P. Halleux, and L. Thiry.** 1976. Repression of *Escherichia coli* carbamoylphosphate synthase: relationships with enzyme synthesis in the arginine and pyrimidine pathways. *J. Bacteriol.* **127**:291–301.
607. **Pinn, P. A., K. J. Towner, and F. W. O'Grady.** 1983. Genetic analysis of chromosomal resistance to trimethoprim derived from clinical isolates of *Escherichia coli*. *J. Gen. Microbiol.* **128**:85–92.
608. **Plate, C. A., and J. L. Suit.** 1981. The *eup* genetic locus of *Escherichia coli* and its role in proton solute symport. *J. Biol. Chem.* **256**:12974–12980.
609. **Platz, A., and B.-M. Sjoberg.** 1980. Construction and characterization of hybrid plasmids

- containing the *Escherichia coli* *nrd* region. *J. Bacteriol.* **143**:561–568.
610. **Pledger, W. J., and H. E. Umbarger.** 1973. Isoleucine and valine metabolism in *Escherichia coli*. XXI. Mutations affecting derepression and valine resistance. *J. Bacteriol.* **114**:183–194.
611. **Popkin, P. S., and W. K. Maas.** 1980. *Escherichia coli* regulatory mutation affecting lysine transport and lysine decarboxylase. *J. Bacteriol.* **141**:485–492.
612. **Portalier, R., J. Robert-Baudouy, and F. Stoeber.** 1980. Regulation of *Escherichia coli* K-12 hexuronate system genes: *exu* regulon. *J. Bacteriol.* **143**:1095–1107.
613. **Postma, P. W.** 1977. Galactose transport in *Salmonella typhimurium*. *J. Bacteriol.* **129**:630–639.
614. **Postma, P. W., and J. W. Lengeler.** 1985. Phosphoenolpyruvate:carbohydrate phosphotransferase system of bacteria. *Microbiol. Rev.* **49**:232–269.
615. **Pouyssegur, J. M., and F. R. Stoeber.** 1972. Rameau degradatif commun des hexuronates chez *Escherichia coli* K12. Mécanisme d'induction des enzymes assurant le métabolisme du 2-céto-3-désoxy-gluconate. *Eur. J. Biochem.* **30**:479–494.
616. **Prasad, I., B. Young, and S. Schaeffer.** 1973. Genetic determination of the constitutive biosynthesis of phospho- β -glucosidase A in *Escherichia coli* K-12. *J. Bacteriol.* **114**:909–915.
617. **Pritchard, R. H., and S. I. Ahmad.** 1971. Fluorouracil and the isolation of mutants lacking uridine phosphorylase in *E. coli*: location of the gene. *Mol. Gen. Genet.* **111**:84–88.
618. **Prody, C. A., and J. B. Nellands.** 1984. Genetic and biochemical characterization of the *Escherichia coli* K-12 *fhuB* mutation. *J. Bacteriol.* **157**:874–880.
619. **Pueyo, C., and J. Lopez-Barea.** 1979. The L-arabinose-resistance test with *Salmonella typhimurium* strain SV3 selects forward mutations at several *ara* genes. *Mutat. Res.* **64**:249–258.
620. **Pugsley, A. P.** 1985. *Escherichia coli* K12 strains for use in the identification and characterization of colicins. *J. Gen. Microbiol.* **131**:369–376.
621. **Pugsley, A. P., D. R. Lee, and C. A. Schnaitman.** 1980. Genes affecting the major outer membrane proteins of *Escherichia coli* K12: mutations at *nmpA* and *nmpB*. *Mol. Gen. Genet.* **677**:681–690.
622. **Pugsley, A. P., F. Moreno and V. de Lorenzo.** 1986. Microcin-E492-insensitive mutants of *Escherichia coli*. *J. Gen. Microbiol.* **132**:3253–3260.
623. **Pugsley, A. P., and P. Reeves.** 1976. Iron uptake in colicin B-resistant mutants of *Escherichia coli* K-12. *J. Bacteriol.* **126**:1052–1062.
624. **Pugsley, A. P., and P. Reeves.** 1976. Characterization of group B colicin-resistant mutants of *Escherichia coli* K-12: colicin resistance and the role of enterochelin. *J. Bacteriol.* **127**:218–228.
625. **Pugsley, A. P., and C. A. Schnaitman.** 1978. Outer membrane proteins of *Escherichia coli*. VII. Evidence that bacteriophage-directed protein 2 functions as a pore. *J. Bacteriol.* **133**:1181–1189.
626. **Pugsley, A. P., and C. A. Schnaitman.** 1978. Identification of three genes controlling production of new outer membrane pore proteins in *Escherichia coli* K-12. *J. Bacteriol.* **135**:1118–1129.
627. **Puyo, M. F., P. Calsou, and B. Salles.** 1992. UV resistance of *E. coli* K12 deficient in cAMP/CRP regulation. *Mutat. Res.* **282**:247–252.
628. **Rahav-Manor, O., O. Carmel, R. Karpel, D. Taglicht, G. Glaser, S. Schuldiner, and E. Padan.** 1992. NhaR, a protein homologous to a family of bacterial regulatory proteins (LysR), regulates *nhaA*, the sodium proton antiporter gene in *Escherichia coli*. *J. Biol. Chem.* **267**:10433–10438.
629. **Rainwater, S., and P. M. Silverman.** 1990. The Cpx proteins of *Escherichia coli* K-12: evidence that *cpxA*, *ecfB*, *ssd*, and *eup* mutations all identify the same gene. *J. Bacteriol.* **172**:2456–2461.
630. **Rakonjac, J., M. Milic, D. Ajdic-Predic, D. Santos, R. Ivanisevic, and D. J. Savic.** 1992. A new genetic locus that affects the response of *Escherichia coli* K12 to novobiocin. *Mol. Microbiol.* **6**:1547–1553.
631. **Rakonjac, J., M. Milic, and D. J. Savic.** 1991. *cysB* and *cysE* mutants of *Escherichia coli* K12 show increased resistance to novobiocin. *Mol. Gen. Genet.* **228**:307–311.
632. **Ramabhadran, T. V.** 1976. Method for the isolation of *Escherichia coli* relaxed mutants, utilizing near-ultraviolet irradiation. *J. Bacteriol.* **127**:1587–1589.
633. **Ramakrishnan, T., and E. A. Adelberg.** 1965. Regulatory mechanisms in the biosynthesis of

- isoleucine and valine. II. Identification of two operator genes. *J. Bacteriol.* **89**:654–660.
634. **Ramakrishnan, V., and S. W. White.** 1992. The structure of ribosomal protein S5 reveals sites of interaction with 16s rRNA. *Nature (London)* **358**:768–771.
635. **Rancourt, D. E., J. T. Stephenson, G. A. Vickell, and J. M. Wood.** 1984. Proline excretion by *Escherichia coli* K12. *Biotechnol. Bioeng.* **26**:74–80.
636. **Raney, M. E., and R. W. Elliott.** 1978. The biochemical and genetic basis for high frequency thiomethylgalactoside resistance in lambda-lambda-dg lysogens of *Escherichia coli*. *J. Gen. Microbiol.* **104**:287–298.
637. **Ray, J. M., C. Yanofsky, and R. Bauerle.** 1988. Mutational analysis of the catalytic and feedback sites of the tryptophan-sensitive 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase of *Escherichia coli*. *J. Bacteriol.* **170**:5500–5506.
638. **Reeve, E. C. R.** 1968. Genetic analysis of some mutations causing resistance to tetracycline in *Escherichia coli* K12. *Genet. Res.* **11**:303–309.
639. **Reiner, A. M.** 1977. Xylitol and D-arabitol toxicities due to derepressed fructose, galactitol, and sorbitol phosphotransferases of *Escherichia coli*. *J. Bacteriol.* **132**:166–173.
640. **Reynolds, A. E., J. Felton, and A. Wright.** 1981. Insertion of DNA activates the cryptic *bgl* operon in *E. coli* K-12. *Nature (London)* **293**:625–629.
641. **Rick, P. D., and M. J. Osborn.** 1972. Isolation of a mutant of *Salmonella typhimurium* dependent on D-arabinose-5-P for growth and synthesis of 3-deoxy-D-mannoctulonate (ketodeoxyoctonate). *Proc. Natl. Acad. Sci. USA* **69**:3756–3760.
642. **Ried, G., I. Hindennach, and U. Henning.** 1990. Role of lipopolysaccharide in assembly of *Escherichia coli* outer membrane proteins OmpA, OmpC, and OmpF. *J. Bacteriol.* **172**:6048–6053.
643. **Riley, M.** 1993. Functions of the gene products of *Escherichia coli*. *Microbiol. Rev.* **57**:862–952.
644. **Roa, M.** 1979. Interaction of bacteriophage K10 with its receptor, the *lamB* protein of *Escherichia coli*. *J. Bacteriol.* **140**:680–686.
645. **Robbins, A. R.** 1975. Regulation of the *Escherichia coli* methylgalactoside transport system by gene *mglD*. *J. Bacteriol.* **123**:69–74.
646. **Robbins, J. C., and D. L. Oxender.** 1973. Transport systems for alanine, serine, and glycine in *Escherichia coli* K-12. *J. Bacteriol.* **116**:12–18.
647. **Roberton, A. M., P. A. Sullivan, M. C. Jones-Mortimer, and H. L. Kornberg.** 1980. Two genes affecting glucarate utilization in *Escherichia coli* K12. *J. Gen. Microbiol.* **117**:377–382.
648. **Roberts, L. M., and E. C. R. Reeve.** 1970. Two mutations giving low-level streptomycin resistance in *Escherichia coli* K12. *Genet. Res.* **16**:359–365.
649. **Robinson, C. L., and J. H. Jackson.** 1982. New acetohydroxy acid synthetase activity from mutational activation of a cryptic gene in *Escherichia coli* K-12. *Mol. Gen. Genet.* **186**:240–246.
650. **Rodriguez, S. B., and J. L. Ingraham.** 1983. Location on the *Salmonella typhimurium* chromosome of the gene encoding nucleoside diphosphokinase (*ndk*). *J. Bacteriol.* **153**:1101–1103.
651. **Roeder, N., and R. L. Somerville.** 1979. Cloning the *trpR* gene. *Mol. Gen. Genet.* **176**:361–368.
652. **Roehl, R. A., and R. T. Vinopal.** 1980. Genetic locus, distant from *ptsM*, affecting enzyme IIA/IIB function in *Escherichia coli* K-12. *J. Bacteriol.* **142**:120–130.
653. **Rolfe, B., and K. Onodera.** 1971. Demonstration of missing membrane proteins in a colicin-tolerant mutant of *Escherichia*. *Biochem. Biophys. Res. Commun.* **44**:767–773.
654. **Rood, J. I., A. J. Laird, and J. W. Williams.** 1980. Cloning of the *Escherichia coli* K12 dihydrofolate reductase EC-1.5.1.3 gene following phage Mu mediated transposition. *Gene* **8**:255–266.
655. **Rosen, B. P.** 1973. Basic amino acid transport in *Escherichia coli*: properties of canavanine-resistant mutants. *J. Bacteriol.* **116**:627–635.
656. **Rosen, S. M., L. D. Zeleznick, D. Fraenkel, I. M. Wiener, M. J. Osborn, and B. L. Horecker.** 1965. Characterization of the cell wall lipopolysaccharide of a mutant of *Salmonella typhimurium* lacking phosphomannose isomerase. *Biochem. Z.* **342**:375–386.
657. **Roth, J. R., and B. N. Ames.** 1966. Histidine regulatory mutants in *Salmonella typhimurium*. II. Histidine regulatory mutants having altered histidyl-tRNA synthetase. *J. Mol. Biol.* **22**:325–334.

658. **Roth, J. R., D. N. Anton, and P. E. Hartman.** 1966. Histidine regulatory mutants in *Salmonella typhimurium*. I. Isolation and general properties. *J. Mol. Biol.* **22**:305–323.
659. **Rowbury, R. J., M. Goodson, and A. D. Wallace.** 1992. The *phoE* porin and transmission of the chemical stimulus for induction of acid resistance acid habituation in *Escherichia coli*. *J. Appl. Bacteriol.* **72**:233–243.
660. **Rudd, K. E., and R. Menzel.** 1987. *his* operons of *Escherichia coli* and *Salmonella typhimurium* are regulated by DNA supercoiling. *Proc. Natl. Acad. Sci. USA* **84**:517–521.
661. **Rudd, K. E., W. Miller, C. Werner, J. Ostell, C. Tolstoshev, and S. G. Satterfield.** 1991. Mapping sequenced *E. coli* genes by computer: software, strategies and examples. *Nucleic Acids Res.* **19**:637–647.
662. **Russell, R. R. B., and A. J. Pittard.** 1971. Mutants of *Escherichia coli* unable to make protein at 42°C. *J. Bacteriol.* **108**:790–798.
663. **Ryals, J., R.-Y. Hsu, M. N. Lipsett, and H. Bremer.** 1982. Isolation of single-site *Escherichia coli* mutants deficient in thiamine and 4-thiouridine syntheses: identification of a *nuvC* mutant. *J. Bacteriol.* **151**:899–904.
664. **Saedler, H., A. Gullon, L. Fiethen, and P. Starlinger.** 1968. Negative control of the galactose operon in *E. coli*. *Mol. Gen. Genet.* **102**:79–88.
665. **Saier, M. H., Jr., H. Straud, L. S. Massman, J. J. Judice, M. J. Newman, and B. U. Feucht.** 1978. Permease-specific mutations in *Salmonella typhimurium* and *Escherichia coli* that release the glycerol, maltose, melibiose, and lactose transport systems from regulation by the phosphoenolpyruvate:sugar phosphotransferase system. *J. Bacteriol.* **133**:1358–1367.
666. **Saito, H., and C. C. Richardson.** 1981. Genetic analysis of gene 1.2 of bacteriophage T7: isolation of a mutant of *Escherichia coli* unable to support the growth of T7 gene 1.2 mutants. *Virology* **37**:343–351.
667. **Saito, H., and H. Uchida.** 1977. Initiation of the DNA replication of bacteriophage lambda in *Escherichia coli* K12. *J. Mol. Biol.* **113**:1–25.
668. **Sakka, K., T. Watanabe, R. Beers, and H. C. Wu.** 1987. Isolation and characterization of a new globomycin-resistant *dnaE* mutant of *Escherichia coli*. *J. Bacteriol.* **169**:3400–3408.
669. **Salanitro, J. P., and W. S. Wegener.** 1971. Growth of *Escherichia coli* on short-chain fatty acids: nature of the uptake system. *J. Bacteriol.* **18**:893–900.
670. **Samsonov, V. V., E. R. Odoevskaia, and S. P. Sineokii.** 1992. Cloning and complementation analysis of the *Escherichia coli* *gpr* locus, influencing DNA replication of certain lambdoid phages. *Genetika* **28**:39–45.
671. **Sanchez-Anzaldo, F. J., and F. Bastarrachea.** 1974. Genetic characterization of streptomycin-resistant and dependent mutants of *Escherichia coli* K-12. *Mol. Gen. Genet.* **130**:47–64.
672. **Sanchez-Anzaldo, F. J., R. Gomez, and F. Bastarrachea.** 1979. Paromomycin resistant mutants of *Escherichia coli* K12. I. Cross-resistance to streptomycin and synergism of the mixture of both antibiotics. *Rev. Latinoam. Microbiol.* **21**:121–128.
673. **Sanderson, K. E., and J. R. Roth.** 1983. Linkage map of *Salmonella typhimurium*, edition VI. *Microbiol. Rev.* **47**:410–453.
674. **Sanderson, K. E., and J. R. Roth.** 1988. Linkage map of *Salmonella typhimurium*, edition VII. *Microbiol. Rev.* **52**:485–532.
675. **Sanderson, K. E., and B. A. D. Stocker.** 1981. Gene *rfaH*, which affects lipopolysaccharide core structure in *Salmonella typhimurium*, is required also for expression of F-factor functions. *J. Bacteriol.* **146**:535–541.
676. **Sanderson, K. E., J. Van Wyngaarten, O. Luderitz, and B. A. D. Stocker.** 1974. Rough mutants of *Salmonella typhimurium* with defects in the heptose region of the lipopolysaccharide core. *Can. J. Microbiol.* **20**:1127–1134.
677. **Santangelo, J. D., D. T. Jones, and D. R. Woods.** 1991. Metronidazole activation and isolation of *Clostridium acetobutylicum* electron transport genes. *J. Bacteriol.* **173**:1088–1095.
678. **Sarrhy, A., S. Michaels, and J. Beckwith.** 1981. Deletion map of the *Escherichia coli* structural gene for alkaline phosphatase, *phoA*. *J. Bacteriol.* **145**:288–292.

679. **Sasarman, A., P. Chartrand, M. Lavoie, D. Tardif, R. Proscheck, and C. Lapointe.** 1979. Mapping of a new *hem* gene in *Escherichia coli* K12. *J. Gen. Microbiol.* **113**:297–303.
680. **Sasarman, A., P. Chartrand, R. Proscheck, M. Desrochers, D. Tardif, and C. Lapointe.** 1975. Uroporphyrin-accumulating mutant of *Escherichia coli* K-12. *J. Bacteriol.* **124**:1205–1212.
681. **Sasarman, A., and M. Desrochers.** 1976. Uroporphyrinogen III cosynthase-deficient mutant of *Salmonella typhimurium* LT2. *J. Bacteriol.* **128**:717–721.
682. **Sasarman, A., M. Desrochers, S. Sonea, K. E. Sanderson, and M. Surdeanu.** 1976. Porphobilogen-accumulating mutants of *Salmonella typhimurium* LT2. *J. Gen. Microbiol.* **94**:359–366.
683. **Sasarman, A., K. E. Sanderson, M. Surdeanu, and S. Sonea.** 1970. Hemin-deficient mutants of *Salmonella typhimurium*. *J. Bacteriol.* **102**:531–536.
684. **Sastray, S. S., and R. Jayaraman.** 1984. Nitrofurantoin-resistant mutants of *Escherichia coli*: isolation and mapping. *Mol. Gen. Genet.* **196**:379–380.
685. **Satre, M., C. Klein, and P. V. Vignais.** 1978. Isolation of *Escherichia coli* mutants with an adenosine triphosphatase insensitive to aurovertin. *J. Bacteriol.* **134**:17–23.
686. **Schaeffler, S.** 1967. Inducible system for the utilization of β -glucosides in *Escherichia coli*. I. Active transport and utilization of β -glucosides. *J. Bacteriol.* **93**:254–263.
687. **Schellenberg, G. D., and C. E. Furlong.** 1977. Resolution of the multiplicity of the glutamate and aspartate transport systems of *Escherichia coli*. *J. Biol. Chem.* **252**:9055–9064.
688. **Schleif, R.** 1969. Isolation and characterization of a streptolydigin resistant RNA polymerase. *Nature (London)* **223**:1068–1069.
689. **Schwartz, J. H., W. K. Mass, and E. J. Simon.** 1959. An impaired concentrating mechanism for amino acids in mutants of *Escherichia coli* resistant to L-canavanine and D-serine. *Biochim. Biophys. Acta* **32**:582–583.
690. **Schwarz, T. F. R., S. M. Yeats, and P. Connolly.** 1981. Altered transcriptional termination in a rifampicin-resistant mutant of *Escherichia coli* which inhibits the growth of bacteriophage T7. *Mol. Gen. Genet.* **183**:181–186.
691. **Schweizer, H., M. Argast, and W. Boos.** 1982. Characteristics of a binding protein-dependent transport system for *sn*-glycerol 3-phosphate in *Escherichia coli* that is part of the *pho* regulon. *J. Bacteriol.* **150**:1154–1163.
692. **Schweizer, H., T. Grussenmeyer, and W. Boos.** 1982. Mapping of two *ugp* genes coding for the *pho* regulon-dependent *sn*-glycerol 3-phosphate transport system of *Escherichia coli*. *J. Bacteriol.* **150**:1164–1171.
693. **Sedgwick, B., and P. Robins.** 1980. Isolation of mutants of *Escherichia coli* with increased resistance to alkylating agents: mutants deficient in thiols and mutants constitutive for the adaptive response. *Mol. Gen. Genet.* **180**:85–90.
694. **Servin-Gonzalez, L., M. Ortiz, A. Gonzalez, and F. Bastarrachea.** 1987. *glnA* mutations conferring resistance to methylammonium in *Escherichia coli* K12. *J. Gen. Microbiol.* **133**:1631–1639.
695. **Shakulov, R. S., V. A. Livshits, G. G. Zaigraeva, L. F. Lideman, and T. T. D. Mukhamed.** 1978. Partial suppression of the action of the gene *relA* in cells of *fus^r* mutants of *Escherichia coli* K12. *Sov. Genet.* **14**:632–640.
696. **Shaw, L., F. Grau, H. R. Kaback, J. S. Hong, and C. Walsh.** 1975. Vinylglycolate resistance in *Escherichia coli*. *J. Bacteriol.* **121**:1047–1055.
697. **Sheldon, R., and S. Brenner.** 1976. Regulatory mutants of dihydrofolate reductase in *Escherichia coli* K12. *Mol. Gen. Genet.* **147**:91–97.
698. **Sheppard, D. E.** 1964. Mutants of *Salmonella typhimurium* resistant to feedback inhibition by L-histidine. *Genetics* **50**:611–623.
699. **Shifrin, S., B. N. Ames, and G. F.-L. Ames.** 1966. Effect of the α -hydrazino analogue of histidine on histidine transport and arginine biosynthesis. *J. Biol. Chem.* **241**:3424–3429.
700. **Shimmin, L. C., D. Vanderwel, R. E. Harkness, B. R. Currie, C. A. Galloway, and E. E. Ishiguro.** 1984. Temperature-sensitive beta-lactam-tolerant mutants of *Escherichia coli*. *J. Gen.*

Microbiol. **122**:351–354.

701. **Shive, W., and J. Macow.** 1946. Biochemical transformations as determined by competitive analogue-metabolite growth inhibitions. I. Some transformations involving aspartic acid. *J. Biol. Chem.* **162**:451–462.
702. **Siden, I., and H. G. Boman.** 1983. *Escherichia coli* mutants with an altered sensitivity to cecropin D. *J. Bacteriol.* **154**:170–176.
703. **Siegel, E. C., and V. Bryson.** 1967. Mutator gene of *Escherichia coli* B. *J. Bacteriol.* **94**:38–47.
704. **Sigmund, C. D., M. Ettayebi, and E. A. Morgan.** 1984. Antibiotic resistance mutations in 16s and 23s ribosomal RNA genes of *Escherichia coli*. *Nucleic Acids Res.* **12**:4653–4663.
705. **Signer, C. E., G. R. Smith, R. Cortese, and B. N. Ames.** 1972. Mutant tRNA^{his} ineffective in repression and lacking two pseudouridine modifications. *Nature (London) New Biol.* **238**:72–74.
706. **Silbert, D. F., G. R. Fink, and B. N. Ames.** 1966. Histidine regulatory mutants in *Salmonella typhimurium*. III. A class of regulatory mutants deficient in tRNA for histidine. *J. Mol. Biol.* **22**:335–347.
707. **Silhavy, T. J., I. Hartig-Beecken, and W. Boos.** 1976. Periplasmic protein related to the *sn*-glycerol 3-phosphate transport system of *Escherichia coli*. *J. Bacteriol.* **126**:951–958.
708. **Silver, S., P. Johnseine, E. Whitney, and D. Clark.** 1972. Manganese-resistant mutants of *Escherichia coli*: physiological and genetic studies. *J. Bacteriol.* **110**:186–195.
709. **Silverman, M., and M. Simon.** 1973. Genetic analysis of flagellar mutants in *Escherichia coli*. *J. Bacteriol.* **113**:105–113.
710. **Silverman, M., and M. I. Simon.** 1977. Bacterial flagella. *Annu. Rev. Microbiol.* **31**:397–419.
711. **Silverman, P., K. Nat, J. McEwen, and R. Birchman.** 1980. Selection of *Escherichia coli* K-12 mutants that prevent expression of F-plasmid functions. *J. Bacteriol.* **143**:1519–1523.
712. **Silverstone, A. E., M. Goman, and J. G. Scaife.** 1972. ALT: a new factor involved in the synthesis of RNA by *Escherichia coli*. *Mol. Gen. Genet.* **118**:223–234.
713. **Simons, R W., P. A. Egan, H. T. Chute, and W. D. Nunn.** 1980. Regulation of fatty acid degradation in *Escherichia coli*: isolation and characterization of strains bearing insertion and temperature-sensitive mutations in *fadR*. *J. Bacteriol.* **142**:621–632.
714. **Sivasubramanian, N., and R. Jayaraman.** 1980. Mapping of two transcription mutations (*tlnI* and *tlnII*) conferring thiolutin resistance, adjacent to *dnaZ* and *rho* in *Escherichia coli*. *Mol. Gen. Genet.* **180**:609–615.
715. **Slater, A. C., M. C. Jones-Mortimer, and H. L Kornberg.** 1981. L-sorbose phosphorylation in *Escherichia coli* K-12. *Biochim. Biophys. Acta* **646**:365–367.
716. **Slayman, C. W.** 1973. The genetic control of membrane transport. *Curr. Top. Membr. Transp.* **4**:1–174.
717. **Sledziewska, E., and D. Hulanicka.** 1978. Method of isolation of cysteine constitutive mutants of the cysteine regulon in *Salmonella typhimurium*. *Mol. Gen. Genet.* **165**:289–293.
718. **Smith, D. R., and J. M. Calvo.** 1979. Regulation of dihydrofolate reductase EC-1.5.1.3 synthesis in *Escherichia coli*. *Mol. Gen. Genet.* **175**:31–38.
719. **Smith, D. R., J. I. Rood, P. I. Bird, M. K. Sneddon, J. M. Calvo, and J. F. Morrison.** 1982. Amplification and modification of dihydrofolate reductase EC-1.5.1.3 in *Escherichia coli* nucleotide sequence of *fol* genes from mutationally altered plasmids. *J. Biol. Chem.* **257**:9043–9048.
720. **Smith, J. M., F. J. Smith, and H. E. Umbarger.** 1979. Mutations affecting the formation of acetohydroxyacid synthase II in *Escherichia coli* K12. *Mol. Gen. Genet.* **169**:299–314.
721. **Smith, T. F., and J. R. Sadler.** 1971. The nature of lactose operator constitutive mutations. *J. Mol. Biol.* **59**:273–305.
722. **Solomon, E., and E. C. C. Lin.** 1972. Mutations affecting the dissimilation of mannitol by *Escherichia coli* K-12. *J. Bacteriol.* **111**:566–574.
723. **Somers, J. M., and W. W. Kay.** 1983. Genetic fine structure of the tricarboxylate transport (*tct*) locus of *Salmonella typhimurium*. *Mol. Gen. Genet.* **190**:20–26.
724. **Somers, J. M., G. D. Sweet, and W. W. Kay.** 1981. Fluorocitrate resistant tricarboxylate transport mutants of *Salmonella typhimurium*. *Mol. Gen. Genet.* **181**:338–345.

725. Sparling, P. F., and E. Blackman. 1973. Mutation to erythromycin dependence in *Escherichia coli* K-12. *J. Bacteriol.* **116**:74–83.
726. Sparling, P. F., Y. Ikeya, and D. Elliot. 1973. Two genetic loci for resistance to kasugamycin in *Escherichia coli*. *J. Bacteriol.* **113**:704–710.
727. Sprague, G. F., Jr., R. M. Bell, and J. E. Cronan, Jr. 1975. A mutant of *Escherichia coli* auxotrophic for organic phosphates: evidence for two defects in inorganic phosphate transport. *Mol. Gen. Genet.* **143**:71–77.
728. Springer, S. E., and R. E. Huber. 1973. Sulfate and selenate uptake and transport in wild and in two selenate-tolerant strains of *Escherichia coli* K-12. *Arch. Biochem. Biophys.* **156**:595–603.
729. Sprinson, D. B., E. G. Gollub, R. C. Hu, and K.-P. Liu. 1976. Regulation of tyrosine and phenylalanine biosynthesis in *Salmonella*. *Acta Microbiol. Acad. Sci. Hung.* **23**:167–170.
730. Stacey, K. A., and E. Simson. 1965. Improved method for the isolation of thymine-requiring mutants of *Escherichia coli*. *J. Bacteriol.* **90**:554–555.
731. Stalker, D. M., W. R. Hiatt, and L. Comai. 1985. A single amino acid substitution in the enzyme 5-enolpyruvylshikimate-3-phosphate synthase confers resistance to the herbicide glyphosate. *J. Biol. Chem.* **260**:4724–4728.
732. Stalmach, M. E., S. Grothe, and J. M. Wood. 1983. Two proline porters in *Escherichia coli* K-12. *J. Bacteriol.* **156**:481–486.
733. Staskawicz, B. J., and N. J. Panopoulos. 1980. Phaseolotoxin transport in *Escherichia coli* and *Salmonella typhimurium* via the oligopeptide permease. *J. Bacteriol.* **142**:474–479.
734. Staudenbauer, W. L. 1976. Replication of *Escherichia coli* DNA *in vitro*: inhibition by oxolinic acid. *Eur. J. Biochem.* **62**:491–497.
735. Stauffer, G. V., and J. E. Brenchley. 1977. Influence of methionine biosynthesis on serine transhydroxymethylase (EC 2.1.2.1) regulation in *Salmonella typhimurium* LT2. *J. Bacteriol.* **129**:740–749.
736. Steffes, C., J. Ellis, J. Wu, and B. P. Rosen. 1992. The *lysP* gene encodes the lysine-specific permease. *J. Bacteriol.* **174**:3242–3249.
737. Stern, J. R., and R. W. O'Brien. 1969. Oxidation of D-malic and β-alkyl malic acids by wild-type and mutant strains of *Salmonella typhimurium* and by *Aerobacter aerogenes*. *J. Bacteriol.* **98**:147–151.
738. Stevens, F. J., and T. T. Wu. 1976. Growth on D-lyxose of a mutant strain of *Escherichia coli* K12 using a novel isomerase and enzymes related to D-xylose metabolism. *J. Gen. Microbiol.* **97**:257–265.
739. Stewart, V., and C. H. MacGregor. 1982. Nitrate reductase in *Escherichia coli* K-12: involvement of *chlC*, *chlE*, and *chlG* loci. *J. Bacteriol.* **151**:788–799.
740. Stitt, B. L., H. R. Revel, I. Lielausis, and W. B. Wood. 1980. Role of the host cell in bacteriophage T4 development. II. Characterization of host mutants that have pleiotropic effects on T4 growth. *J. Virol.* **35**:775–789.
741. Stocker, B. A. D., M. Nurminen, and P. H. Makela. 1979. Mutants defective in the 33K outer membrane protein of *Salmonella typhimurium*. *J. Bacteriol.* **139**:376–383.
742. Stoeber, F., A. Lagarde, G. Nemoz, G. Novel, M. Novel, R. Portalier, J. Pouyssegur, and J. Robert-Baudouy. 1974. Le métabolisme des hexuronides et des hexuronates chez *Escherichia coli* K12: aspects physiologiques et génétiques de sa régulation. *Biochimie* **56**:199–213.
743. Stouthamer, A. H. 1969. A genetical and biochemical study of chlorate-resistant mutants of *Salmonella typhimurium*. *Antonie van Leeuwenhoek J. Microbiol. Serol.* **35**:505–521.
744. Stouthamer, A. H., and C. W. Bettenhausen. 1970. Mapping a gene causing resistance to chlorate in *Salmonella typhimurium*. *Antonie van Leeuwenhoek J. Microbiol. Serol.* **36**:555–565.
745. Straus, D. S., and G. R. Hoffman. 1975. Selection for a large genetic duplication in *Salmonella typhimurium*. *Genetics* **80**:227–237.
746. Stuttard, C. 1972. Location of *trpR* mutations in the *serB-thr* region of *Salmonella typhimurium*. *J. Bacteriol.* **111**:368–374.
747. Sullivan, M. A., and R. M. Bock. 1985. Isolation and characterization of antisuppressor mutations

- in *Escherichia coli*. *J. Bacteriol.* **161**:377–384.
748. **Sullivan, M. A., J. F. Cannon, F. H. Webb, and R. M. Bock.** 1985. Antisuppressor mutation in *Escherichia coli* defective in biosynthesis of 5-methylaminomethyl-2-thiouridine. *J. Bacteriol.* **161**:368–376.
749. **Summers, W. C., and P. Raskin.** 1993. A method for selection of mutations at the *tdk* locus in *Escherichia coli*. *J. Bacteriol.* **175**:6049–6051.
750. **Sun, T.-P., and R. E. Webster.** 1986. *fii*, a bacterial locus required for filamentous phage infection, and its relation to colicin-tolerant *tolA* and *tolB*. *J. Bacteriol.* **165**:107–115.
751. **Sun, T.-P., and R. E. Webster.** 1987. Nucleotide sequence of a gene cluster involved in entry of *E. coli* colicins and single-stranded DNA of infecting filamentous bacteriophages into *Escherichia coli*. *J. Bacteriol.* **169**:2667–2674.
752. **Sundararajan, T. A.** 1963. Interference with glycerokinase induction in mutants of *E. coli* accumulating gal-1-P. *Proc. Natl. Acad. Sci. USA* **50**:463–469.
753. **Sunshine, M., M. Feiss, J. Stuart, and J. Yochem.** 1977. A new host gene (*groPC*) necessary for lambda DNA replication. *Mol. Gen. Genet.* **151**:27–34.
754. **Sunshine, M. G., and B. Sauer.** 1975. A bacterial mutation blocking P2 phage late gene expression. *Proc. Natl. Acad. Sci. USA* **72**:2770–2774.
755. **Sutton, A., T. Newman, M. Francis, and M. Freundlich.** 1981. Valine-resistant *Escherichia coli* K-12 strains with mutations in the *ilvB* operon. *J. Bacteriol.* **148**:998–1001.
756. **Swedberg, C., S. Castensson, and O. Skold.** 1979. Characterization of mutationally altered dihydropteroate synthase and its ability to form a sulfonamide-containing dihydrofolate analog. *J. Bacteriol.* **137**:129–136.
757. **Szentirmai, A., M. Szentirmai, and H. E. Umbarger.** 1968. Isoleucine and valine metabolism of *Escherichia coli*. XV. Biochemical properties of mutants resistant to thiaisoleucine. *J. Bacteriol.* **95**:1672–1679.
758. **Takahashi, H.** 1978. Genetic and physiological characterization of *Escherichia coli* K12 mutants (*tabC*) which induce the abortive infection of bacteriophage T4. *Virology* **87**:256–265.
759. **Tamaki, S., H. Matsuzawa, and M. Matsuhashi.** 1980. Cluster of *mrdA* and *mrdB* genes responsible for the rod shape and mecinillinam sensitivity of *Escherichia coli*. *J. Bacteriol.* **141**:52–57.
760. **Tamaki, S., T. Sato, and M. Matsuhashi.** 1971. Role of lipopolysaccharides in antibiotic resistance and bacteriophage adsorption of *Escherichia coli* K-12. *J. Bacteriol.* **105**:968–975.
761. **Tanaka, N., G. Kawano, and T. Kinoshita.** 1971. Chromosomal location of a fusidic acid resistant marker in *Escherichia coli*. *Biochem. Biophys. Res. Commun.* **42**:564–567.
762. **Tang, C.-T., R. Engel, and B. E. Tropp.** 1977. L-Glyceraldehyde 3-phosphate, a bactericidal agent. *Antimicrob. Agents Chemother.* **11**:147–153.
763. **Tapio, S., and L. A. Isaksson.** 1990. Antisuppression by mutations in elongation factor Tu. *Eur. J. Biochem.* **188**:339–346.
764. **Thakar, J. H., and G. P. Kalle.** 1968. Defective guanine uptake in an 8-azaguanine-resistant mutant of *Salmonella typhimurium*. *J. Bacteriol.* **95**:458–464.
765. **Thèze, J., D. Margarita, G. N. Cohen, F. Borne, and J. C. Patte.** 1974. Mapping of the structural genes of the three aspartokinases and the two homoserine dehydrogenases of *Escherichia coli* K-12. *J. Bacteriol.* **117**:133–143.
766. **Thirion, J. P., and M. Hofnung.** 1982. On some genetic aspects of phage λ resistance in *E. coli* K12. *Genetics* **71**:207–216.
767. **Thomas, G., and A. Favre.** 1977. Genetic mapping of a mutant exhibiting no near ultraviolet induced growth delay and lacking 4-thiouridine in its tRNA. *C. R. Acad. Sci.* **284**:2285–2288.
768. **Thorbjarnardottir, S. H., R. A. Magnusdottir, and C. Eggertsson.** 1978. Mutations determining generalized resistance to aminoglycoside antibiotics in *Escherichia coli*. *Mol. Gen. Genet.* **161**:89–98.
769. **Thorne, C. M., and L. M. Corwin.** 1975. Mutations affecting aromatic amino acid transport in *Escherichia coli* and *Salmonella typhimurium*. *J. Gen. Microbiol.* **90**:203–216.
770. **Tomas, J. M., and W. W. Kay.** 1986. Tellurite susceptibility and non-plasmid-mediated

- resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.* **30**:127–131.
771. **Tommassen, J., and B. Lugtenberg.** 1981. Localization of *phoE*, the structural gene for outer membrane protein E in *Escherichia coli* K-12. *J. Bacteriol.* **147**:118–123.
772. **Toone, W. M., K. E. Rudd, and J. D. Friesen.** 1992. Mutations causing aminotriazole resistance and temperature sensitivity reside in *gyrB*, which encodes the β subunit of DNA gyrase. *J. Bacteriol.* **174**:5479–5481.
773. **Torriani, A., and F. Rothman.** 1961. Mutants of *Escherichia coli* constitutive for alkaline phosphatase. *J. Bacteriol.* **81**:835–836.
774. **Tosa, T., and L. I. Pizer.** 1971. Biochemical bases for the antimetabolite action of L-serine hydroxamate. *J. Bacteriol.* **106**:972–982.
775. **Tristram, H., and S. Neale.** 1968. The activity and specificity of the proline permease in wild-type and analogue-resistant strains of *Escherichia coli*. *J. Gen. Microbiol.* **50**:121–137.
776. **Trun, N. J., and S. Gottesman.** 1990. On the bacterial cell cycle: *Escherichia coli* mutants with altered ploidy. *Genes Dev.* **4**:2036–2047.
777. **Trun, N. J., and S. Gottesman.** 1991. Characterization of *Escherichia coli* mutants with altered ploidy. *Res. Microbiol.* **142**:195–200.
778. **Tsay, J.-T., C. O. Rock, and S. Jackowski.** 1992. Overproduction of beta ketoacyl-acyl carrier protein synthase I imparts thiolutomycin resistance to *Escherichia coli* K-12. *J. Bacteriol.* **174**:508–513.
779. **Udaka, S., and H. S. Moyed.** 1963. Inhibition of parental and mutant xanthosine 5'-phosphate aminases by psicofuranine. *J. Biol. Chem.* **238**:2797–2803.
780. **Umbarger, H. E.** 1969. Regulation of the biosynthesis of the branched-chain amino acids. *Curr. Top. Cell. Regul.* **1**:57–76.
781. **Umbarger, H. E.** 1971. Metabolite analogs as genetic and biochemical probes. *Adv. Genet.* **16**:119–140.
782. **Umbarger, H. E.** 1987. Biosynthesis of the branched-chain amino acids, p. 352–367. In F. C. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology*. American Society for Microbiology, Washington, D.C.
783. **Uzan, M., and A. Danchin.** 1976. A rapid test for the *relA* mutation in *E. coli*. *Biochem. Biophys. Res. Commun.* **69**:751–758.
784. **Uzan, M., and A. Danchin.** 1978. Correlation between the serine sensitivity and the derepressibility of the *ilv* genes in *Escherichia coli* *relA* mutants. *Mol. Gen. Genet.* **165**:21–30.
785. **Vaara, M.** 1981. Increased outer membrane resistance to ethylenediamine-tetraacetate and cations in novel lipid A mutants. *J. Bacteriol.* **148**: 426–434.
786. **Vaara, M., and T. Vaara.** 1981. Outer membrane permeability barrier disruption by polymyxin in polymyxin-susceptible and resistant *Salmonella typhimurium*. *Antimicrob. Agents Chemother.* **19**:578–583.
787. **Vaara, M., T. Vaara, M. Jensen, I. Helander, M. Nurminen, E. T. Rietschel, and P. H. Makela.** 1981. Characterization of the lipopolysaccharide from the polymyxin-resistant *pmrA* mutants of *Salmonella typhimurium*. *FEBS Lett.* **129**:145–149.
788. **Vaara, M., T. Vaara, and M. Sarvas.** 1979. Decreased binding of polymyxin by polymyxin-resistant mutants of *Salmonella typhimurium*. *J. Bacteriol.* **139**:664–667.
789. **Vallari, D. S., and S. Jackowski.** 1988. Biosynthesis and degradation both contribute to the regulation of coenzyme A content in *Escherichia coli*. *J. Bacteriol.* **170**:3961–3966.
790. **Vallari, D. S., and C. O. Rock.** 1987. Isolation and characterization of temperature-sensitive pantothenate kinase (*coaA*) mutants of *Escherichia coli*. *J. Bacteriol.* **169**:5795–5800.
791. **Van Alphen, L., B. Lugtenberg, R. Van Boxtel, A.-M. Hack, C. Verhoef, and L. Havekes.** 1979. *meoA* is the structural gene for outer membrane protein C of *Escherichia coli* K12. *Mol. Gen. Genet.* **169**:147–156.
792. **Van Alphen, W., B. Lugtenberg, and W. Berendsen.** 1976. Heptose-deficient mutants of *Escherichia coli* K12 deficient in up to three major outer membrane proteins. *Mol. Gen. Genet.*

147:263–269.

793. **Van Buul, C. P. J. J., and P. H. Van Knippenberg.** 1985. Nucleotide sequence of the *ksgA* gene of *Escherichia coli*—comparison of methyltransferases effecting dimethylation of adenosine in ribosomal RNA. *Gene* **38**:65–72.
794. **Van de Klundert, J. A. M., E. Den Turk, A. H. Borman, P. H. Van der Meide, and L. Bosch.** 1977. Isolation and characterization of a mocomycin resistant mutant of *Escherichia coli* with an altered elongation factor EF-Tu. *FEBS Lett.* **81**:303–307.
795. **Van de Klundert, J. A. M., P. H. Van der Meide, P. Van de Putte, and L. Bosch.** 1978. Mutants of *Escherichia coli* altered in both genes coding for the elongation factor Tu. *Proc. Natl. Acad. Sci. USA* **75**:4470–4473.
796. **Van Dyk, T. K., and R. A. LaRossa.** 1986. Sensitivity of a *Salmonella typhimurium* *aspC* mutant to sulfometuron methyl, a potent inhibitor of acetolactate synthase II. *J. Bacteriol.* **165**:386–392.
797. **Van Dyk, T. K., and R. A. LaRossa.** 1987. Involvement of *ack-pta* operon products in α -ketobutyrate metabolism by *Salmonella typhimurium*. *Mol. Gen. Genet.* **207**:435–440.
798. **Vasiljevic, B., and L. Topisirovic.** 1987. Properties of ribosomes from neamine-dependent (NeaD) mutants of *Escherichia coli*. *Period. Biol.* **89**:89–93.
799. **Venables, W. A., and J. R. Guest.** 1968. Transduction of nitrate reductase loci of *Escherichia coli* by phages Pl and λ . *Mol. Gen. Genet.* **103**:127–140.
800. **Venkateswaran, P. S., and H. C. Wu.** 1972. Isolation and characterization of a phosphonomycin-resistant mutant of *Escherichia coli* K-12. *J. Bacteriol.* **110**:935–944.
801. **Verhof, C., B. Lugtenberg, R. van Boxtel, P. de Craaff, and H. Verheij.** 1979. Genetics and biochemistry of the peptidoglycan-associated proteins b and c of *Escherichia coli* K12. *Mol. Gen. Genet.* **169**:137–146.
802. **Vinella, D., R. D'Ari, and P. Bouloc.** 1992. Penicillin-binding protein 2 is dispensable in *Escherichia coli* when ppGpp synthesis is induced. *EMBO J.* **11**:1493–1501.
803. **Vinopal, R. T.** 1987. Selectable phenotypes, p. 990–1015. In F. C. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology*. American Society for Microbiology, Washington, D.C.
804. **Voll, M. J.** 1967. Polarity in the histidine operon. III. The isolation of prototrophic polar mutations. *J. Mol. Biol.* **30**:109–124.
805. **Voll, M. J., and L. Leive.** 1970. Release of lipopolysaccharide in *Escherichia coli* resistant to the permeability increase induced by ethylenediaminetetraacetate. *J. Biol. Chem.* **245**:1108–1114.
806. **Vonder Haar, R. A., and H. E. Umbarger.** 1972. Isoleucine and valine metabolism in *Escherichia coli*. XIX. Inhibition of isoleucine biosynthesis by glycyl-leucine. *J. Bacteriol.* **112**:142–147.
807. **Wachi, M., M. Doi, S. Tamaki, W. Park, S. Nakajima-Iijima, and M. Matsuhashi.** 1987. Mutant isolation and molecular cloning of *mre* genes which determine cell shape sensitivity to meccillinam and amount of penicillin-binding proteins in *Escherichia coli*. *J. Bacteriol.* **169**:4935–4940.
808. **Wada, C., and T. Yura.** 1971. Phenethyl alcohol resistance in *Escherichia coli*. II. Replication of F (fertility) factor in the resistant strain C600. *Genetics* **69**:275–287.
809. **Wada, C., and T. Yura.** 1974. Phenethyl alcohol resistance in *Escherichia coli*. III. A temperature-sensitive mutation (*dnaP*) affecting DNA replication. *Genetics* **77**:199–220.
810. **Walker, G. C.** 1987. The SOS response of *Escherichia coli*, p. 1346–1357. In F. C. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology*. American Society for Microbiology, Washington, D.C.
811. **Wallace, B. J., and J. Pittard.** 1969. Regulator gene controlling enzymes concerned in tyrosine biosynthesis in *Escherichia coli*. *J. Bacteriol.* **97**:1234–1241.
812. **Wandersman, C., F. Moreno, and M. Schwartz.** 1980. Pleiotropic mutations rendering *Escherichia coli* K-12 resistant to bacteriophage TP1. *J. Bacteriol.* **143**:1374–1383.

813. **Wargel, R. J., C. A. Shadur, and F. C. Neuhaus.** 1971. Mechanism of D-cycloserine action: transport mutants for D-alanine, D-cycloserine, and glycine. *J. Bacteriol.* **105**:1028–1035.
814. **Watanabe, H., H. Hashimoto, and S. Mitsuhashi.** 1980. *Salmonella typhimurium* LT2 mutation affecting the deletion of resistance determinants on R plasmids. *J. Bacteriol.* **142**:145–152.
815. **Watanabe, N.-A., T. Nagasu, K. Katsu, and K. Kitoh.** 1987. E-0702, a new cephalosporin, is incorporated into *Escherichia coli* cells via the *tonB*-dependent iron transport system. *Antimicrob. Agents Chemother.* **31**:497–504.
816. **Watson, C., and K. Paigen.** 1971. Isolation and characterization of an *Escherichia coli* bacteriophage requiring cell wall galactose. *J. Virol.* **8**:669–674.
817. **Webb, M.** 1970. The mechanism of acquired resistance to Co^{2+} and Ni^{2+} in gram-positive and gram-negative bacteria. *Biochim. Biophys. Acta* **222**:440–446.
818. **Weber, J., R. S. F. Lee, E. Grell, and A. E. Senior.** 1992. Investigation of the aurovertin binding site of *Escherichia coli* F-1 ATPase by fluorescence spectroscopy and site-directed mutagenesis. *Biochemistry* **31**:5112–5116.
819. **Wei, C. R., and S. Kustu.** 1981. Glutamine auxotrophs with mutations in a nitrogen regulatory gene, *ntrC*, that is near *glnA*. *Mol. Gen. Genet.* **183**:392–399.
820. **Weiner, J. H., C. E. Furlong, and L. A. Heppel.** 1971. A binding protein for L-glutamine and its relation to active transport in *E. coli*. *Arch. Biochem. Biophys.* **142**:715–717.
821. **Weiner, J. H., and L. A. Heppel.** 1971. A binding protein for glutamine and its relation to active transport in *E. coli*. *J. Biol. Chem.* **246**:6933–6941.
822. **White, B. J., S. J. Hochhauser, N. M. Cintron, and B. Weiss.** 1976. Genetic mapping of *xthA*, the structural gene for exonuclease III in *Escherichia coli* strain K12. *J. Bacteriol.* **126**:1082–1088.
823. **White, R. J., and P. W. West.** 1970. An examination of the inhibitory effects of N-iodoacetylglucosamine on *Escherichia coli* and isolation of resistant mutants. *Biochem. J.* **118**:81–87.
824. **Whitfield, H. J., Jr.** 1971. Purification and properties of the wild type and a feedback resistant phosphoribosyladenosine triphosphate pyrophosphate phosphoribosyltransferase, the first enzyme of histidine biosynthesis in *Salmonella typhimurium*. *J. Biol. Chem.* **246**:899–908.
825. **Wiater, A., M. Filutowicz, and D. Hulanicka.** 1982. A new class of mutants of the *cysB* regulatory gene for cysteine biosynthesis in *Salmonella typhimurium*. *J. Gen. Microbiol.* **128**:1785–1790.
826. **Wiater, A., and D. Hulanicka.** 1978. The regulatory *cysK* mutant of *S. typhimurium*. *Acta Biochim. Pol.* **25**:281–287.
827. **Wiater, A., and D. Hulanicka.** 1979. Properties of *cysK* mutants of *Escherichia coli* K12. *Acta Biochim. Pol.* **26**:21–28.
828. **Wiater, A., and T. Kłopotowski.** 1972. Mutations rendering *Salmonella typhimurium* resistant to 3-aminoimidazole in the presence of histidine. *Acta Biochim. Pol.* **19**:191–199.
829. **Wijsman, H. J. W., and H. C. Pafort.** 1974. Pleiotropic mutations in *Escherichia coli* conferring tolerance to glycine and sensitivity to penicillin. *Mol. Gen. Genet.* **128**:349–357.
830. **Wild, D. G.** 1988. Reversion from erythromycin dependence in *Escherichia coli*: strains altered in ribosomal sub-unit association and ribosome assembly. *J. Gen. Microbiol.* **134**:1251–1263.
831. **Wild, J., and T. Kłopotowski.** 1975. Insensitivity of D-amino acid dehydrogenase synthesis to catabolite repression in *dadR* mutants of *Salmonella typhimurium*. *Mol. Gen. Genet.* **136**:63–73.
832. **Wild, J., and T. Kłopotowski.** 1981. D-amino acid dehydrogenase of *Escherichia coli* K12: positive selection of mutants defective in the enzyme activity and localization of the structural gene. *Mol. Gen. Genet.* **181**:373–378.
833. **Wilkinson, R. C., P. Gemski, Jr., and B. A. D. Stocker.** 1972. Non-smooth mutants of *Salmonella typhimurium*: differentiation by phage sensitivity and genetic mapping. *J. Gen. Microbiol.* **70**:527–554.
834. **Williams, J. C., C. E. Lee, and J. R. Wild.** 1980. Genetic and biochemical characterization of distinct transport systems for uracil, uridine, and cytidine in *Salmonella typhimurium*. *Mol. Gen. Genet.* **178**:121–130.
835. **Williams, M. D., J. A. Fuchs, and M. C. Flickinger.** 1991. Null mutations in the stringent

- starvation protein of *Escherichia coli* disrupt lytic development of bacteriophage P1. *Gene* **109**:21–30.
836. **Williams, M. V., T. J. Kerr, R. D. Lemmon, and C. J. Tritz.** 1980. Azaserine resistance in *Escherichia coli*: chromosomal location of multiple genes. *J. Bacteriol.* **143**:383–388.
837. **Williams, M. V., J. J. Rowe, T. J. Kerr, and G. J. Tritz.** 1977. Studies on the modes of action of azaserine in *Escherichia coli* mechanism of resistance to azaserine. *Microbios* **19**:181–190.
838. **Willsky, G. R., R. L. Bennett, and M. H. Malamy.** 1973. Inorganic phosphate transport in *Escherichia coli*: involvement of two genes which play a role in alkaline phosphatase regulation. *J. Bacteriol.* **113**:529–539.
839. **Wittenbach, V. A., D. Rayner, and J. V. Schloss.** 1992. Pressure points in the biosynthetic pathway for branched chain amino acids, p. 69–88. In B. K. Singh, H. E. Flores, and J. C. Shannon (ed.), *Biosynthesis and Molecular Regulation of Amino Acids in Plants*. American Society of Plant Physiologists, Rockville, Md.
840. **Wittman, H. G., C. Stoffler, D. Apirion, L. Rosen, K. Tanaka, M. Tamaki, R. Takata, S. Dekio, E. Otaka, and S. Osawa.** 1973. Biochemical and genetic studies on two different types of erythromycin resistant mutants of *Escherichia coli* with altered ribosomal proteins. *Mol. Gen. Genet.* **127**:175–189.
841. **Wolfner, M. D. Yep, F. Messenguy, and G. Fink.** 1975. Integration of amino acid biosynthesis into the cell cycle of *Saccharomyces cerevisiae*. *J. Mol. Biol.* **96**:273–290.
842. **Wolfson, J. S., D. C. Hooper, G. L. McHugh, M. A. Bozza, and M. N. Swartz.** 1990. Mutants of *Escherichia coli* K12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents. *Antimicrob. Agents Chemother.* **34**:1938–1943.
843. **Wood, J. M.** 1981. Genetics of L-proline utilization in *Escherichia coli*. *J. Bacteriol.* **146**:895–901.
844. **Woodward, M. J., and H. P. Charles.** 1982. Genes for L-sorbose utilization in *Escherichia coli*. *J. Gen. Microbiol.* **128**:1969–1980.
845. **Woodward, M. J., and H. P. Charles.** 1983. Polymorphism in *Escherichia coli*: *rtl*, *atl*, and *gat* regions behave as chromosomal alterations. *J. Gen. Microbiol.* **129**:75–84.
846. **Wooldridge, K. G., and P. H. Williams.** 1991. Sensitivity of *Escherichia coli* to cloacin DF13 involves the major outer membrane protein OmpF. *J. Bacteriol.* **173**:2420–2424.
847. **Wu, R., S. Yang, K. Jin, X. Chu, and M. Li.** 1987. Cloning and mutagenesis of threonine operon. *Shengwu Gongcheng Xuebao* **3**:177–182.
848. **Wu, T. T.** 1976. Growth of a mutant of *Escherichia coli* K12 on xylitol by recruiting enzymes for D-xylose and L-1,2-propanediol. *Biochim. Biophys. Acta* **428**:656–666.
849. **Wu, T. T.** 1976. Growth on D-arabitol of a mutant strain of *Escherichia coli* K12 using a novel dehydrogenase and enzymes related to L-1,2-propanediol and D-xylose metabolism. *J. Gen. Microbiol.* **94**:246–256.
850. **Xu, S., and T. Qi.** 1990. Enhancing effect of chuangxinmycin on synthesis of enzymes in tryptophan synthesis pathway of chuangxinmycin resistant mutant strain of *E. coli*. *Zhongguo Yixue Kexueyuan Xuebao* **12**:25–30.
851. **Yadav, N., R. E. McDevitt, S. Benard, and S. C. Falco.** 1986. Single amino acid substitutions in the enzyme acetolactate synthase confer resistance to the herbicide sulfometuron methyl. *Proc. Natl. Acad. Sci. USA* **83**:4418–4422.
852. **Yagil, E., and H. Be'eri.** 1977. Arsenate-resistant alkaline phosphatase-constitutive mutants of *Escherichia coli*. *Mol. Gen. Genet.* **154**:185–189.
853. **Yamada, T., and J. Davies.** 1971. A genetic and biochemical study of streptomycin- and spectinomycin-resistance in *Salmonella typhimurium*. *Mol. Gen. Genet.* **110**:197–210.
854. **Yamagata, H., C. Ippolito, M. Inukai, and M. Inouye.** 1982. Temperature-sensitive processing of outer membrane lipoprotein in an *Escherichia coli* mutant. *J. Bacteriol.* **152**:1163–1168.
855. **Yamagishi, J., H. Yoshida, M. Yamayoshi, and S. Nakamura.** 1986. Nalidixic acid resistant mutations of the *gyrB* gene of *Escherichia coli*. *Mol. Gen. Genet.* **204**:367–373.
856. **Yamamoto, T., and Y. Fujiwara.** 1990. Uracil DNA glycosylase causes 5-bromodeoxyuridine photosensitization in *Escherichia coli* K-12. *J. Bacteriol.* **172**:5278–5285.

857. **Yamasaki, M., R. Aono, and G. Tamura.** 1976. FL-1060 binding protein of *Escherichia coli* is probably under the control of cyclic AMP. *Agric. Biol. Chem.* **40**:1665–1667.
858. **Yanagisawa, T., J. T. Lee, H. C. Wu, and M. Kawakam.** 1994. Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of *Escherichia coli*: a proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. *J. Biol. Chem.* **269**:24304–24309.
859. **Yarmolinsky, M. B., H. Wiesmeyer, H. M. Kalckar, and E. Jordan.** 1959. Hereditary defects in galactose metabolism in *Escherichia coli* mutants. II. Galactose-induced sensitivity. *Proc. Natl. Acad. Sci. USA* **45**:1786–1791.
860. **Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura.** 1990. Quinolone resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob. Agents Chemother.* **34**:1271–1272.
861. **Yoshikawa, M., A. Okuyuma, and N. Tanaka.** 1975. A third kasugamycin resistance locus, *ksgC*, affecting ribosomal protein S2 in *Escherichia coli* K-12. *J. Bacteriol.* **122**:796–797.
862. **Yudkin, M. D.** 1977. Unstable mutations that relieve catabolite repression of tryptophanase synthesis by *Escherichia coli*. *J. Bacteriol.* **130**:57–61.
863. **Yura, T., and K. Igarishi.** 1968. RNA polymerase mutants of *Escherichia coli*. I. Mutants resistant to streptovaricin. *Proc. Natl. Acad. Sci. USA* **61**:1313–1319.
864. **Yura, T., and C. Wada.** 1968. Phenethyl alcohol resistance in *Escherichia coli*. I. Resistance of strain C600 and its relation to azide resistance. *Genetics* **59**:177–190.
865. **Zak, V. L., and R. A. Kelln.** 1978. 5-Fluoroornotate-resistant mutants of *Salmonella typhimurium*. *Can. J. Microbiol.* **24**:1339–1345.
866. **Zak, V. L., and R. A. Kelln.** 1981. A *Salmonella typhimurium* mutant dependent upon carbamyl aspartate for resistance to 5-fluorouracil is specifically altered in ubiquinone biosynthesis. *J. Bacteriol.* **145**:1095–1098.
867. **Zissler, J., E. Signer, and F. Schaefer.** 1971. The role of recombination in growth of bacteriophage lambda. I. The gamma gene, p. 455–468. In A. D. Hershey (ed.), *The Bacteriophage Lambda*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
868. **Zwiebel, L. J., M. Inukai, K. Nakamura, and M. Inouye.** 1981. Preferential selection of deletion mutations of the outer membrane lipoprotein gene of *Escherichia coli* by globomycin. *J. Bacteriol.* **145**:654–656.